dalteparin has been researched along with Complication, Postoperative in 553 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 9.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| " We aimed to perform a competing risk analysis to assess the efficacy of the low molecular weight heparin dalteparin versus unfractionated heparin (UFH) in venous thromboembolism (VTE) in medical-surgical critically ill patients, taking death as a competing risk." | 9.20 | Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. ( Arabi, YM; Bellomo, R; Cook, DJ; Cooper, DJ; Crowther, M; Ferguson, ND; Finfer, S; Guyatt, G; Heels-Ansdell, D; Holbrook, A; Lamontagne, F; Levine, MAH; Li, G; Thabane, L; Walter, SD, 2015) |
| "Venous thromboembolism (VTE) has a significant impact on healthcare costs but is largely preventable with anticoagulant prophylaxis using low-molecular-weight heparins (LMWHs), such as enoxaparin or dalteparin." | 9.17 | Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. ( Brosa, M; Diamantopoulos, A; Folkerts, K; Imberti, D; Monreal, M, 2013) |
| "Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile." | 9.12 | Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. ( Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN, 2007) |
| " The objective of this study was to evaluate the efficacy of dalteparin during lower-limb immobilization after surgical treatment of Achilles tendon rupture." | 9.12 | Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. ( de Bri, E; Elvin, A; Lapidus, LJ; Lärfars, G; Levander, C; Ponzer, S; Rosfors, S, 2007) |
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 9.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| " The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12." | 9.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| "To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted dose warfarin in preventing venous thromboembolism after knee arthroplasty." | 9.08 | Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. ( Cruickshank, M; Delorme, F; Demers, C; Desjardins, L; Geerts, WH; Kassis, J; L'Espérance, B; Laflamme, GH; Leclerc, JR; Whitman, L, 1996) |
| "The meta-analysis indicated that rivaroxaban prophylaxis was associated with lower rates of symptomatic venous thromboembolism (VTE) (relative risk[RR]:0." | 8.98 | Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis. ( Huang, HF; Li, SS; Tian, XB; Xie, Q; Yang, XT, 2018) |
| "To compare the efficacy and safety of aspirin with rivaroxaban following treatment with enoxaparin for prevention of venous thromboembolism (VTE) after hip fracture surgery (HFS)." | 7.91 | Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery. ( Huang, Q; Shen, B; Si, HB; Xing, SX; Zeng, Y; Zhou, ZK, 2019) |
| "Rivaroxaban is a cost-effective alternative to enoxaparin for VTE prophylaxis in patients undergoing THR and TKR." | 7.85 | Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. ( Ananthapavan, J; Diamantopoulos, A; Forster, F; Lees, M; McDonald, H; Wells, PS, 2010) |
| "To compare the efficacy, in the prevention of venous thromboembolism (VTE), and safety, of rivaroxaban and dabigatran relative to the common comparator enoxaparin." | 7.77 | An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. ( Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P, 2011) |
| "Oral dabigatran etexilate is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement or total hip replacement." | 7.76 | Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. ( Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2010) |
| "The purpose of this study was to determine the clinical outcomes of abciximab combined with the low molecular weight heparin (LMWH), dalteparin, in high-risk percutaneous coronary intervention (PCI) patients with acute myocardial infarction (AMI)." | 7.73 | Comparison of abciximab combined with dalteparin or unfractionated heparin in high-risk percutaneous coronary intervention in acute myocardial infarction patients. ( Ahn, YK; Cho, JG; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, KH; Kim, W; Park, JC, 2006) |
| "Warfarin-induced skin necrosis is a rare complication associated with the use of oral anticoagulants." | 7.72 | A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. ( Alexander, JB; Ierardi, R; Tai, CY, 2004) |
| "Many orthopaedic surgeons use warfarin to prevent venous thromboembolism (VTE) following hip or knee arthroplasty." | 7.72 | Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty. ( Brotman, DJ; Hurbanek, JG; Jaffer, AK; Morra, N, 2004) |
| "Of 263 patients who underwent total knee arthroplasty, 122 received adjusted low-dose warfarin and 141 received enoxaparin as deep vein thrombosis (DVT) prophylaxis." | 7.70 | Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty. ( O'Connor, D; Stern, SH; Wixson, RL, 2000) |
| " Secondary outcomes included incidence of venous thromboembolic events, adverse events, medication adherence, participant quality of life, and medication satisfaction." | 6.94 | Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. ( Babayan, LM; Behbakht, K; Breed, CA; Brennecke, A; Cheng, G; Corr, BR; Flink, D; Guntupalli, SR; Lefkowits, C; Matsuo, K; Ramzan, AA; Sheeder, J; Tayebnejad, A; Wheeler, LJ, 2020) |
| "Warfarin dosing with a target international normalized ratio (INR) range of 1." | 6.71 | Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005) |
| " We did a multicentre, randomised, double-blind study to examine the dose-response relation of subcutaneous melagatran, a direct thrombin inhibitor, followed by oral ximelagatran as thromboprophylaxis after total hip or knee replacement." | 6.70 | Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. ( Bergqvist, D; Bylock, A; Dahl, OE; Eriksson, BI; Eriksson, UG; Frison, L; Gustafsson, D; Kälebo, P; Lindbratt, S; Welin, L, 2002) |
| " The study did not evaluate a dose-response for efficacy, and no differences between the three dose levels of melagatran and ximelagatran were shown." | 6.70 | A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in ( Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P, 2002) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 6.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "Oral apixaban is an effective alternative to enoxaparin as a thromboprophylactic drug for patients undergoing elective total knee replacement surgery." | 5.62 | Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study. ( Ali Hasan, M; Azeez Alsaadi, M; Tahseen Mehsen, J, 2021) |
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 5.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| "Apixaban is a new oral anticoagulant with the potential to overcome these limitations." | 5.43 | Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. ( Dickison, DM; King, DA; Pow, RE; Vale, PR, 2016) |
| "We also investigated the occurrence of pulmonary embolism (PE) and its associated risk factors." | 5.42 | Prophylactic effect of fondaparinux and enoxaparin for preventing pulmonary embolism after total hip or knee arthroplasty: A retrospective observational study using the Japanese Diagnosis Procedure Combination database. ( Fushimi, K; Horiguchi, H; Kadono, Y; Matsuda, S; Shoda, N; Tanaka, S; Yasunaga, H, 2015) |
| "Apixaban is a direct factor Xa inhibitor that has been shown in clinical trial use to safely reduce the composite of VTE and mortality rates in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA); however, the cost-effectiveness of apixaban treatment in Canadian settings has not been studied." | 5.39 | A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. ( El-Hadi, W; Kadambi, A; Patterson, J; Raymond, V; Revankar, N, 2013) |
| "Fondaparinux is an effective and safe alternative." | 5.36 | Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. ( Ageno, W; Capri, S; Imberti, D; Moia, M; Palareti, G; Piovella, F; Scannapieco, G, 2010) |
| "In this international, parallel-group, randomized, double-blind, noninferiority trial, we randomly assigned adult patients undergoing lower-limb nonmajor orthopedic surgery who were considered to be at risk for venous thromboembolism on the basis of the investigator's judgment to receive either rivaroxaban or enoxaparin." | 5.34 | Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. ( Cucherat, M; Deygas, B; Duverger, D; Fisher, W; Girard, P; Laporte, S; Llau, J; Martínez-Martín, J; Mismetti, P; Mouret, P; Presles, E; Rosencher, N; Samama, CM, 2020) |
| " Low-molecular-weight heparins prevent venous thrombosis as effectively as heparin and have better bioavailability and a longer plasma half-life, which explains the increased use of low-molecular-weight heparins as substitutes for heparin in clinical practice." | 5.32 | Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. ( Arnljots, B; Dahlbäck, B; Malm, K, 2003) |
| "A 77-year-old man developed chronic disseminated intravascular coagulation (DIC) after surgical repair of a large infrarenal aortic aneurysm." | 5.31 | Chronic disseminated intravascular coagulation after surgery for abdominal aortic aneurysm: clinical and haemostatic response to dalteparin. ( Awad, R; Cummins, D; Hunt, BJ; Maddox, A; Segal, H, 2001) |
| "We examined the blood conserving effect of tranexamic acid in total hip arthroplasty using the direct anterior approach with enoxaparin as deep vein thrombosis (DVT) chemoprophylaxis, and whether this translates to an effect on functional outcomes in the perioperative period." | 5.30 | OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial. ( Duggan, J; Duncan, S; Fraval, A; Murray, T; Tirosh, O; Tran, P, 2019) |
| " We aimed to perform a competing risk analysis to assess the efficacy of the low molecular weight heparin dalteparin versus unfractionated heparin (UFH) in venous thromboembolism (VTE) in medical-surgical critically ill patients, taking death as a competing risk." | 5.20 | Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. ( Arabi, YM; Bellomo, R; Cook, DJ; Cooper, DJ; Crowther, M; Ferguson, ND; Finfer, S; Guyatt, G; Heels-Ansdell, D; Holbrook, A; Lamontagne, F; Levine, MAH; Li, G; Thabane, L; Walter, SD, 2015) |
| "Venous thromboembolism (VTE) has a significant impact on healthcare costs but is largely preventable with anticoagulant prophylaxis using low-molecular-weight heparins (LMWHs), such as enoxaparin or dalteparin." | 5.17 | Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. ( Brosa, M; Diamantopoulos, A; Folkerts, K; Imberti, D; Monreal, M, 2013) |
| " The phase III RECORD programme compared rivaroxaban with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement surgery in more than 12,500 patients." | 5.17 | Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). ( Berkowitz, SD; Homering, M; Llau, JV; Loewe, A; Mueck, W; Rosencher, N, 2013) |
| " Apixaban, a specific factor Xa inhibitor, may provide effective thromboprophylaxis with a low risk of bleeding and improved ease of use." | 5.14 | Apixaban or enoxaparin for thromboprophylaxis after knee replacement. ( Chen, D; Gallus, A; Lassen, MR; Pineo, G; Portman, RJ; Raskob, GE, 2009) |
| "In patients undergoing hip or knee arthroplasty, enoxaparin and dabigatran showed similar rates of efficacy and bleeding." | 5.14 | Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. ( Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S, 2010) |
| " Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use." | 5.14 | Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. ( Chen, D; Gallus, A; Lassen, MR; Pineo, G; Ramirez, LM; Raskob, GE, 2010) |
| "The aim of the EXTEND study was to assess safety and efficacy of extended administration (35 days) of ximelagatran or enoxaparin for the prevention of venous thromboembolism after elective hip replacement and hip fracture surgery." | 5.14 | Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. ( Agnelli, G; Andersson, M; Bergqvist, D; Boberg, B; Bylock, A; Cohen, AT; Dahl, OE; Eriksson, BI; Jensen, E; Lassen, MR; Mouret, P; Rosencher, N, 2009) |
| "The goal of this study was to evaluate glycoprotein IIb/IIIa inhibition with eptifibatide when administered with indirect thrombin inhibition as compared with monotherapy with direct thrombin inhibition with bivalirudin among patients with non-ST-segment elevation acute coronary syndromes (ACS)." | 5.12 | A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. ( Braunwald, E; Bulle, T; Cohen, DJ; Fish, P; Gibson, CM; Jennings, LK; Kovach, R; Lakkis, N; Lui, HH; McCabe, CH; Morrow, DA; Murphy, SA; Palabrica, TM; Stone, PH, 2006) |
| "Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile." | 5.12 | Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. ( Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN, 2007) |
| " Masked postoperative examinations assessed visual acuity, intraocular pressure (IOP), anterior chamber cell and flare, and fibrin formation with slitlamp examinations 1, 3, 7, 30, and 90 days after surgery." | 5.12 | Inhibition of intraocular fibrin formation after infusion of low-molecular-weight heparin during combined phacoemulsification-trabeculectomy surgery. ( Abdollahi, A; Amini, H; Azimi, R; Eslami, Y; Fakhraii, G; Moghimi, S; Zarei, R, 2006) |
| " The objective of this study was to evaluate the efficacy of dalteparin during lower-limb immobilization after surgical treatment of Achilles tendon rupture." | 5.12 | Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. ( de Bri, E; Elvin, A; Lapidus, LJ; Lärfars, G; Levander, C; Ponzer, S; Rosfors, S, 2007) |
| "Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery." | 5.11 | A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. ( Ahnfelt, L; Bravo, ML; Büller, HR; Dahl, OE; Eriksson, BI; Hettiarachchi, R; Kälebo, P; Piovella, F; Reilly, P; Rosencher, N; Stangier, J, 2005) |
| "We compared enoxaparin and adjusted-dose warfarin with respect to their safety and their efficacy in the prevention of clinically important venous thromboembolic disease, defined as distal or proximal deep venous thrombosis or pulmonary embolism, or both, during hospitalization after total hip arthroplasty." | 5.09 | Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. ( Bigler, GT; Collis, DK; Colwell, CW; Hardwick, ME; Lutz, S; McCutchen, JW; Paulson, R, 1999) |
| " Rates of overall venous thromboembolism (and proximal deep vein thrombosis or pulmonary embolism) for the 8-, 12-, 18-, and 24-mg doses of ximelagatran were 27% (6." | 5.09 | Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. ( Berkowitz, SD; Colwell, CW; Francis, CW; Ginsberg, JS; Heit, JA; Peters, G; Whipple, J, 2001) |
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 5.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| " The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12." | 5.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| "To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted dose warfarin in preventing venous thromboembolism after knee arthroplasty." | 5.08 | Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. ( Cruickshank, M; Delorme, F; Demers, C; Desjardins, L; Geerts, WH; Kassis, J; L'Espérance, B; Laflamme, GH; Leclerc, JR; Whitman, L, 1996) |
| "The meta-analysis indicated that rivaroxaban prophylaxis was associated with lower rates of symptomatic venous thromboembolism (VTE) (relative risk[RR]:0." | 4.98 | Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis. ( Huang, HF; Li, SS; Tian, XB; Xie, Q; Yang, XT, 2018) |
| " This study aims to use a network meta-analysis to compare effects of 9 anticoagulant drugs (edoxaban, dabigatan, apixaban, rivaroxaban, warfarin, heparin, bemiparin, ximelagatran, and enoxaparin) in preventing postoperative complications in arthroplasty patients." | 4.95 | Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. ( Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX, 2017) |
| " The cluster ranking of major outcomes indicated that FXI-ASO, ardeparin, aspirin, and apixaban were ideal for preventing all-cause VTE and avoiding all bleeding events." | 4.95 | Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis. ( Chen, X; Jin, Y; Wang, Z; Xiang, Y; Zhao, Y; Zheng, J, 2017) |
| "To compare the cost-effectiveness of warfarin or enoxaparin with no prophylaxis for prevention of venous thromboembolism in patients undergoing total knee replacement (TKR) or knee arthroplasty." | 4.81 | Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty. ( Martin, BC; Nerurkar, J; Wade, WE, 2002) |
| "Dalteparin is an LMWH indicated for patients undergoing abdominal surgery who are considered to be at risk for deep-vein thrombosis (DVT), which may lead to pulmonary embolism (PE)." | 4.79 | Dalteparin: a low-molecular-weight heparin. ( Howard, PA, 1997) |
| " Of the 7 readmissions in the enoxaparin group, one was due to bleeding requiring transfusion; there were no readmissions for bleeding in the apixaban group." | 4.31 | Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy. ( Covens, A; Geerts, W; Gien, LT; Kupets, R; Lin, Y; Spénard, E; Vicus, D, 2023) |
| "This study aims to validate the application of a multicriteria decision analysis in a real-world problem, the use of rivaroxaban and enoxaparin to prevent deep venous thrombosis." | 3.96 | Multi-Criteria Model for Evaluating Drugs to Prevent Deep Venous Thrombosis Associated With Orthopedic Surgery: A Hospital-Based Case Study. ( Morais, QCD; Santos, MS, 2020) |
| "To compare the efficacy and safety of aspirin with rivaroxaban following treatment with enoxaparin for prevention of venous thromboembolism (VTE) after hip fracture surgery (HFS)." | 3.91 | Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery. ( Huang, Q; Shen, B; Si, HB; Xing, SX; Zeng, Y; Zhou, ZK, 2019) |
| "To analyze the cost-utility of oral dabigatran etexilate, enoxaparin sodium injection, and no intervention for venous thromboembolism (VTE) prophylaxis after total hip or knee replacement (THR/TKR) surgery among Thai patients." | 3.85 | A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand. ( Chaiyakunapruk, N; Chongmelaxme, B; Kotirum, S, 2017) |
| "The aim of this study was to evaluate the cost-effectiveness of rivaroxaban and apixaban versus enoxaparin for the universal prophylaxis of venous thromboembolism (VTE) and associated long-term complications in Chinese patients after total hip replacement (THR)." | 3.85 | Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China. ( Gu, X; Lin, H; Wu, B; Xu, Z; Yan, X, 2017) |
| "To evaluate the occurrence of bleeding and venous thromboembolic (VTE) events in patients receiving rivaroxaban, warfarin, or warfarin with the addition of enoxaparin during the immediate postoperative period following major orthopedic surgery." | 3.85 | Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital. ( Cieri, NE; Hassan, AK; Kusmierski, K; Lackie, C; Van Opdorp, A, 2017) |
| "Rivaroxaban is a cost-effective alternative to enoxaparin for VTE prophylaxis in patients undergoing THR and TKR." | 3.85 | Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. ( Ananthapavan, J; Diamantopoulos, A; Forster, F; Lees, M; McDonald, H; Wells, PS, 2010) |
| "An uncommon case of delayed-onset dalteparin-induced skin necrosis in an 83-year-old Caucasian female patient associated with heparin-induced thrombocytopaenia (HIT) presenting on day 30 following dalteparin therapy is reported." | 3.85 | Delayed-onset heparin-induced skin necrosis: a rare complication of perioperative heparin therapy. ( Gan, WK, 2017) |
| "Our experience with rivaroxaban in elective hip and knee arthroplasty showed no significant difference in the incidence of VTE or major bleeding." | 3.79 | Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. ( Jeer, P; Rose, B; Saran, D; Shrivastava, R; Sindali, K; Soueid, H, 2013) |
| "Treatment with dalteparin reduced the risk of death and myocardial infarction in high-risk (i." | 3.79 | Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial. ( Wallentin, L, 2000) |
| "This study compared the effectiveness of a change from enoxaparin to dalteparin for the prophylaxis of patients at risk of venous thromboembolism (VTE)." | 3.78 | Comparative effectiveness of dalteparin and enoxaparin in a hospital setting. ( Carson, W; Choe, Y; Faria, C; Parks, C; Powers, A; Schilling, B; Simons, WR, 2012) |
| "Our institution has used a thromboprophylaxis regimen consisting of inpatient enoxaparin and outpatient aspirin for patients at standard risk for venous thrombosis after hip and knee arthroplasty." | 3.78 | Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study. ( Anderson, BJ; Bradbury, TL; Erens, GA; Hamilton, SC; Roberson, JR; Whang, WW, 2012) |
| " In this analysis of pooled data from four large, randomised, phase III clinical trials that compared the oral, direct Factor Xa inhibitor rivaroxaban with subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement (n = 12,729), the incidence of complications, including bleeding and adverse events related to surgery (such as wound infection, wound dehiscence and haemarthrosis) are reported." | 3.78 | The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. ( Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Turpie, AG, 2012) |
| "The risk of late thrombosis and pulmonary embolism is discussed from pathogenetic factors and data on frequencies of thromboembolic complications in the literature." | 3.78 | Prolonged prophylaxis against postoperative venous thromboembolism. ( Bergqvist, D, 1996) |
| "A 35-year-old man developed priapism with the use of low-molecular-weight heparin and warfarin following repair of left brachial artery sustained after gunshot injury." | 3.78 | Anticoagulant-induced priapism progressing to penile gangrene: a devastating complication! ( Goel, A; Kumar, A; Nagathan, DS; Pahwa, HS, 2012) |
| "To compare the efficacy, in the prevention of venous thromboembolism (VTE), and safety, of rivaroxaban and dabigatran relative to the common comparator enoxaparin." | 3.77 | An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. ( Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P, 2011) |
| "Oral dabigatran etexilate is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement or total hip replacement." | 3.76 | Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. ( Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2010) |
| "The purpose of this study was to determine the clinical outcomes of abciximab combined with the low molecular weight heparin (LMWH), dalteparin, in high-risk percutaneous coronary intervention (PCI) patients with acute myocardial infarction (AMI)." | 3.73 | Comparison of abciximab combined with dalteparin or unfractionated heparin in high-risk percutaneous coronary intervention in acute myocardial infarction patients. ( Ahn, YK; Cho, JG; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, KH; Kim, W; Park, JC, 2006) |
| "Warfarin-induced skin necrosis is a rare complication associated with the use of oral anticoagulants." | 3.72 | A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. ( Alexander, JB; Ierardi, R; Tai, CY, 2004) |
| "Many orthopaedic surgeons use warfarin to prevent venous thromboembolism (VTE) following hip or knee arthroplasty." | 3.72 | Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty. ( Brotman, DJ; Hurbanek, JG; Jaffer, AK; Morra, N, 2004) |
| "Of 263 patients who underwent total knee arthroplasty, 122 received adjusted low-dose warfarin and 141 received enoxaparin as deep vein thrombosis (DVT) prophylaxis." | 3.70 | Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty. ( O'Connor, D; Stern, SH; Wixson, RL, 2000) |
| " The dose-response relationship with twice-daily milvexian was significant (one-sided P<0." | 3.01 | Milvexian for the Prevention of Venous Thromboembolism. ( Ageno, W; Gailani, D; Hylek, EM; Lassen, MR; Mahaffey, KW; Notani, RS; Raskob, GE; Roberts, R; Segers, A; Strony, J; Weitz, JI, 2021) |
| "Short-term (3 days) use of enoxaparin was shown to be effective and safe for VTE prophylaxis, comparable to regular use (at least 7 days), in postoperative management of gastric cancer surgery." | 3.01 | Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study. ( Fujiwara, T; Hinotsu, S; Kagawa, S; Kakiuchi, Y; Kikuchi, S; Kuroda, S; Kuwada, K; Nishizaki, M; Tsumura, T; Watanabe, M, 2021) |
| "Venous thromboembolism is an important patient safety issue in thoracic surgery patients." | 2.94 | Fixed or Weight-Tiered Enoxaparin After Thoracic Surgery for Venous Thromboembolism Prevention. ( Barnett, S; Bertolaccini, C; Fleming, KI; Lin, J; Moulton, L; Pannucci, CJ; Stringham, J; Varghese, TK, 2020) |
| " Secondary outcomes included incidence of venous thromboembolic events, adverse events, medication adherence, participant quality of life, and medication satisfaction." | 2.94 | Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. ( Babayan, LM; Behbakht, K; Breed, CA; Brennecke, A; Cheng, G; Corr, BR; Flink, D; Guntupalli, SR; Lefkowits, C; Matsuo, K; Ramzan, AA; Sheeder, J; Tayebnejad, A; Wheeler, LJ, 2020) |
| "Proximal deep vein thrombosis and/or pulmonary embolism occurred in seven patients (3·4 per cent) in the IPC group and one patient (0·5 per cent) in the IPC with enoxaparin group (P = 0·050)." | 2.94 | Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial. ( Amano, T; Funakoshi, T; Homma, S; Ichikawa, N; Kamachi, H; Kawamura, H; Maeda, Y; Ohno, Y; Takahashi, N; Taketomi, A; Yokota, R; Yoshida, T, 2020) |
| "This study aimed to assess whether low-molecular-weight heparin (LMWH) is effective and safe in preventing postoperative venous thromboembolism (VTE) in patients undergoing esophageal cancer surgery." | 2.90 | Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study. ( Hirata, S; Matsuhashi, N; Sakuratani, T; Shimokawa, T; Tanaka, H; Tanaka, Y; Yamada, A; Yamaguchi, K; Yoshida, K, 2019) |
| " Patients were significantly more likely to achieve an in-range peak aFXa with real-time dose adjustment as opposed to fixed dosing alone (85." | 2.90 | Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. ( Bertolaccini, CB; Fleming, KI; Huang, LC; Pannucci, CJ; Pickron, TB; Prazak, AM, 2019) |
| " Future research should examine the impact of weight-based once daily enoxaparin dosing versus twice daily enoxaparin dosing on prophylaxis adequacy." | 2.87 | Enoxaparin 40 mg per Day Is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgical Procedure. ( Fleming, KI; Holoyda, K; Moulton, L; Pannucci, CJ; Prazak, AM; Varghese, TK, 2018) |
| " In addition, the incidence of all enoxaparin treatment- and operation-related adverse events was investigated." | 2.87 | Prophylaxis of Postoperative Venous Thromboembolism Using Enoxaparin After Esophagectomy: A Prospective Observational Study of Effectiveness and Safety. ( Baba, H; Baba, Y; Hiyoshi, Y; Imamura, Y; Ishimoto, T; Iwatsuki, M; Miyamoto, Y; Watanabe, M; Yoshida, N, 2018) |
| " In conclusion, this study suggests that 40 mg once daily of Ce, a biosimilar enoxaparin, is as effective and safe as the branded Sanofi enoxaparin in the prophylaxis of VTE in patients submitted to major abdominal surgery at risk for VTE." | 2.87 | Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial. ( Afiune, JB; Agati, L; Aguiar, VCR; Araujo, GR; Assao, VT; Caffaro, RA; Caltabiano, TB; Castelli, V; Colnago, EMDS; Correa, JA; Costa, AJV; DalAcqua, LZ; Davila, R; de Lima, TAM; de Souza, DG; Ferreira, U; Fugii, EY; Magella, FM; Matheus, WE; Mussalem, JS; Neto, SG; Osvaldt, AB; Pazetto, LE; Ramacciotti, E; Raymundo, SRO; Rodrigues, DG; Russeff, GJDS; Sato, DY; Toffoletto, O; Volpiani, GG, 2018) |
| "Among 94 patients, weight-based dosing ranged from 0." | 2.84 | Weight-Based Dosing for Once-Daily Enoxaparin Cannot Provide Adequate Anticoagulation for Venous Thromboembolism Prophylaxis. ( Fleming, KI; Hunt, MM; Pannucci, CJ; Prazak, AM, 2017) |
| "The primary outcome was deep vein thrombosis (DVT) identified by color Doppler ultrasonography and/or pulmonary embolism (PE)." | 2.84 | Enoxaparin versus No Anticoagulation Prophylaxis after Total Knee Arthroplasty in Thai Patients: A Randomized Controlled Trial. ( Intiyanaravut, T; Kunopart, M; Sinthuvanich, N; Teavirat, S; Thongpulsawasdi, N, 2017) |
| "Dabigatran is an effective oral alternative to enoxaparin for thromboprophylaxis as demonstrated by the RE-NOVATE II study global results." | 2.84 | Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study. ( Babhulkar, S; Clemens, A; Dadi, A; Iyer, R; Kamath, S; Malhotra, R; Mody, B; Mutha, S; Reddy, G; Sanjib, KB; Shah, V; Shetty, N; Tapasvi, S; Wadhwa, M, 2017) |
| "No episodes of transfusion, pulmonary embolism, or major bleeding occurred in either group." | 2.84 | Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study. ( Huang, Q; Ma, J; Pei, F; Xie, J; Yue, C, 2017) |
| "This manuscript establishes inadequate enoxaparin dosing as a plausible mechanism for breakthrough VTE in surgical patients, and identifies anticoagulant dose adequacy as a novel target for process improvement measures." | 2.82 | Low Anti-Factor Xa Level Predicts 90-Day Symptomatic Venous Thromboembolism in Surgical Patients Receiving Enoxaparin Prophylaxis: A Pooled Analysis of Eight Clinical Trials. ( Bertolaccini, C; Fleming, KI; Huang, LC; Momeni, A; Pannucci, CJ; Pickron, TB; Prazak, AM; Stringham, J; Varghese, TK, 2022) |
| "There were 23 patients with hemophilia, 18 (78%) with hemophilia A and 5 (22%) with hemophilia B, who underwent high-risk surgeries (39% THR and 61% TKA)." | 2.82 | Thromboprophylaxis and Incidence of Venous Thromboembolism in Patients With Hemophilia A or B Who Underwent High-Risk Orthopedic Surgeries. ( Akbar, SA; Doll, DC; Dong, X; Freter, CE; Holm, L; Hopkins, T; Hossain, AM; Kale, G; Kim, D; Naidzionak, U; Raza, S, 2016) |
| "Body weight is a better predictor of anti-Xa levels compared to lean body weight." | 2.80 | Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels. ( Brandjes, DP; Celik, F; Gerdes, VE; Hooijberg, JH; Huitema, AD; van de Laar, AW, 2015) |
| "Our current dosing practice of 40 mg SC for individuals with a BMI ≤50 kg/m(2) and 60 mg for individuals with a BMI ≥50 kg/m(2) resulted in anti-factor Xa activity that was sufficient for adequate thromboprophylaxis in adolescent bariatric surgical patients." | 2.80 | Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study. ( Mushtaq, A; Nadler, EP; van den Anker, JN; Vaughns, JD; Ziesenitz, VC, 2015) |
| "Prevention of deep venous thrombosis (DVT) and associated pulmonary embolism following major orthopedic surgeries is challenging, and there is an increased interest in developing new treatment strategies." | 2.80 | Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement. ( Altıntaş, F; Önal, A; Özler, T; Uluçay, Ç, 2015) |
| "Venous thromboembolism is an important complication following major abdominal surgery." | 2.79 | Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. ( Agnelli, G; Fisher, W; George, D; Kakkar, AK; Lassen, MR; Lawson, F; Mismetti, P; Mouret, P; Murphy, J; Turpie, AG, 2014) |
| "The aim of this study was to evaluate the pharmacodynamic parameters of two doses of the LMWH parnaparin administered to patients undergoing bariatric surgery." | 2.74 | Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). ( Baldini, E; Cini, M; De Paoli, M; Guerra, M; Imberti, D; Legnani, C; Nicolini, A; Palareti, G; Zanardi, A, 2009) |
| "There are limited data on appropriate dosing of low-molecular-weight heparins (LMWHs) for venous thromboembolism (VTE) prophylaxis in bariatric surgery." | 2.73 | Prophylaxis of thromboembolism in bariatric surgery with parnaparin. ( Cuocolo, A; De Caterina, M; Ferrari, P; Forestieri, P; Formato, A; Pilone, V; Quarto, G; Ruocco, A, 2007) |
| "Eight (1." | 2.73 | Safety of deep venous thrombosis prophylaxis with low-molecular-weight heparin in brain surgery. Prospective study on 746 patients. ( Chibbaro, S; Tacconi, L, 2008) |
| "The optimal thromboprophylactic dosage regimen of low-molecular-weight heparins in high-risk general surgery remains debatable." | 2.72 | A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. ( Bergman, JF; Derlon, A; Laporte, S; Mismetti, P; Samama, CM; Samii, K; Simonneau, G, 2006) |
| " The primary efficacy analysis did not demonstrate any significant trend in dose-response relationship for BAY 59-7939." | 2.72 | Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. ( Borris, L; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F, 2006) |
| "Ximelagatran was to be initiated within the first two postoperative days." | 2.71 | Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. ( Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N, 2003) |
| "After undergoing surgery for a ruptured aneurysm, 170 patients were randomized in a prospective, double-blind, placebo-controlled trial to test the effect of enoxaparin on the occurrence of ischemic lesions, which were demonstrated on follow-up CT scans available for 156 patients." | 2.71 | Risk factors for ischemic lesions following aneurysmal subarachnoid hemorrhage. ( Juvela, S; Porras, M; Poussa, K; Siironen, J; Varis, J, 2005) |
| "Warfarin dosing with a target international normalized ratio (INR) range of 1." | 2.71 | Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005) |
| "The incidences of fatal pulmonary embolism and death in surgical patients receiving low-molecular-weight heparin thromboprophylaxis have not been previously determined in large, adequately designed clinical trials and information on the relative efficacy and safety of unfractionated and low-molecular-weight heparin in preventing these clinical endpoints is not available." | 2.71 | Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. ( Encke, A; Fareed, J; Haas, S; Kakkar, AK; Wolf, H, 2005) |
| "Fatal pulmonary embolism was significantly more frequent in cancer patients (0." | 2.71 | Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. ( Encke, A; Haas, S; Kakkar, AK; Wolf, H, 2005) |
| " In morbidity obese patients, the limited number of comparative trials are too sparse to allow a consensus on the effective dose and dosing schedule." | 2.70 | Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. ( Dimitrakopoulos, A; Kalfarentzos, F; Karamesini, M; Kehagias, I; Maniati, A; Stavropoulou, F; Yarmenitis, S, 2001) |
| "Deep vein thrombosis was assessed by routine bilateral contrast venography performed between postoperative day 5 and 9, or earlier if clinically suspected." | 2.70 | Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. ( Anderson, DR; Atkinson, KG; Barton, P; Burnstein, M; Burul, CJ; Geerts, WH; Greenwood, C; Gregoire, RC; Marshall, JC; McLeod, RS; Ross, T; Silverman, RE; Sniderman, KW; Taylor, BM; Wilson, SR, 2001) |
| " However, different LMWHs vary significantly in their pharmacokinetic profile and bioavailability pattern." | 2.70 | [Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients]. ( Bergauer, F; Hagena, FW; Janni, W; Lohscheidt, K; Rjosk, D, 2001) |
| "Venous thromboembolism is a frequent complication of total hip replacement." | 2.70 | A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. ( Gallus, AS; Hoek, JA; Turpie, AG, 2001) |
| " We did a multicentre, randomised, double-blind study to examine the dose-response relation of subcutaneous melagatran, a direct thrombin inhibitor, followed by oral ximelagatran as thromboprophylaxis after total hip or knee replacement." | 2.70 | Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. ( Bergqvist, D; Bylock, A; Dahl, OE; Eriksson, BI; Eriksson, UG; Frison, L; Gustafsson, D; Kälebo, P; Lindbratt, S; Welin, L, 2002) |
| "Venous thrombosis was diagnosed in two patients receiving low molecular weight heparin and in one patient receiving external pneumatic compression." | 2.70 | Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. ( Carroll, B; Clarke-Pearson, DL; Dodge, R; Maxwell, GL; Synan, I, 2001) |
| " The study did not evaluate a dose-response for efficacy, and no differences between the three dose levels of melagatran and ximelagatran were shown." | 2.70 | A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in ( Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P, 2002) |
| "The composite endpoint of screened deep vein thrombosis (DVT) and symptomatic pulmonary embolism (PE) during prophylaxis did not differ significantly between patients with or without these mutations." | 2.70 | Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. ( Andersson, C; Bylock, A; Eriksson, BI; Frison, L; Gustafsson, D; Larson, G; Lindahl, TL; Wåhlander, K, 2002) |
| " We conclude that one daily subcutaneous injection of calcium nadroparin in a fixed, weight-adjusted dosage scheme is superior to intermittent pneumatic compression of the foot for thromboprophylaxis after TKA." | 2.69 | Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. ( Blanchard, J; Bounameaux, H; Didier, D; Hoffmeyer, P; Leyvraz, PF; Meuwly, JY; Miron, MJ; Schneider, PA, 1999) |
| "The overall incidence of deep venous thrombosis was 42% (33 of 78 patients)." | 2.69 | How "gold" is the standard? Interobservers' variation on venograms. ( Al-Kutoubi, A; Cunningham, DA; Kalodiki, E; Mandalia, S; Nicolaides, AN, 1998) |
| " However, body weight-adjusted dosage of low-molecular-weight heparin may be cumbersome and could lead possibly to incorrect dosing." | 2.69 | Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. ( Büller, HR; Harenberg, J; Huisman, MV; Koppenhagen, K; Schmidt, JA; Tolle, A, 2000) |
| " Bleeding complications and other adverse events were registered throughout the study period." | 2.69 | Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. ( Andersen, G; Anderson, BS; Appelquist, E; Borris, LC; Christensen, F; Erin-Madsen, J; Hansen, BR; Hvidt, P; Hørlyck, E; Jensen, BV; Jensen, HP; Jensen, NK; Jørgensen, PS; Lassen, MR; Møller, JC; Nielsen, AB; Nielsen, JB; Paaske, B; Petersen, AO; Rotwitt, L; Siem, P; Skejø Bro, HP; Thomsen, PB; Tjalve, E; Tørholm, C, 1998) |
| "Bleeding was determined according to pre-defined objective criteria for major and minor episodes." | 2.68 | Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. ( Büller, HR; d'Azemar, P; Gent, M; Haley, S; Henkens, CM; Hoek, JA; Koopman, MM; Nurmohamed, MT; Que, GT; Sicurella, A; ten Cate, JW; Turpie, AG; van der Heul, C; van der Meer, J; van Riel, AM, 1996) |
| " In these clinical studies, Enoxaparin, 30 mg twice daily, was shown to be as effective and safe as low dose unfractionated heparin to prevent deep venous thrombosis after hip arthroplasty." | 2.68 | Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. ( Colwell, CW; Spiro, TE, 1995) |
| "There was only one pulmonary embolism (PE) in a patient belonging to UH-group (1." | 2.68 | Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. ( Avikainen, V; Hakkinen, S; Kaaja, R; Kaira, P; Partio, E; Usenius, JP; von Bonsdorff, H, 1995) |
| "The incidence of silent pulmonary embolism (PE) (new defect on V/Q scan) was 28% (8 out of 29) in patients with and 5% (2 out of 43) in patients without DVT (chi 2; p < 0." | 2.68 | Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. ( al-Kutoubi, A; Birch, R; Cunningham, DA; Fareed, J; Gill, K; Harris, N; Hoppensteadt, DA; Hunt, D; Johnson, J; Kalodiki, EP; Marx, C; Nicolaides, AN; Regan, F, 1996) |
| " Safety outcomes were defined as the occurrence of major and minor haemorrhage, other adverse events and changes in laboratory parameters." | 2.68 | Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. ( Bellaud, M; Compan, D; Darmon, JY; Fagola, M; Huet, Y; Planes, A; Saliba, E; Vochelle, N; Weisslinger, N, 1996) |
| "Bleeding was assessed on the basis of intraoperative blood loss, transfusion requirements, a decrease in hematocrit, and clinically identified bleeding complications." | 2.68 | Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. ( Ayers, DC; Boyd, AD; Francis, CW; Johanson, NA; Kessler, C; Liebert, KM; Marder, VJ; Pellegrini, VD; Rosenberg, A; Stulberg, BN; Totterman, S, 1997) |
| " Excessive bleeding, on the basis of specified criteria, severe adverse effects, or occurrence of clinically detected venous thromboembolism was classified as failure." | 2.67 | Safety of enoxaparin and dextran-70 in the prevention of venous thromboembolism in digestive surgery. A play-the-winner-designed study. ( Andersen, OK; Larsen, S; Lund, H; Løvig, T; Mowinckel, P; Reiertsen, O; Størkson, R; Trondsen, E, 1993) |
| "The incidence of DVT and of pulmonary embolism was 4." | 2.67 | An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. ( Boneu, B, 1993) |
| " Inadequate enoxaparin dosing has been correlated with both asymptomatic and symptomatic VTE events." | 2.55 | Utility of anti-factor Xa monitoring in surgical patients receiving prophylactic doses of enoxaparin for venous thromboembolism prophylaxis. ( Pannucci, CJ; Prazak, AM; Scheefer, M, 2017) |
| "Two enoxaparin dosage regimens are used as comparators to evaluate new anticoagulants for thromboprophylaxis in patients undergoing major orthopaedic surgery, but so far no satisfactory direct comparison between them has been published." | 2.50 | Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs. ( Bertoletti, L; Chapelle, C; Cucherat, M; Darmon, JY; Laporte, S; Lega, JC; Mismetti, P; Zufferey, PJ, 2014) |
| " Of note, for both filters and augmented pharmacologic dosing strategies, patients at highest risk for VTE were more likely to receive more intensive interventions, limiting our ability to attribute outcomes to prophylactic strategies used." | 2.49 | Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. ( Brotman, DJ; Chelladurai, Y; Haut, ER; Kebede, S; Prakasa, KR; Segal, JB; Sharma, R; Shermock, K; Shihab, HM; Singh, S, 2013) |
| "It presents as an acute spinal cord compression and usually requires emergency surgical decompression." | 2.48 | [Spontaneous resolution of a paraparesis due to a dorsolumbar epidural haematoma associated with subarachnoid anaesthesia and postoperative analgesia using an epidural catheter]. ( Alemán Martín, A; Coronado Hijón, V; Jiménez Delgado, P; Sánchez Gutiérrez, C, 2012) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 2.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| " Selection of the appropriate dosage is strongly recommended." | 2.45 | Safety evaluation of enoxaparin in currently approved indications. ( Meneveau, N, 2009) |
| " Furthermore, there is no difference according to liver enzymes elevation and cardio-vascular adverse events." | 2.44 | [Rivaroxaban (Xarelto): efficacy and safety]. ( Arnaout, L; Bellamy, L; Chabbouh, T; Rosencher, N, 2008) |
| "Retroperitoneal hematomas are often fatal, and treatment involves aggressive fluid resuscitation with possible surgical decompression." | 2.43 | Massive retroperitoneal hematoma during enoxaparin treatment of pulmonary embolism after primary total hip arthroplasty: case reports and review of the literature. ( Lee, MC; Limbird, RS; Nickisch, F, 2006) |
| "Fondaparinux has been recently approved for use in thromboprophylaxis after major orthopedic surgery." | 2.42 | New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2003) |
| " Due to a longer plasma half life together with high bioavailability and a linear dose-response relationship, the drugs can be safely and effectively administered in the hospital or ambulatory settings without the need to monitor the anticoagulant effect." | 2.42 | Clinical application of enoxaparin. ( Hofmann, T, 2004) |
| "Fondaparinux was also used, with promising results, in prophylaxis in patients undergoing major abdominal surgery and high risk medical patients." | 2.42 | Pentasaccharides. The new anticoagulants. ( Abdel-Razeq, H, 2004) |
| "Guidelines for deep venous thrombosis (DVT) and pulmonary embolism (PE) prophylaxis have been developed for patients undergoing total hip arthroplasty (THA)." | 2.41 | Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty. ( Hawkins, DW; Wade, WE, 2000) |
| " As prophylaxis, reviparin 1,750 anti-XaIU once daily was as effective as unfractionated heparin 5,000IU twice daily in 1,311 patients undergoing abdominal surgery and, in a once daily dosage of 4,200 anti-XaIU, was as effective as subcutaneous enoxaparin sodium 40 mg/day or acenocoumarol in patients undergoing hip replacement surgery." | 2.41 | Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism. ( Jarvis, B; McClellan, K; Wellington, K, 2001) |
| "Dalteparin is a low molecular weight heparin (LMWH) with a mean molecular weight of 5000." | 2.41 | Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. ( Dunn, CJ; Jarvis, B, 2000) |
| " Compared with unfractionated heparin (UFH), nadroparin has a greater ratio of anti-factor Xa to anti-factor Ha activity, greater bioavailability and a longer duration of action, allowing it to be administered by subcutaneous injection for prophylaxis or treatment of thromboembolic disorders." | 2.40 | Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. ( Davis, R; Faulds, D, 1997) |
| " Moreover, subcutaneous parnaparin has a greater bioavailability and longer half-life than heparin, permitting once-daily administration for the prophylaxis of deep venous thrombosis (DVT) or the treatment of established vascular disorders." | 2.39 | Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. ( Faulds, D; Frampton, JE, 1994) |
| " In comparative clinical trials, this dosage demonstrated either improved efficacy and a similar haemorrhagic profile, or a similar degree of efficacy with a lower rate of haemorrhagic events, compared with unfractionated heparin 5000IU 3 times daily." | 2.39 | Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. ( Goa, KL; Noble, S; Peters, DH, 1995) |
| " The enhanced bioavailability of these drugs, in conjunction with their prolonged half-life, makes subcutaneous therapy, in one to two daily doses, possible." | 2.39 | Low molecular weight heparins and their use in obstetrics and gynecology. ( Fejgin, MD; Lourwood, DL, 1994) |
| "Four trials of enoxaparin (involving 567 patients) and six trials of warfarin (involving 630) met the following criteria: randomized controlled trial, prophylaxis started no later than 24 hours after surgery and continued for at least 7 days, warfarin dose monitored and adjusted appropriately, enoxaparin dosage 30 mg twice daily, and DVT confirmed by bilateral venography." | 2.39 | Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. ( Anderson, DR; Goeree, R; O'Brien, BJ, 1994) |
| " Studies have shown that weight-based dosing influences significantly both the time to reach a therapeutic intensity of anticoagulation and the incidence of thromboembolic recurrence." | 2.39 | Contemporary use of and future roles for heparin in antithrombotic therapy. ( Gibaldi, M; Wittkowsky, AK, 1995) |
| " Further clinical trials are required to test different dosage regimens as a thromboprophylactic agent in high risk patients." | 2.39 | Patients at risk of venous thromboembolism--clinical results with reviparin. ( Cohen, AT; Kakkar, VV; Mohamed, MS, 1996) |
| "The incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) after total joint arthroplasty (TJA) procedures are lower in Asian populations than in Caucasian populations." | 1.91 | Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population. ( Chang, WL; Chen, CF; Chen, WM; Chou, TA; Pai, FY; Tsai, SW; Wu, PK, 2023) |
| "Aspirin 81 mg was cost-effective if the initial symptomatic VTE rates decreased by an absolute risk reduction (ARR) of 0." | 1.72 | Cost-Effective Modeling of Thromboembolic Chemoprophylaxis for Total Ankle Arthroplasty. ( Aynardi, MC; Bonaddio, V; Kirchner, GJ; Koroneos, Z; Lorenz, FJ; Manto, KM; Martinazzi, BJ; Stauch, CM, 2022) |
| "The overall purpose of this study was to describe the impact of a tinzaparin weight-band dosing table for VTE prophylaxis on wound healing, thrombosis, and bleeding outcomes in patients undergoing total joint arthroplasty." | 1.72 | Impact of Weight-Band Dosing of Tinzaparin for Venous Thromboembolism Prophylaxis on Persistent Wound Drainage in Adult Patients Undergoing Hip and Knee Arthroplasty. ( Antle, O; Cooper, C; Dersch-Mills, D; Kenny, A; Lowerison, J, 2022) |
| "Oral apixaban is an effective alternative to enoxaparin as a thromboprophylactic drug for patients undergoing elective total knee replacement surgery." | 1.62 | Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study. ( Ali Hasan, M; Azeez Alsaadi, M; Tahseen Mehsen, J, 2021) |
| "Treatment with dalteparin or dabigatran was associated with a decreased 90-day risk of VTE following primary TKA surgery compared with treatment with rivaroxaban." | 1.62 | Thromboembolic and bleeding complications following primary total knee arthroplasty : a Danish nationwide cohort study. ( Gromov, K; Jensen, TB; Jimenez-Solem, E; Olesen, JB; Overgaard, S; Petersen, J; Schelde, AB, 2021) |
| "VTE was defined as symptomatic deep vein thrombosis or pulmonary embolism and was confirmed via radiological imaging or autopsy." | 1.56 | Nadroparin Plus Compression Stockings versus Nadroparin Alone for Prevention of Venous Thromboembolism in Cerebellopontine Angle Tumour Excisions: A Cohort Study. ( Cannegieter, SC; Koopmans, RJ; Koot, RW; Vleggeert-Lankamp, CLA, 2020) |
| " Incidence of in-hospital VTE and major bleeding after changes in enoxaparin dosing were monitored." | 1.56 | Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients. ( Kramme, K; Munene, G; Sarraf, P, 2020) |
| " The patient developed a left thigh hematoma requiring surgical evacuation 1 month after initiation of weight-based dosing of enoxaparin." | 1.56 | Successful Long-term Anticoagulation with Enoxaparin in a Patient with a Mechanical Heart Valve. ( Bathini, VG; Korapati, S; Mathew, C; Wang, X, 2020) |
| "Empirically dosed enoxaparin is routinely given in the postoperative period for venous thromboembolism (VTE) prophylaxis after radical cystectomy (RC)." | 1.56 | Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy. ( Ambani, SN; Corona, LE; Hafez, K; Herrel, LA; Kaffenberger, SD; Montgomery, JS; Morgan, TM; Qin, Y; Singhal, U; Weizer, AZ, 2020) |
| "1." | 1.51 | Underdosing of Prophylactic Enoxaparin Is Common in Orthopaedic Trauma and Predicts 90-Day Venous Thromboembolism. ( Fleming, KI; Higgins, TF; Jones, DL; Jones, WA; Pannucci, CJ; Rothberg, DL; Zhang, Y, 2019) |
| " Real-time enoxaparin dose adjustment significantly increased the proportion of patients who achieved in-range peak aFXa levels, compared to standard dosing (74." | 1.48 | Anti-Factor Xa measurements in acute care surgery patients to examine enoxaparin dose. ( Fleming, KI; Lonardo, N; Nirula, R; Nunez, J; Pannucci, CJ; Shipley, RW; Tonna, JE; Wall, V, 2018) |
| "A personal history of malignancy and type 2 diabetes increase the risk of PMVT." | 1.48 | Assessing risk factors, presentation, and management of portomesenteric vein thrombosis after sleeve gastrectomy: a multicenter case-control study. ( Blanco, DG; Boyce, SG; De La Cruz-Munoz, N; Domkowski, P; Funes, DR; Ghanem, M; Jawad, MA; Menzo, EL; Moon, RC; Radecke, J; Rosenthal, R; Teixeira, AF; Young, MK, 2018) |
| "Based on pharmacodynamic data, the majority of plastic surgery patients receive inadequate enoxaparin prophylaxis using fixed dosing." | 1.46 | Inadequate Enoxaparin Dosing Predicts 90-Day Venous Thromboembolism Risk among Plastic Surgery Inpatients: An Examination of Enoxaparin Pharmacodynamics. ( Agarwal, J; Fleming, KI; Ghanem, M; Momeni, A; Pannucci, CJ; Rockwell, WB, 2017) |
| "Delayed catheter-related intracranial hemorrhage is not rare after a ventriculoperitoneal (VP) or ventriculoatrial (VA) shunt for the treatment of hydrocephalus." | 1.46 | Delayed Catheter-Related Intracranial Hemorrhage After a Ventriculoperitoneal or Ventriculoatrial Shunt in Hydrocephalus. ( Gao, L; Pandey, S; Qian, Z; Wang, K, 2017) |
| "Twelve additional patients experienced deep vein thrombosis and 6 had pulmonary embolism." | 1.46 | Abdominal thrombotic complications following bariatric surgery. ( Elazary, R; Kalish, Y; Rottenstreich, A, 2017) |
| " The primary outcome was the incidence of symptomatic pulmonary embolism after surgery, and the secondary outcome was the incidence of bleeding as an adverse effect of enoxaparin injection." | 1.46 | Safety and efficacy of postoperative pharmacologic thromboprophylaxis with enoxaparin after pancreatic surgery. ( Adachi, T; Eguchi, S; Fujita, F; Hidaka, M; Imamura, H; Kitasato, A; Kuroki, T; Soyama, A; Takatsuki, M; Tanaka, T, 2017) |
| "Apixaban is a new oral anticoagulant with the potential to overcome these limitations." | 1.43 | Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. ( Dickison, DM; King, DA; Pow, RE; Vale, PR, 2016) |
| " In the patients of both groups the product dabigatran etexilate in the standard dosage (220 mg/day) was used for specific prevention." | 1.43 | [Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities]. ( Akhtyamov, IF; Shigaev, ES; Ziatdinov, BG, 2016) |
| " The usage of enoxaparin for venous thromboembolism prophylaxis is safe for Japanese patients after gastrectomy." | 1.43 | Safety and Effectiveness of Enoxaparin as Venous Thromboembolism Prophylaxis after Gastric Cancer Surgery in Japanese Patients. ( Kusanagi, H; Yanagita, T, 2016) |
| " We administered body-weight adjusted full dose of low-molecular weight heparin (enoxaparin) in a therapeutic dosage for 10 days." | 1.42 | Penile Mondor's syndrome after endovenous treatment of the great saphenous vein with 1470 nm diode laser. ( Knittel, M; Schwarz, T; Zeller, T; Zerweck, C, 2015) |
| "Outpatient implantation of implantable cardioverter-defibrillators is safe and reduces costs." | 1.42 | Safety of Outpatient Implantation of the Implantable Cardioverter-defibrillator. ( Arenal Maíz, Á; Atienza Fernández, F; Ávila Alonso, P; Datino, T; Eidelman, G; Fernández-Avilés, F; González-Torrecilla, E; Hernández-Hernández, J; Miracle Blanco, Á; Núñez García, A, 2015) |
| "We also investigated the occurrence of pulmonary embolism (PE) and its associated risk factors." | 1.42 | Prophylactic effect of fondaparinux and enoxaparin for preventing pulmonary embolism after total hip or knee arthroplasty: A retrospective observational study using the Japanese Diagnosis Procedure Combination database. ( Fushimi, K; Horiguchi, H; Kadono, Y; Matsuda, S; Shoda, N; Tanaka, S; Yasunaga, H, 2015) |
| " Thirty patients undergoing unilateral or bilateral total knee replacement, admitted to the intensive care unit on a therapeutic dosage of subcutaneous enoxaparin (30-mg injections administered twice daily), were included into the study." | 1.42 | Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgery. ( Kaso, G; Tekkesin, M; Tekkesin, N, 2015) |
| "Incidences of symptomatic deep vein thrombosis (DVT) and PE, and major or minor bleeding complications were evaluated." | 1.42 | Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients. ( Cho, KJ; Fang, R; Kim, TK; Kim, YH; Na, YG, 2015) |
| "Changes in the hemostasis system in choledocholithiasis, taking into account the obturation jaundice severity and possibility of the correction conduction, using miniinvasive operative interventions, were studied." | 1.40 | [Changes of the hemostasis system in patients with obturation jaundice caused by choledocholithiasis, and possibilities of their correction with the help of miniinvasive operative interventions]. ( Tkachenko, AI, 2014) |
| "Rivaroxaban does not increase the risk of hidden blood loss for TKA when compared with enoxaparin, but enoxaparin can increase the risk of dominant blood." | 1.40 | [Comparison of rivaroxaban and enoxaparin on blood loss after total knee arthroplasty]. ( Jing, J; Li, J; Yao, Y; Zhan, J; Zhou, Y, 2014) |
| "Symptomatic pulmonary embolism constitutes a significant risk following abdominal flap breast reconstruction." | 1.39 | Pulmonary embolism after abdominal flap breast reconstruction: prediction and prevention. ( Damen, THC; Enajat, M; Geenen, A; Mureau, MAM; Timman, R; van der Hulst, RRWJ, 2013) |
| "A patient with a history of intracranial hemorrhage who was hospitalized due to massive pulmonary thromboembolism (PTE) was presented." | 1.39 | [Intracranial hemorrhage due to pulmonary thromboembolism in heparin therapy and therapeutic management of patients hospitalized with massive pulmonary embolism after discharge]. ( Alişir, MF; Beşli, F; Güngören, F; Keçebaş, M, 2013) |
| "Venous thromboembolism and subsequent pulmonary embolism are frequent and sometimes fatal complications in patients after surgical interventions." | 1.39 | [Compliance of patients undergoing thromboprophylaxis with enoxaparin: the COMFORT study]. ( Guschmann, M; Kaiser, J; Rübenacker, S, 2013) |
| "Patients undergoing elective colorectal cancer surgery from 2007 to 2009 at the Royal Adelaide and Queen Elizabeth hospitals were identified from a prospective database." | 1.39 | Is extended thromboprophylaxis necessary in elective colorectal cancer surgery? ( Chandra, R; Hunter, RA; Lawrence, MJ; Melino, G; Moore, J; Thomas, M, 2013) |
| "Apixaban is a direct factor Xa inhibitor that has been shown in clinical trial use to safely reduce the composite of VTE and mortality rates in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA); however, the cost-effectiveness of apixaban treatment in Canadian settings has not been studied." | 1.39 | A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. ( El-Hadi, W; Kadambi, A; Patterson, J; Raymond, V; Revankar, N, 2013) |
| "Increased perioperative thromboprophylaxis dosage does not increase pericardial effusion rates or mortality in proximal aortic surgery." | 1.39 | NICE thromboprophylaxis guidelines are not associated with increased pericardial effusion after surgery of the proximal thoracic aorta. ( Bryan, AJ; Davies, A; Hussain, A; Rahman, IA, 2013) |
| "One fatal pulmonary embolism was recorded (1/1093, 0." | 1.39 | Therapeutic effect of low-molecular weight heparin and incidence of lower limb deep venous thrombosis and pulmonary embolism after laparoscopic bariatric surgery. ( Al-Asfar, F; Al-Bader, I; Al-Mozaini, A; Fingerhut, A; Khoursheed, M; Marouf, R; Sayed, A, 2013) |
| " The aim of this retrospective study was to measure the therapeutic response to standard dosing with LMWH (using anti-Xa) in patients after ablative and reconstructive surgery for head and neck cancer, and to review the associated risk of bleeding." | 1.39 | Low molecular weight heparin in patients undergoing free tissue transfer following head and neck ablative surgery: review of efficacy and associated complications. ( Eley, KA; Parker, RJ; Watt-Smith, SR, 2013) |
| "Dependent variables included symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) within the first 60 postoperative days and time to DVT or PE." | 1.37 | Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. ( Bailey, SH; Dreszer, G; Fisher Wachtman, C; Hamill, JB; Hoxworth, RE; Hume, KM; Jaber, RM; Kalliainen, LK; Neligan, PC; Pannucci, CJ; Pusic, AL; Rubin, JP; Wilkins, EG; Zumsteg, JW, 2011) |
| "He was initially diagnosed with a pulmonary thromboembolism." | 1.37 | Metastatic osteosarcoma presenting as a single pulmonary microembolus. ( Chin, C; Midulla, P; Shapiro, M; Wistinghausen, B, 2011) |
| "Venous thromboembolism is a major patient safety issue." | 1.37 | Postoperative enoxaparin prevents symptomatic venous thromboembolism in high-risk plastic surgery patients. ( Bailey, SH; Dreszer, G; Hamill, JB; Hoxworth, RE; Hume, KM; Kalliainen, LK; Pannucci, CJ; Portschy, PR; Pusic, AL; Rubin, JP; Wachtman, CF; Wilkins, EG, 2011) |
| "Rivaroxaban has been recommended for routine use as a thromboprophylactic agent in patients undergoing lower-limb arthroplasty." | 1.37 | Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. ( Jensen, CD; Muller, SD; Partington, PF; Reed, MR; Steval, A, 2011) |
| "Fondaparinux is an effective and safe alternative." | 1.36 | Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. ( Ageno, W; Capri, S; Imberti, D; Moia, M; Palareti, G; Piovella, F; Scannapieco, G, 2010) |
| " Standard enoxaparin dosing was defined as 0." | 1.36 | Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients. ( Blanc, PD; Boettger, RF; Golden, J; Hoopes, C; Huang, MY; Hui, C; Leard, LE; Singer, JP; Watkins, K, 2010) |
| "To evaluate the rates of deep vein thrombosis (DVT) and pulmonary embolism (PE) in hip fracture patients receiving mechanical thromboprophylaxis." | 1.36 | Mechanical thromboprophylaxis for patients undergoing hip fracture surgery. ( Lee, HC; Loh, JS; Mehta, KV, 2010) |
| "Gastrointestinal stromal tumors are the commonest stromal tumors of the digestive tract." | 1.36 | [Gastrointestinal stromal tumor in pregnancy and control. Case report]. ( Cuerva-González, MJ; de la Calle-Fernández, M; Lacoponi, S; Pozo-Krielinger, J, 2010) |
| "Body weight is an important risk factor for thromboses and is used in algorithms to determine dosages in prophylaxis." | 1.35 | A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. ( Grohs, JG; Lunzer, A; Vavken, P, 2009) |
| " They analyzed rates of documented symptomatic venous thromboembolism (VTE) (deep vein thrombosis and pulmonary embolism) confirmed by objective methods, major bleeding, death, thrombocytopenia, and other adverse events." | 1.35 | Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice. ( Fontcuberta, J; Gómez-Outes, A; Martínez-González, J; Otero-Fernández, R; Rocha, E, 2008) |
| "Fondaparinux was associated with significantly lower costs and fewer VTEs compared to enoxaparin without an increase in bleed rates or all-cause inpatient mortality." | 1.35 | Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery. ( Farias-Eisner, R; Franklin, M; Happe, LE; Horblyuk, R; Lunacsek, OE, 2009) |
| "Patients with brain tumors including intracranial meningiomas are at increased risk for developing deep vein thrombosis (DVTs) and suffering thromboembolic events (VTEs)." | 1.35 | Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas. ( Berger, MS; Cage, TA; Chakalian, L; Frankfurt, A; Lamborn, KR; McDermott, MW; Ware, ML, 2009) |
| "Many cancer patients are still poorly assessed for risk of VTE." | 1.34 | Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. ( Altimiras, J; Balibrea, JL; Gómez-Outes, A; Larruzea, I; Martínez-González, J; Rocha, E, 2007) |
| "Dalteparin was associated with a lower rate of major bleeding events than was fondaparinux, but there were no significant differences in such events among fondaparinux, enoxaparin, and unfractionated heparin." | 1.34 | Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery. ( Farrelly, E; Happe, LE; Peeples, PJ; Sarnes, MW; Shorr, AF; Stanford, RH, 2007) |
| "The incidence of deep venous thrombosis in both cohorts was 0." | 1.34 | Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin. ( Kothari, SN; Lambert, PJ; Mathiason, MA, 2007) |
| "When a hematoma is large, the initial clinical picture may include hypovolemic shock, which may develop during surgery if the hematoma is not diagnosed early." | 1.33 | [Hypovolemic shock during surgery caused by a rectus sheath hematoma]. ( García, R; López-Escobar, M; Medina, C; Torres, LM; Vidal, MA, 2005) |
| "After 48 h, the rate of venous thrombosis, as evaluated microscopically, was significantly decreased in hemodiluted animals (1/8) as compared with controls (10/10); in rats treated with dextran-40 (7/10) and enoxaparin (5/10) the rate of venous thrombosis was significantly higher as compared with rats of the group hemodiluted." | 1.33 | Comparative study of isovolemic hemodilution with 3% albumin, dextran-40, and prophylactic enoxaparin (LMWH) on thrombus formation at venous microanastomosis in rats. ( Campos, AD; Farina, JA; Piccinato, CE; Rossi, MA, 2006) |
| "epigastrica superficialis." | 1.32 | [Serious complication after subcutaneous injection of heparin for prophylaxis of thromboembolism. Case report]. ( Andereya, S; Buschmeier, M; Hopf, KF; Kälicke, T; Muhr, G, 2003) |
| " Dosing was determined individually by the investigators with a goal of maintaining an AT activity of 80 to 150 percent." | 1.32 | Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. ( Bauer, KA; Bonfiglio, J; Greist, A; Holmes, HE; Konkle, BA; Weinstein, R, 2003) |
| " The rates of minor bleeding complications in the aspirin group, the < 12-hour postoperative dosing of the enoxaparin group, and the 12 to 24-hour postoperative dosing of the enoxaparin group were 3." | 1.32 | Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting. ( Ennis, RS, 2003) |
| "The early detection of deep venous thrombosis (DVT) and treatment with systemic anticoagulation to prevent pulmonary embolism (PE) are essential in the management of patients undergoing total joint arthroplasty (TJA)." | 1.32 | Surveillance venous duplex is not clinically useful after total joint arthroplasty when effective deep venous thrombosis prophylaxis is used. ( Endean, ED; Hartford, JM; Kwolek, CJ; Matthews, MR; Mentzer, RM; Minion, DJ; Quick, RC; Schwarcz, TH, 2004) |
| " Low-molecular-weight heparins prevent venous thrombosis as effectively as heparin and have better bioavailability and a longer plasma half-life, which explains the increased use of low-molecular-weight heparins as substitutes for heparin in clinical practice." | 1.32 | Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. ( Arnljots, B; Dahlbäck, B; Malm, K, 2003) |
| " The drugs are marked by bioavailability approximating 100%, linear dose-dependent pharmacokinetic profile at subcutaneous injection; they do not undergo metabolism and are excreted largely with urine." | 1.32 | [Prevention and treatment of venous thromboses and thromboembolism: pentasaccharides as novel anticoagulants selectively blocking Xe factor, their position and potential (data of the XIX International Congress on Thromboses and Hemostasis)]. ( Averkov, OV, 2004) |
| "We investigated the incidence of venous thrombosis in patients hospitalised from 1992 to 1996 and related our findings to literature reports." | 1.31 | Thrombosis prophylaxis in hospitalised medical patients: does prophylaxis in all patients make sense? ( den Heijer, M; Nijs, AM; Schuurman, B, 2000) |
| "Deep venous thrombosis is 1 of the most common postoperative complications resulting in significant mortality and morbidity in patients undergoing total hip and total knee arthroplasty." | 1.31 | Noncompliance in the inpatient administration of enoxaparin in conjunction with epidural or spinal anesthesia. ( Bailey, M; Del Schutte, H; McEvoy, MD; Taylor, D, 2000) |
| "Major bleeding was defined as a postoperative drop of > or = 5 g/dL) of hemoglobin." | 1.31 | Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery. ( Abdullah, H; Camblin, J; Fareed, J; Hakki, SI; Hamadeh, O; Hoppensteadt, DA; Nasseri, AF; Wright, T, 2000) |
| "Thromboprophylaxis with 60 mg enoxaparin daily, in split doses, starting before surgery, is safe and appropriate in patients with hip fractures." | 1.31 | Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. ( Greiner, N; Korninger, C; Roller, RE; Sim, E; Thaler, HW, 2001) |
| "Dalteparin and warfarin treatment was started, and symptoms relieved rapidly." | 1.31 | Superior mesenteric and portal vein thrombosis following laparoscopic nissen fundoplication. ( Kemppainen, E; Kiviluoto, T; Kokkola, A; Sirén, J, 2000) |
| " Incremental cost-effectiveness ratio calculations demonstrate that warfarin dosed to an international normalized ratio of 2-2." | 1.31 | Cost effectiveness of deep venous thrombosis prophylaxis after hip fracture. ( Chisholm, MA; Wade, WE, 2000) |
| "A 77-year-old man developed chronic disseminated intravascular coagulation (DIC) after surgical repair of a large infrarenal aortic aneurysm." | 1.31 | Chronic disseminated intravascular coagulation after surgery for abdominal aortic aneurysm: clinical and haemostatic response to dalteparin. ( Awad, R; Cummins, D; Hunt, BJ; Maddox, A; Segal, H, 2001) |
| "We found evidence of only parietal thrombus formation 3 times (10%) in the arteries and 4 times (13." | 1.29 | [Histologic changes in ligated stumps of ovarian blood vessels in preoperative low-molecular weight preventive heparin administration]. ( Slunsky, R, 1995) |
| "No deep venous thrombosis and no pulmonary embolism were observed." | 1.29 | [General perioperative prevention of thromboembolism in gynecology with low-molecular weight heparin: clinical experiences with enoxaparin over 7 years]. ( Slunsky, R, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 106 (19.17) | 18.2507 |
| 2000's | 197 (35.62) | 29.6817 |
| 2010's | 193 (34.90) | 24.3611 |
| 2020's | 57 (10.31) | 2.80 |
| Authors | Studies |
|---|---|
| Koopmans, RJ | 1 |
| Cannegieter, SC | 1 |
| Koot, RW | 1 |
| Vleggeert-Lankamp, CLA | 1 |
| van der Veen, L | 1 |
| Segers, M | 1 |
| van Raay, JJ | 1 |
| Gerritsma-Bleeker, CL | 1 |
| Brouwer, RW | 1 |
| Veeger, NJ | 1 |
| van Hulst, M | 1 |
| Atamanova, EA | 1 |
| Andryukhin, MI | 1 |
| Vasilenko, IA | 1 |
| Makarov, OV | 1 |
| Mihaljević, Z | 1 |
| Dimnjaković, D | 1 |
| Tripković, B | 1 |
| Buljan, M | 1 |
| Aljinović, A | 1 |
| Delimar, D | 1 |
| Bićanić, G | 1 |
| Enajat, M | 1 |
| Damen, THC | 1 |
| Geenen, A | 1 |
| Timman, R | 1 |
| van der Hulst, RRWJ | 1 |
| Mureau, MAM | 1 |
| Heckmann, M | 1 |
| Thermann, H | 1 |
| Heckmann, F | 1 |
| Bruntink, MM | 1 |
| Groutars, YME | 1 |
| Schipper, IB | 1 |
| Breederveld, RS | 1 |
| Tuinebreijer, WE | 1 |
| Derksen, RJ | 1 |
| Adişen, E | 1 |
| Seker, U | 1 |
| Gürer, MA | 1 |
| Camporese, G | 1 |
| Bernardi, E | 1 |
| Noventa, F | 1 |
| Galimov, OV | 1 |
| Galeev, FS | 1 |
| Khanov, VO | 1 |
| Mukhametov, AR | 1 |
| Andreev, PP | 1 |
| Muslimova, LR | 1 |
| Aminova, LN | 1 |
| O'Flaherty, M | 1 |
| Lerum, K | 1 |
| Martin, P | 1 |
| Grassi, D | 1 |
| Reznikov, AV | 1 |
| Driuk, NF | 1 |
| Betrosian, AP | 1 |
| Theodossiades, G | 1 |
| Lambroulis, G | 1 |
| Kostantonis, D | 1 |
| Balla, M | 1 |
| Papanikolaou, M | 1 |
| Georgiades, G | 1 |
| Hartung, O | 1 |
| Miranda, E | 1 |
| Alimi, YS | 1 |
| Juhan, C | 1 |
| Gerlach, R | 1 |
| Raabe, A | 1 |
| Beck, J | 1 |
| Woszczyk, A | 1 |
| Seifert, V | 1 |
| Kutlay, J | 1 |
| Ozer, Y | 1 |
| Isik, B | 1 |
| Kargici, H | 1 |
| Bergqvist, D | 9 |
| Vidal, MA | 1 |
| López-Escobar, M | 1 |
| Medina, C | 1 |
| García, R | 1 |
| Torres, LM | 1 |
| Simonneau, G | 1 |
| Laporte, S | 3 |
| Mismetti, P | 4 |
| Derlon, A | 1 |
| Samii, K | 1 |
| Samama, CM | 3 |
| Bergman, JF | 1 |
| Pavlović, S | 1 |
| Zivković, S | 1 |
| Koraćević, G | 1 |
| Holland, K | 1 |
| Schain, FH | 2 |
| Sisková, E | 1 |
| Cernák, A | 1 |
| Pont'uchová, E | 1 |
| Doganov, N | 1 |
| Iarŭkov, A | 1 |
| Mladenova, A | 1 |
| Doncheva, O | 1 |
| Ogoĭska, I | 1 |
| Mironov, SP | 1 |
| Burmakova, GM | 1 |
| Fedotova, TM | 1 |
| Nurmohamed, MT | 1 |
| van Riel, AM | 1 |
| Henkens, CM | 1 |
| Koopman, MM | 1 |
| Que, GT | 1 |
| d'Azemar, P | 1 |
| Büller, HR | 8 |
| ten Cate, JW | 1 |
| Hoek, JA | 2 |
| van der Meer, J | 1 |
| van der Heul, C | 1 |
| Turpie, AG | 13 |
| Haley, S | 1 |
| Sicurella, A | 1 |
| Gent, M | 4 |
| Haentjens, P | 2 |
| Mabilia, MA | 1 |
| Minicucci, S | 1 |
| Pettiti, G | 1 |
| Tamponi, G | 1 |
| Bogli, F | 1 |
| Davis, R | 1 |
| Faulds, D | 2 |
| Llau, JV | 2 |
| Hoyas, L | 1 |
| Ezpeleta, J | 1 |
| García-Polit, J | 1 |
| Martyin, T | 1 |
| Jakucs, J | 1 |
| Iványi, J | 1 |
| Kis, E | 1 |
| Varga, I | 1 |
| Mellár, E | 1 |
| Suri, C | 1 |
| Liptay, L | 1 |
| Gáspár, L | 1 |
| Lloyd, A | 1 |
| Aitken, JA | 1 |
| Hoffmeyer, UK | 1 |
| Kelso, EJ | 1 |
| Wakerly, EC | 1 |
| Barber, ND | 1 |
| Blanchard, J | 1 |
| Meuwly, JY | 1 |
| Leyvraz, PF | 1 |
| Miron, MJ | 1 |
| Bounameaux, H | 4 |
| Hoffmeyer, P | 1 |
| Didier, D | 2 |
| Schneider, PA | 1 |
| Goldberg, A | 1 |
| Kobza, II | 1 |
| Lisets'kyĭ, VA | 1 |
| Lukashevych, AB | 1 |
| Oliĭnychenko, HP | 1 |
| Kliusov, OM | 1 |
| Iatsenko, SM | 1 |
| Kalfarentzos, F | 1 |
| Stavropoulou, F | 1 |
| Yarmenitis, S | 1 |
| Kehagias, I | 1 |
| Karamesini, M | 1 |
| Dimitrakopoulos, A | 1 |
| Maniati, A | 1 |
| Schaepkens Van Riempst, JT | 1 |
| Van Hee, RH | 1 |
| Weyler, JJ | 1 |
| Imberti, D | 3 |
| Legnani, C | 1 |
| Baldini, E | 1 |
| Cini, M | 1 |
| Nicolini, A | 1 |
| Guerra, M | 1 |
| De Paoli, M | 1 |
| Zanardi, A | 1 |
| Palareti, G | 2 |
| Forestieri, P | 1 |
| Quarto, G | 1 |
| De Caterina, M | 1 |
| Cuocolo, A | 1 |
| Pilone, V | 1 |
| Formato, A | 1 |
| Ruocco, A | 1 |
| Ferrari, P | 2 |
| Frampton, JE | 1 |
| Yu, R | 1 |
| Nansubuga, F | 1 |
| Yang, J | 2 |
| Ding, W | 1 |
| Li, K | 1 |
| Weng, D | 1 |
| Wu, P | 1 |
| Chen, G | 1 |
| Ma, D | 1 |
| Wei, J | 1 |
| Beghi, C | 1 |
| Fragnito, C | 1 |
| Antonelli, A | 1 |
| Reverberi, C | 1 |
| Saccani, S | 1 |
| Fesani, F | 1 |
| Sagüillo, K | 1 |
| Pérez-Flecha, F | 1 |
| Almeida, F | 1 |
| Picón, M | 1 |
| Acero, J | 1 |
| Revilla-Peñaloza, F | 1 |
| Olsoff-Pagovich, PJ | 1 |
| Ochoa-Gomez, JR | 1 |
| Castaneda-Gaxiola, R | 1 |
| Rubio-Gayosso, ÁI | 1 |
| Ceballos, G | 1 |
| Molina-Guarneros, JA | 1 |
| Gao, JH | 1 |
| Chu, XC | 1 |
| Wang, LL | 1 |
| Ning, B | 1 |
| Zhao, CX | 1 |
| Muñoz-Atienza, V | 1 |
| Gil-Rendo, A | 1 |
| Amo-Salas, M | 1 |
| Núñez-Guerrero, P | 1 |
| Martín-Fernández, J | 1 |
| Beşli, F | 1 |
| Keçebaş, M | 1 |
| Alişir, MF | 1 |
| Güngören, F | 1 |
| Muñoa, L | 1 |
| González, AB | 1 |
| Díaz de Rada, P | 1 |
| Valentí, A | 1 |
| Valentí, JR | 1 |
| Tkachenko, AI | 1 |
| Vavken, P | 1 |
| Lunzer, A | 1 |
| Grohs, JG | 1 |
| San Juan Alvarez, M | 1 |
| Márquez Garrido, G | 1 |
| Rodríguez Bertos, C | 1 |
| González Pérez, L | 1 |
| Planès, A | 8 |
| Balibrea, JL | 1 |
| Altimiras, J | 1 |
| Larruzea, I | 1 |
| Gómez-Outes, A | 3 |
| Martínez-González, J | 2 |
| Rocha, E | 2 |
| Otero-Fernández, R | 1 |
| Fontcuberta, J | 1 |
| Kakkar, VV | 5 |
| Howes, J | 1 |
| Sharma, V | 1 |
| Kadziola, Z | 1 |
| Weitz, JI | 5 |
| Strony, J | 1 |
| Ageno, W | 3 |
| Gailani, D | 2 |
| Hylek, EM | 1 |
| Lassen, MR | 17 |
| Mahaffey, KW | 1 |
| Notani, RS | 1 |
| Roberts, R | 1 |
| Segers, A | 3 |
| Raskob, GE | 7 |
| Gosnell, H | 1 |
| Stein, A | 1 |
| Vanegas Acosta, DE | 1 |
| Byrne, EM | 1 |
| Khattab, A | 1 |
| Chen, F | 1 |
| Bhagavatula, R | 1 |
| Martinazzi, BJ | 1 |
| Kirchner, GJ | 1 |
| Stauch, CM | 1 |
| Lorenz, FJ | 1 |
| Manto, KM | 1 |
| Bonaddio, V | 1 |
| Koroneos, Z | 1 |
| Aynardi, MC | 1 |
| Sidhu, VS | 3 |
| Kelly, TL | 1 |
| Pratt, N | 1 |
| Graves, SE | 1 |
| Buchbinder, R | 1 |
| Adie, S | 2 |
| Cashman, K | 1 |
| Ackerman, I | 1 |
| Bastiras, D | 1 |
| Brighton, R | 1 |
| Burns, AWR | 1 |
| Chong, BH | 1 |
| Clavisi, O | 1 |
| Cripps, M | 1 |
| Dekkers, M | 1 |
| de Steiger, R | 1 |
| Dixon, M | 1 |
| Ellis, A | 1 |
| Griffith, EC | 1 |
| Hale, D | 1 |
| Hansen, A | 1 |
| Harris, A | 1 |
| Hau, R | 1 |
| Horsley, M | 2 |
| James, D | 1 |
| Khorshid, O | 1 |
| Kuo, L | 1 |
| Lewis, P | 1 |
| Lieu, D | 2 |
| Lorimer, M | 1 |
| MacDessi, S | 1 |
| McCombe, P | 1 |
| McDougall, C | 1 |
| Mulford, J | 1 |
| Naylor, JM | 2 |
| Page, RS | 1 |
| Radovanovic, J | 1 |
| Solomon, M | 1 |
| Sorial, R | 1 |
| Summersell, P | 1 |
| Tran, P | 2 |
| Walter, WL | 1 |
| Webb, S | 1 |
| Wilson, C | 1 |
| Wysocki, D | 1 |
| Harris, IA | 4 |
| Saadoun, R | 1 |
| Bengur, FB | 1 |
| Moroni, EA | 1 |
| Surucu, Y | 1 |
| Veit, JA | 1 |
| Khan, NI | 1 |
| Daniels, K | 1 |
| Rothenberger, SD | 1 |
| Kubik, M | 1 |
| Solari, MG | 1 |
| Sridharan, S | 1 |
| Maradei-Pereira, JAR | 3 |
| Sauma, ML | 3 |
| Demange, MK | 3 |
| Hsu, CH | 1 |
| Chen, CH | 1 |
| Hsu, NC | 1 |
| Hsu, CC | 1 |
| Hsu, CJ | 1 |
| Wei, JC | 1 |
| DeMik, DE | 1 |
| Mont, MA | 1 |
| Dunbar, M | 1 |
| Walker, R | 1 |
| Kim, RG | 1 |
| Alsehly, AA | 1 |
| Wang, TF | 1 |
| Carrier, M | 2 |
| Kulkarni, NS | 1 |
| Spénard, E | 1 |
| Geerts, W | 1 |
| Lin, Y | 1 |
| Gien, LT | 1 |
| Kupets, R | 1 |
| Covens, A | 1 |
| Vicus, D | 1 |
| Reiter, AJ | 1 |
| Prinz, J | 1 |
| Li, Y | 1 |
| Nagle, AP | 1 |
| Hungness, ES | 1 |
| Teitelbaum, EN | 1 |
| Tsai, SW | 1 |
| Chang, WL | 1 |
| Pai, FY | 1 |
| Chou, TA | 1 |
| Chen, CF | 2 |
| Wu, PK | 1 |
| Chen, WM | 2 |
| Palmieri, A | 1 |
| Hicks, V | 1 |
| Aikman, N | 1 |
| Borowsky, M | 1 |
| Haggerty, A | 1 |
| ElSahwi, K | 1 |
| Dziri, C | 1 |
| Ben Hmida, W | 1 |
| Dougaz, W | 1 |
| Khalfallah, M | 1 |
| Samaali, I | 1 |
| Jerraya, H | 1 |
| Bouasker, I | 1 |
| Nouira, R | 1 |
| Batakji, M | 1 |
| Theodore, D | 1 |
| Jones, DL | 1 |
| Jones, WA | 1 |
| Fleming, KI | 11 |
| Higgins, TF | 1 |
| Rothberg, DL | 1 |
| Zhang, Y | 1 |
| Pannucci, CJ | 18 |
| Vasilakis, V | 1 |
| Klein, GM | 1 |
| Trostler, M | 1 |
| Mukit, M | 1 |
| Marquez, JE | 1 |
| Dagum, AB | 1 |
| Khan, SU | 1 |
| Huang, Q | 2 |
| Xing, SX | 1 |
| Zeng, Y | 1 |
| Si, HB | 1 |
| Zhou, ZK | 1 |
| Shen, B | 1 |
| Pelargos, PE | 1 |
| Dunn, IF | 1 |
| Yun, R | 1 |
| Sciubba, DM | 1 |
| Lewin, JJ | 1 |
| Streiff, MB | 1 |
| Haut, ER | 2 |
| Lau, BD | 1 |
| Shermock, KM | 1 |
| Kraus, PS | 1 |
| Popoola, VO | 1 |
| Dalpoas, SE | 1 |
| Bao, Y | 1 |
| Zhao, G | 1 |
| Qu, S | 1 |
| Xiong, T | 1 |
| Yao, X | 1 |
| Wu, B | 2 |
| Kramme, K | 1 |
| Sarraf, P | 1 |
| Munene, G | 1 |
| Wang, X | 2 |
| Mathew, C | 1 |
| Korapati, S | 1 |
| Bathini, VG | 1 |
| Bauersachs, R | 1 |
| Becker, B | 1 |
| Berkowitz, SD | 4 |
| Freitas, MCS | 1 |
| Metzig, C | 1 |
| Murphy, RF | 1 |
| Williams, D | 1 |
| Hogue, GD | 1 |
| Spence, DD | 1 |
| Epps, H | 1 |
| Chambers, HG | 1 |
| Shore, BJ | 1 |
| Bertolaccini, C | 3 |
| Moulton, L | 2 |
| Stringham, J | 2 |
| Barnett, S | 1 |
| Lin, J | 1 |
| Varghese, TK | 3 |
| Mula, V | 1 |
| Parikh, S | 1 |
| Suresh, S | 1 |
| Bottle, A | 1 |
| Loeffler, M | 1 |
| Alam, M | 2 |
| Rosencher, N | 9 |
| Girard, P | 2 |
| Llau, J | 1 |
| Mouret, P | 5 |
| Fisher, W | 2 |
| Martínez-Martín, J | 1 |
| Duverger, D | 1 |
| Deygas, B | 1 |
| Presles, E | 1 |
| Cucherat, M | 2 |
| Ní Cheallaigh, S | 1 |
| Fleming, A | 1 |
| Dahly, D | 1 |
| Kehoe, E | 1 |
| O'Byrne, JM | 1 |
| McGrath, B | 1 |
| O'Connell, C | 1 |
| Sahm, LJ | 1 |
| Guntupalli, SR | 2 |
| Brennecke, A | 2 |
| Behbakht, K | 1 |
| Tayebnejad, A | 2 |
| Breed, CA | 1 |
| Babayan, LM | 1 |
| Cheng, G | 1 |
| Ramzan, AA | 1 |
| Wheeler, LJ | 1 |
| Corr, BR | 1 |
| Lefkowits, C | 1 |
| Sheeder, J | 1 |
| Matsuo, K | 1 |
| Flink, D | 1 |
| Carbajal-Mamani, SL | 1 |
| Dideban, B | 1 |
| Schweer, D | 1 |
| Balavage, KT | 1 |
| Chuang, L | 1 |
| Wang, Y | 2 |
| Wang, S | 1 |
| Lee, JH | 1 |
| Amaro, B | 1 |
| Cardenas-Goicoechea, J | 1 |
| Dall, CP | 1 |
| Shaw, N | 1 |
| Egan, J | 1 |
| Carvalho, FL | 1 |
| Galloway, LAS | 1 |
| Krasnow, R | 1 |
| Stamatakis, L | 1 |
| Corona, LE | 1 |
| Singhal, U | 1 |
| Hafez, K | 1 |
| Herrel, LA | 1 |
| Kaffenberger, SD | 1 |
| Montgomery, JS | 1 |
| Morgan, TM | 1 |
| Weizer, AZ | 1 |
| Qin, Y | 1 |
| Ambani, SN | 1 |
| Ross, ME | 1 |
| Glickman, A | 1 |
| Kamachi, H | 1 |
| Homma, S | 1 |
| Kawamura, H | 1 |
| Yoshida, T | 1 |
| Ohno, Y | 1 |
| Ichikawa, N | 1 |
| Yokota, R | 1 |
| Funakoshi, T | 1 |
| Maeda, Y | 1 |
| Takahashi, N | 1 |
| Amano, T | 1 |
| Taketomi, A | 1 |
| Obitsu, T | 1 |
| Tanaka, N | 1 |
| Oyama, A | 1 |
| Ueno, T | 1 |
| Saito, M | 3 |
| Yamaguchi, T | 1 |
| Takagi, A | 1 |
| Rikiyama, T | 1 |
| Unno, M | 2 |
| Naitoh, T | 2 |
| Nozawa, H | 1 |
| Emoto, S | 1 |
| Sonoda, H | 1 |
| Kawai, K | 1 |
| Sasaki, K | 1 |
| Kaneko, M | 1 |
| Murono, K | 1 |
| Ishii, H | 1 |
| Ishihara, S | 1 |
| Huang, LC | 2 |
| Pickron, TB | 2 |
| Prazak, AM | 6 |
| Momeni, A | 4 |
| Morais, QCD | 1 |
| Santos, MS | 1 |
| Chuzi, S | 1 |
| Eucalitto, P | 1 |
| Yee, LM | 1 |
| Yamashita, S | 1 |
| Nishi, M | 1 |
| Ikemoto, T | 1 |
| Yoshikawa, K | 1 |
| Higashijima, J | 1 |
| Tokunaga, T | 1 |
| Takasu, C | 1 |
| Kashihara, H | 1 |
| Eto, S | 1 |
| Yoshimoto, T | 1 |
| Shimada, M | 1 |
| Stillson, JE | 1 |
| Bunch, CM | 1 |
| Gillespie, L | 1 |
| Khan, R | 1 |
| Wierman, M | 1 |
| Pulvirenti, J | 1 |
| Phyu, H | 1 |
| Anderson, S | 1 |
| Al-Fadhl, M | 1 |
| Thomas, AV | 1 |
| Kwaan, HC | 2 |
| Moore, E | 1 |
| Moore, H | 1 |
| Walsh, MM | 1 |
| Runner, RP | 1 |
| Shau, DN | 1 |
| Staley, CA | 1 |
| Roberson, JR | 2 |
| Agarwal, J | 3 |
| Rockwell, WB | 3 |
| Mendenhall, SD | 1 |
| Kwok, A | 1 |
| Goodwin, I | 1 |
| Gociman, B | 1 |
| Kuroda, S | 2 |
| Kikuchi, S | 2 |
| Kakiuchi, Y | 1 |
| Watanabe, M | 2 |
| Kuwada, K | 1 |
| Tsumura, T | 1 |
| Nishizaki, M | 2 |
| Kagawa, S | 2 |
| Hinotsu, S | 2 |
| Fujiwara, T | 2 |
| Ali Hasan, M | 1 |
| Azeez Alsaadi, M | 1 |
| Tahseen Mehsen, J | 1 |
| Verhamme, P | 2 |
| Yi, BA | 1 |
| Salter, J | 1 |
| Bloomfield, D | 1 |
| Ghanem, M | 2 |
| Hwang, HG | 1 |
| Koo, SM | 1 |
| Uh, ST | 1 |
| Kim, YK | 1 |
| Bala, A | 2 |
| Huddleston, JI | 1 |
| Goodman, SB | 1 |
| Maloney, WJ | 1 |
| Amanatullah, DF | 1 |
| Wall, V | 1 |
| Tonna, JE | 1 |
| Nunez, J | 1 |
| Lonardo, N | 1 |
| Shipley, RW | 1 |
| Nirula, R | 1 |
| Sáez-Giménez, B | 1 |
| Berastegui, C | 1 |
| Sintes, H | 1 |
| Perez-Miranda, J | 1 |
| Figueredo, A | 1 |
| López Meseguer, M | 1 |
| Monforte, V | 1 |
| Bravo, C | 1 |
| Santamaría, A | 1 |
| Ramon, MA | 1 |
| Gómez-Ollés, S | 1 |
| Roman, A | 1 |
| Rottenstreich, A | 2 |
| Kleinstern, G | 1 |
| Spectre, G | 1 |
| Da'as, N | 1 |
| Ziv, E | 1 |
| Kalish, Y | 2 |
| Qian, Z | 1 |
| Gao, L | 1 |
| Wang, K | 1 |
| Pandey, S | 1 |
| Jones, CW | 1 |
| Spasojevic, S | 1 |
| Goh, G | 1 |
| Joseph, Z | 1 |
| Wood, DJ | 1 |
| Yates, PJ | 1 |
| Thind, M | 1 |
| Cohen, DA | 1 |
| Hunt, MM | 1 |
| Schomburg, J | 1 |
| Krishna, S | 1 |
| Soubra, A | 1 |
| Cotter, K | 1 |
| Fan, Y | 1 |
| Brown, G | 1 |
| Konety, B | 1 |
| Campbell, ST | 1 |
| Jiang, SY | 1 |
| Gardner, MJ | 1 |
| Bishop, JA | 1 |
| Moon, RC | 1 |
| Teixeira, AF | 1 |
| De La Cruz-Munoz, N | 1 |
| Young, MK | 1 |
| Domkowski, P | 1 |
| Radecke, J | 1 |
| Boyce, SG | 1 |
| Rosenthal, R | 1 |
| Menzo, EL | 1 |
| Blanco, DG | 1 |
| Funes, DR | 1 |
| Jawad, MA | 1 |
| Holoyda, K | 1 |
| Altieri, MS | 1 |
| Hajagos, J | 1 |
| Spaniolas, K | 1 |
| Park, J | 1 |
| Gasparis, AP | 1 |
| Bates, AT | 1 |
| Docimo, S | 1 |
| Talamini, M | 1 |
| Shroyer, AL | 1 |
| Pryor, AD | 1 |
| Indirayani, I | 1 |
| Kalok, A | 1 |
| Nik Ismail, NA | 1 |
| Shah, SA | 1 |
| Lim, PS | 1 |
| Mohamed Ismail, NA | 1 |
| Nur Azurah, AG | 1 |
| Omar, MH | 1 |
| Shafiee, MN | 1 |
| Yoshida, N | 1 |
| Baba, Y | 1 |
| Miyamoto, Y | 1 |
| Iwatsuki, M | 1 |
| Hiyoshi, Y | 1 |
| Ishimoto, T | 1 |
| Imamura, Y | 1 |
| Baba, H | 1 |
| Kelecy, MW | 1 |
| Shutt, T | 1 |
| Rostas, J | 1 |
| Martin, RCG | 1 |
| Intiyanaravut, T | 1 |
| Thongpulsawasdi, N | 1 |
| Sinthuvanich, N | 1 |
| Teavirat, S | 1 |
| Kunopart, M | 1 |
| Hoe, V | 1 |
| Kinnear, N | 1 |
| Christidis, D | 1 |
| O'Connell, H | 1 |
| Ramacciotti, E | 1 |
| Ferreira, U | 1 |
| Costa, AJV | 1 |
| Raymundo, SRO | 1 |
| Correa, JA | 1 |
| Neto, SG | 1 |
| Osvaldt, AB | 1 |
| Agati, L | 1 |
| Aguiar, VCR | 1 |
| Davila, R | 1 |
| Caltabiano, TB | 1 |
| Magella, FM | 1 |
| Volpiani, GG | 1 |
| Castelli, V | 1 |
| Caffaro, RA | 1 |
| DalAcqua, LZ | 1 |
| Matheus, WE | 1 |
| Sato, DY | 1 |
| Russeff, GJDS | 1 |
| de Souza, DG | 1 |
| Pazetto, LE | 1 |
| de Lima, TAM | 1 |
| Colnago, EMDS | 1 |
| Fugii, EY | 1 |
| Mussalem, JS | 1 |
| Assao, VT | 1 |
| Toffoletto, O | 1 |
| Rodrigues, DG | 1 |
| Afiune, JB | 1 |
| Araujo, GR | 1 |
| Fraval, A | 1 |
| Duncan, S | 1 |
| Murray, T | 1 |
| Duggan, J | 1 |
| Tirosh, O | 1 |
| Bawa, H | 1 |
| Weick, JW | 1 |
| Dirschl, DR | 1 |
| Luu, HH | 1 |
| Marques de Marino, P | 1 |
| Rial Horcajo, R | 1 |
| Garcia Grandal, T | 1 |
| Sanchez Hervas, L | 1 |
| Serrano Hernando, FJ | 1 |
| Herraiz Martinez, MA | 1 |
| Coronado Martin, PJ | 1 |
| Einerson, BD | 1 |
| Branch, DW | 1 |
| Ng, QX | 1 |
| Seng, C | 1 |
| Ho, CYX | 1 |
| Yeo, WS | 1 |
| Petersen, PB | 1 |
| Kehlet, H | 1 |
| Jørgensen, CC | 1 |
| Huang, HF | 1 |
| Li, SS | 1 |
| Yang, XT | 1 |
| Xie, Q | 1 |
| Tian, XB | 1 |
| Bassiri-Tehrani, B | 1 |
| Karanetz, I | 1 |
| Bernik, SF | 1 |
| Dec, W | 1 |
| Lehman, JC | 1 |
| Lerman, OZ | 1 |
| Woon, CYL | 1 |
| Shah, RR | 1 |
| Pardi, BM | 1 |
| Schwartz, BE | 1 |
| Goldstein, JM | 1 |
| Cipparrone, NE | 1 |
| Goldstein, WM | 1 |
| Boyle, E | 1 |
| Reid, J | 1 |
| O'Donnell, M | 1 |
| Harkin, D | 1 |
| Badger, S | 1 |
| Haughton, B | 1 |
| Haughton, J | 1 |
| George Norman, J | 1 |
| Navid, A | 1 |
| Allport, K | 1 |
| Andrews, M | 1 |
| Mannan, K | 1 |
| Livesey, J | 1 |
| Koduri, S | 1 |
| Wilkinson, DA | 1 |
| Griauzde, JM | 1 |
| Gemmete, JJ | 1 |
| Maher, CO | 1 |
| Rodarte, RRP | 1 |
| Guimarães, JAM | 1 |
| Franco, JS | 1 |
| Fonseca, L | 1 |
| Nascimento, V | 1 |
| Aramburu, JPG | 1 |
| Barretto, JM | 1 |
| Tanaka, Y | 1 |
| Yamada, A | 1 |
| Hirata, S | 1 |
| Tanaka, H | 1 |
| Sakuratani, T | 1 |
| Matsuhashi, N | 1 |
| Yamaguchi, K | 1 |
| Shimokawa, T | 1 |
| Yoshida, K | 1 |
| Bertolaccini, CB | 1 |
| Kerr, DL | 1 |
| Butler, S | 1 |
| Read, AC | 1 |
| Trepanier, M | 1 |
| Alhassan, N | 1 |
| Sabapathy, CA | 1 |
| Liberman, AS | 1 |
| Charlebois, P | 1 |
| Stein, BL | 1 |
| S Feldman, L | 1 |
| Lee, L | 1 |
| Nakagawa, K | 2 |
| Watanabe, J | 1 |
| Ota, M | 1 |
| Suwa, Y | 1 |
| Suzuki, S | 1 |
| Suwa, H | 1 |
| Momiyama, M | 1 |
| Ishibe, A | 1 |
| Saigusa, Y | 1 |
| Yamanaka, T | 1 |
| Kunisaki, C | 1 |
| Endo, I | 1 |
| Rübenacker, S | 1 |
| Kaiser, J | 1 |
| Guschmann, M | 1 |
| Sindali, K | 1 |
| Rose, B | 1 |
| Soueid, H | 1 |
| Jeer, P | 1 |
| Saran, D | 1 |
| Shrivastava, R | 1 |
| Brotman, DJ | 2 |
| Shihab, HM | 1 |
| Prakasa, KR | 1 |
| Kebede, S | 1 |
| Sharma, R | 1 |
| Shermock, K | 1 |
| Chelladurai, Y | 1 |
| Singh, S | 1 |
| Segal, JB | 1 |
| Li, J | 2 |
| Zhou, Y | 2 |
| Jing, J | 2 |
| Zhan, J | 2 |
| Chandra, R | 1 |
| Melino, G | 1 |
| Thomas, M | 1 |
| Lawrence, MJ | 1 |
| Hunter, RA | 1 |
| Moore, J | 1 |
| Revankar, N | 1 |
| Patterson, J | 1 |
| Kadambi, A | 1 |
| Raymond, V | 1 |
| El-Hadi, W | 1 |
| Monreal, M | 1 |
| Folkerts, K | 1 |
| Diamantopoulos, A | 3 |
| Brosa, M | 1 |
| Collet, JP | 3 |
| Huber, K | 1 |
| Cohen, M | 2 |
| Zeymer, U | 1 |
| Goldstein, P | 1 |
| Pollack, C | 1 |
| Silvain, J | 1 |
| Henry, P | 1 |
| Varenne, O | 1 |
| Carrié, D | 1 |
| Coste, P | 1 |
| Angioi, M | 1 |
| Le Breton, H | 1 |
| Cayla, G | 1 |
| Elhadad, S | 1 |
| Teiger, E | 1 |
| Filippi, E | 1 |
| Aout, M | 1 |
| Vicaut, E | 2 |
| Montalescot, G | 3 |
| Rahman, IA | 1 |
| Hussain, A | 1 |
| Davies, A | 1 |
| Bryan, AJ | 1 |
| Ilhan, O | 1 |
| Ilhan, N | 1 |
| Coşkun, M | 1 |
| Dağlioğlu, MC | 1 |
| Ayhan Tuzcu, E | 1 |
| Ayintap, E | 1 |
| Keskın, U | 1 |
| Oksüz, H | 1 |
| Khoursheed, M | 1 |
| Al-Bader, I | 1 |
| Al-Asfar, F | 1 |
| Sayed, A | 1 |
| Al-Mozaini, A | 1 |
| Marouf, R | 1 |
| Fingerhut, A | 1 |
| Zerweck, C | 1 |
| Knittel, M | 1 |
| Zeller, T | 1 |
| Schwarz, T | 1 |
| Yassin, M | 1 |
| Mitchell, C | 1 |
| Diab, M | 1 |
| Senior, C | 1 |
| Kakkar, AK | 6 |
| Agnelli, G | 6 |
| George, D | 1 |
| Murphy, J | 1 |
| Lawson, F | 1 |
| Changolkar, A | 1 |
| Menditto, L | 1 |
| Shah, M | 1 |
| Puto, K | 1 |
| Farrelly, E | 4 |
| Hayashi, H | 1 |
| Morikawa, T | 1 |
| Yoshida, H | 1 |
| Motoi, F | 1 |
| Okada, T | 1 |
| Mizuma, M | 1 |
| Katayose, Y | 1 |
| Campbell, W | 1 |
| Pierson, J | 1 |
| Cohen-Shohet, R | 1 |
| Mast, BA | 1 |
| Yao, Y | 1 |
| Bytsaĭ, AN | 1 |
| Chapelle, C | 1 |
| Bertoletti, L | 1 |
| Lega, JC | 1 |
| Zufferey, PJ | 1 |
| Darmon, JY | 4 |
| Weber, CF | 1 |
| Meybohm, P | 1 |
| Kramer, S | 1 |
| Linke, R | 1 |
| Risteski, P | 1 |
| Moritz, A | 1 |
| Zacharowski, K | 1 |
| Stein, P | 1 |
| Miesbach, W | 1 |
| Raza, S | 2 |
| Kale, G | 1 |
| Kim, D | 1 |
| Akbar, SA | 1 |
| Holm, L | 1 |
| Naidzionak, U | 1 |
| Hossain, AM | 1 |
| Dong, X | 1 |
| Doll, DC | 1 |
| Freter, CE | 1 |
| Hopkins, T | 1 |
| Song, KY | 1 |
| Yoo, HM | 1 |
| Kim, EY | 1 |
| Kim, JI | 1 |
| Yim, HW | 1 |
| Jeon, HM | 1 |
| Park, CH | 1 |
| Migita, K | 1 |
| Bito, S | 1 |
| Nakamura, M | 1 |
| Miyata, S | 1 |
| Kakizaki, H | 1 |
| Nakayama, Y | 1 |
| Matsusita, T | 1 |
| Furuichi, I | 1 |
| Sasazaki, Y | 1 |
| Tanaka, T | 2 |
| Yoshida, M | 1 |
| Kaneko, H | 1 |
| Abe, I | 1 |
| Mine, T | 1 |
| Ihara, K | 1 |
| Kuratsu, S | 1 |
| Saisho, K | 1 |
| Miyahara, H | 1 |
| Segata, T | 1 |
| Nakagawa, Y | 1 |
| Kamei, M | 1 |
| Torigoshi, T | 1 |
| Motokawa, S | 1 |
| Yamashita, Y | 1 |
| Bekki, Y | 1 |
| Imai, D | 1 |
| Ikegami, T | 1 |
| Yoshizumi, T | 1 |
| Ikeda, T | 1 |
| Kawanaka, H | 1 |
| Nishie, A | 1 |
| Shirabe, K | 1 |
| Maehara, Y | 1 |
| Celik, F | 1 |
| Huitema, AD | 1 |
| Hooijberg, JH | 1 |
| van de Laar, AW | 1 |
| Brandjes, DP | 1 |
| Gerdes, VE | 1 |
| Datino, T | 1 |
| Miracle Blanco, Á | 1 |
| Núñez García, A | 1 |
| González-Torrecilla, E | 1 |
| Atienza Fernández, F | 1 |
| Arenal Maíz, Á | 1 |
| Hernández-Hernández, J | 1 |
| Ávila Alonso, P | 1 |
| Eidelman, G | 1 |
| Fernández-Avilés, F | 1 |
| Bethune, C | 1 |
| Bhanot, S | 1 |
| Monia, BP | 1 |
| Shoda, N | 1 |
| Yasunaga, H | 1 |
| Horiguchi, H | 1 |
| Fushimi, K | 1 |
| Matsuda, S | 1 |
| Kadono, Y | 1 |
| Tanaka, S | 1 |
| Patel, N | 1 |
| Singhal, D | 1 |
| Mushtaq, A | 1 |
| Vaughns, JD | 1 |
| Ziesenitz, VC | 1 |
| Nadler, EP | 1 |
| van den Anker, JN | 1 |
| Russell, CE | 1 |
| Wadhera, RK | 1 |
| Piazza, G | 1 |
| Squizzato, A | 1 |
| Lussana, F | 1 |
| Cattaneo, M | 1 |
| Nagata, C | 1 |
| Tanabe, H | 1 |
| Takakura, S | 1 |
| Narui, C | 1 |
| Yanaihara, N | 1 |
| Okamoto, A | 1 |
| Ong, WL | 1 |
| Koh, TL | 1 |
| Fletcher, J | 1 |
| Gruen, R | 1 |
| Royce, P | 1 |
| Özler, T | 1 |
| Uluçay, Ç | 1 |
| Önal, A | 1 |
| Altıntaş, F | 1 |
| Tekkesin, N | 1 |
| Tekkesin, M | 1 |
| Kaso, G | 1 |
| Giuliani, E | 1 |
| Melegari, G | 1 |
| Farinetti, A | 1 |
| Barbieri, A | 1 |
| Mattioli, AV | 1 |
| Na, YG | 1 |
| Fang, R | 1 |
| Kim, YH | 1 |
| Cho, KJ | 1 |
| Kim, TK | 1 |
| Hachey, KJ | 1 |
| Sterbling, H | 1 |
| Choi, DS | 1 |
| Pinjic, E | 1 |
| Hewes, PD | 1 |
| Munoz, J | 1 |
| McAneny, D | 1 |
| Tripodis, Y | 1 |
| Fernando, HC | 1 |
| Litle, VR | 1 |
| Kim, SM | 1 |
| Moon, YW | 1 |
| Lim, SJ | 1 |
| Kim, DW | 1 |
| Park, YS | 1 |
| Malhotra, R | 1 |
| Babhulkar, S | 1 |
| Sanjib, KB | 1 |
| Clemens, A | 3 |
| Dadi, A | 1 |
| Iyer, R | 1 |
| Kamath, S | 1 |
| Mody, B | 1 |
| Mutha, S | 1 |
| Reddy, G | 1 |
| Shah, V | 2 |
| Shetty, N | 1 |
| Tapasvi, S | 1 |
| Wadhwa, M | 1 |
| King, DA | 1 |
| Pow, RE | 1 |
| Dickison, DM | 1 |
| Vale, PR | 1 |
| Akhtyamov, IF | 1 |
| Ziatdinov, BG | 1 |
| Shigaev, ES | 1 |
| Elazary, R | 1 |
| Pariser, JJ | 1 |
| Pearce, SM | 1 |
| Anderson, BB | 1 |
| Packiam, VT | 1 |
| Prachand, VN | 1 |
| Smith, ND | 1 |
| Steinberg, GD | 1 |
| Scheefer, M | 1 |
| Kotirum, S | 1 |
| Chongmelaxme, B | 1 |
| Chaiyakunapruk, N | 1 |
| Rondina, MT | 1 |
| Yan, X | 1 |
| Gu, X | 1 |
| Xu, Z | 1 |
| Lin, H | 1 |
| Cieri, NE | 1 |
| Kusmierski, K | 1 |
| Lackie, C | 1 |
| Van Opdorp, A | 1 |
| Hassan, AK | 1 |
| Jones, CE | 1 |
| Hollis, RH | 1 |
| Gullick, AA | 1 |
| Wahl, T | 1 |
| Richman, JS | 1 |
| Graham, LA | 1 |
| Lucy, AT | 1 |
| Chu, DI | 1 |
| Morris, MS | 1 |
| Xie, J | 1 |
| Ma, J | 1 |
| Yue, C | 1 |
| Pei, F | 1 |
| Imamura, H | 1 |
| Adachi, T | 1 |
| Kitasato, A | 1 |
| Soyama, A | 1 |
| Hidaka, M | 1 |
| Fujita, F | 1 |
| Takatsuki, M | 1 |
| Kuroki, T | 1 |
| Eguchi, S | 1 |
| Yanagita, T | 1 |
| Kusanagi, H | 1 |
| Eikelboom, JW | 2 |
| Comp, P | 1 |
| Happe, LE | 3 |
| Sarnes, M | 2 |
| McKenna, GS | 1 |
| Karthikesalingam, A | 1 |
| Walsh, SR | 1 |
| Tang, TY | 1 |
| Quick, CR | 1 |
| Stamenkovic, DM | 1 |
| Jankovic, ZB | 1 |
| Toogood, GJ | 1 |
| Lodge, JP | 1 |
| Bellamy, MC | 1 |
| Arnaout, L | 1 |
| Chabbouh, T | 1 |
| Bellamy, L | 1 |
| Albaladejo, P | 1 |
| Stiefelhagen, P | 1 |
| Farias-Eisner, R | 1 |
| Horblyuk, R | 1 |
| Franklin, M | 1 |
| Lunacsek, OE | 1 |
| Laalou, FZ | 1 |
| Kuntzmann, H | 1 |
| Mahoudeau, G | 1 |
| Kremer, S | 1 |
| Pain, L | 1 |
| Prudente, LA | 1 |
| Moorman, JR | 1 |
| Lake, D | 1 |
| Xiao, Y | 1 |
| Greebaum, H | 1 |
| Mangrum, JM | 1 |
| DiMarco, JP | 1 |
| Ferguson, JD | 1 |
| Varela Rois, P | 1 |
| González García, J | 1 |
| Pérez Rodríguez, MT | 1 |
| Paseiro García, MJ | 1 |
| Carcacía Hermilla, ID | 1 |
| Cage, TA | 1 |
| Lamborn, KR | 1 |
| Ware, ML | 1 |
| Frankfurt, A | 1 |
| Chakalian, L | 1 |
| Berger, MS | 1 |
| McDermott, MW | 1 |
| Varpe, P | 1 |
| Huhtinen, H | 1 |
| Rantala, A | 1 |
| Grönroos, J | 1 |
| Ali, Z | 1 |
| Prabhakar, H | 1 |
| Rath, GP | 1 |
| Dash, HH | 1 |
| Salomon, O | 1 |
| Dulitzky, M | 1 |
| Apter, S | 1 |
| Gallus, A | 3 |
| Pineo, G | 3 |
| Chen, D | 3 |
| Portman, RJ | 1 |
| De, A | 1 |
| Roy, P | 1 |
| Garg, VK | 1 |
| Pandey, NK | 1 |
| Meneveau, N | 1 |
| Capri, S | 1 |
| Piovella, F | 3 |
| Scannapieco, G | 1 |
| Moia, M | 1 |
| Suárez-Gea, ML | 1 |
| Pozo-Hernández, C | 1 |
| Byrne, M | 2 |
| Reynolds, JV | 1 |
| O'Donnell, JS | 1 |
| Keogan, M | 1 |
| White, B | 1 |
| Murphy, S | 1 |
| Maher, SG | 1 |
| Pidgeon, GP | 1 |
| Wolowacz, SE | 1 |
| Roskell, NS | 1 |
| Plumb, JM | 2 |
| Noack, H | 1 |
| Robinson, PA | 1 |
| Dolan, G | 1 |
| Brenkel, IJ | 1 |
| Verma, AK | 1 |
| Saxer, F | 1 |
| Dick, W | 1 |
| Rao, SV | 1 |
| Ohman, EM | 1 |
| Fareed, J | 4 |
| Hull, R | 1 |
| Hornick, P | 1 |
| Kiudelis, M | 1 |
| Gerbutavicius, R | 1 |
| Gerbutaviciene, R | 1 |
| Griniūte, R | 1 |
| Mickevicius, A | 1 |
| Endzinas, Z | 1 |
| Pundzius, J | 1 |
| Omel'ianovskiĭ, VV | 1 |
| Zagorodniĭ, NV | 1 |
| Margieva, AV | 1 |
| Tsfasman, FM | 1 |
| Bakaeen, FG | 1 |
| Chow, M | 1 |
| Ghadir, M | 1 |
| Albo, D | 1 |
| Berger, DH | 1 |
| Chu, D | 1 |
| Singer, JP | 1 |
| Huang, MY | 1 |
| Hui, C | 1 |
| Blanc, PD | 1 |
| Boettger, RF | 1 |
| Golden, J | 1 |
| Watkins, K | 1 |
| Hoopes, C | 1 |
| Leard, LE | 1 |
| Chilukuri, K | 1 |
| Mayer, SA | 1 |
| Scherr, D | 1 |
| Dalal, D | 1 |
| Abraham, T | 1 |
| Henrikson, CA | 1 |
| Cheng, A | 1 |
| Nazarian, S | 1 |
| Sinha, S | 1 |
| Spragg, D | 1 |
| Berger, R | 1 |
| Calkins, H | 1 |
| Marine, JE | 1 |
| Lees, M | 2 |
| Wells, PS | 2 |
| Forster, F | 1 |
| Ananthapavan, J | 1 |
| McDonald, H | 1 |
| Monz, BU | 1 |
| Huisman, MV | 3 |
| Quinlan, DJ | 2 |
| Dahl, OE | 13 |
| Schulman, S | 1 |
| Bottaro, FJ | 1 |
| Ceresetto, JM | 1 |
| Raso, JL | 1 |
| Darwich, RZ | 1 |
| Lucca, Fd | 1 |
| Santana, RV | 1 |
| Tanure, MT | 1 |
| Cariri, GA | 1 |
| Furtado, LM | 1 |
| Bailey, SH | 3 |
| Dreszer, G | 3 |
| Fisher Wachtman, C | 1 |
| Zumsteg, JW | 1 |
| Jaber, RM | 2 |
| Hamill, JB | 3 |
| Hume, KM | 3 |
| Rubin, JP | 3 |
| Neligan, PC | 1 |
| Kalliainen, LK | 3 |
| Hoxworth, RE | 3 |
| Pusic, AL | 3 |
| Wilkins, EG | 4 |
| Ramirez, LM | 1 |
| Mehta, KV | 1 |
| Lee, HC | 1 |
| Loh, JS | 1 |
| Loke, YK | 1 |
| Kwok, CS | 1 |
| Chung, LH | 1 |
| Chen, TH | 1 |
| Liu, CL | 1 |
| Eriksson, BI | 22 |
| Huo, MH | 1 |
| Kurth, AA | 3 |
| Hantel, S | 3 |
| Hermansson, K | 1 |
| Schnee, JM | 1 |
| Friedman, RJ | 4 |
| Yokote, R | 1 |
| Matsubara, M | 1 |
| Hirasawa, N | 1 |
| Hagio, S | 1 |
| Ishii, K | 1 |
| Takata, C | 1 |
| Sasaki, S | 1 |
| Miyakoshi, N | 1 |
| Matsuura, H | 1 |
| Saito, H | 1 |
| Nakanishi, T | 1 |
| Kudo, Y | 1 |
| Fujiya, T | 1 |
| Shimada, Y | 1 |
| Prandoni, P | 2 |
| Shapiro, M | 1 |
| Wistinghausen, B | 1 |
| Midulla, P | 1 |
| Chin, C | 1 |
| Lereun, C | 1 |
| Wells, P | 1 |
| Rasul, F | 1 |
| Sengupta, N | 1 |
| Jameson, SS | 1 |
| Sanders, RD | 1 |
| Reed, MR | 2 |
| Hammerstingl, C | 2 |
| Omran, H | 2 |
| Rosenberger, LH | 1 |
| Smith, PW | 1 |
| Sawyer, RG | 1 |
| Zumsteg, JM | 1 |
| Golgotiu, V | 1 |
| Spratke, LM | 1 |
| Tarricone, R | 1 |
| Rachinger, JC | 1 |
| Koman, G | 1 |
| Scheller, C | 1 |
| Prell, J | 1 |
| Rampp, S | 1 |
| Strauss, C | 1 |
| Fecher, K | 1 |
| Ewald, W | 1 |
| Fürst, A | 1 |
| Hohmann, V | 1 |
| Bramlage, P | 1 |
| Wachtman, CF | 2 |
| Portschy, PR | 2 |
| Cuerva-González, MJ | 1 |
| Lacoponi, S | 1 |
| de la Calle-Fernández, M | 1 |
| Pozo-Krielinger, J | 1 |
| Carson, W | 1 |
| Schilling, B | 1 |
| Simons, WR | 1 |
| Parks, C | 1 |
| Choe, Y | 1 |
| Faria, C | 1 |
| Powers, A | 1 |
| Xia, XY | 1 |
| Tan, YL | 1 |
| Sun, YW | 1 |
| Yan, GD | 1 |
| Rong, YX | 1 |
| Ren, QH | 1 |
| Liu, JY | 1 |
| Xu, XZ | 1 |
| Shan, GP | 1 |
| Jin, L | 1 |
| Emami, MJ | 1 |
| Namazi, H | 1 |
| Vosoughi, AR | 1 |
| Nezhad, ST | 1 |
| Oryan, A | 1 |
| Mozaffarian, K | 1 |
| Einecke, D | 1 |
| Migliaccio-Walle, K | 1 |
| Rublee, D | 1 |
| Simon, TA | 1 |
| Martino, MA | 1 |
| George, JG | 1 |
| Chen, CC | 1 |
| Galic, V | 1 |
| Kapoor, R | 1 |
| Murray, KC | 1 |
| Shubella, J | 1 |
| Riker, E | 1 |
| Lancaster, JM | 1 |
| Hoffman, MS | 1 |
| Hamilton, SC | 1 |
| Whang, WW | 1 |
| Anderson, BJ | 1 |
| Bradbury, TL | 1 |
| Erens, GA | 1 |
| Macafee, B | 1 |
| Campbell, JP | 1 |
| Ashpole, K | 1 |
| Cox, M | 1 |
| Matthey, F | 1 |
| Acton, L | 1 |
| Yentis, SM | 1 |
| Manlhiot, C | 1 |
| Brandão, LR | 1 |
| Kwok, J | 1 |
| Kegel, S | 1 |
| Menjak, IB | 1 |
| Carew, CL | 1 |
| Chan, AK | 1 |
| Schwartz, SM | 1 |
| Sivarajan, VB | 1 |
| Caldarone, CA | 1 |
| Van Arsdell, GS | 1 |
| McCrindle, BW | 1 |
| Amin, AG | 1 |
| Ng, J | 1 |
| Hsu, W | 1 |
| Pradilla, G | 1 |
| Quinones-Hinojosa, A | 1 |
| Lim, M | 1 |
| Vasavada, VA | 1 |
| Praveen, MR | 1 |
| Shah, SK | 1 |
| Trivedi, RH | 2 |
| Vasavada, AR | 1 |
| Biteker, M | 1 |
| Tekkeşin, Aİ | 1 |
| Can, MM | 1 |
| Dayan, A | 1 |
| Ilhan, E | 1 |
| Türkmen, FM | 1 |
| Long, X | 1 |
| Lin, C | 1 |
| Zhao, R | 1 |
| Zindel, S | 1 |
| Stock, S | 1 |
| Müller, D | 1 |
| Stollenwerk, B | 1 |
| Sánchez Gutiérrez, C | 1 |
| Alemán Martín, A | 1 |
| Coronado Hijón, V | 1 |
| Jiménez Delgado, P | 1 |
| Barbarash, LS | 1 |
| Burkov, NN | 1 |
| Kudriavtseva, IuA | 1 |
| Anufriev, AI | 1 |
| Zhuravleva, IIu | 1 |
| Uppal, S | 1 |
| Hernandez, E | 1 |
| Dutta, M | 1 |
| Dandolu, V | 1 |
| Rose, S | 1 |
| Hartenbach, E | 1 |
| Pryor, HI | 1 |
| Singleton, A | 1 |
| Lin, E | 1 |
| Lin, P | 1 |
| Vaziri, K | 1 |
| Homering, M | 2 |
| Sukhija, J | 1 |
| Ram, J | 1 |
| Efe, E | 1 |
| Resim, S | 1 |
| Bulut, BB | 1 |
| Eren, M | 1 |
| Garipardic, M | 1 |
| Ozkan, F | 1 |
| Ozkan, KU | 1 |
| Mueck, W | 1 |
| Loewe, A | 1 |
| Chen, WH | 1 |
| Lau, CP | 1 |
| Lau, YK | 1 |
| Ng, W | 1 |
| Lee, PY | 1 |
| Yu, CM | 1 |
| Ma, E | 1 |
| Nerurkar, J | 1 |
| Wade, WE | 4 |
| Martin, BC | 1 |
| Garces, K | 1 |
| Fox, KA | 1 |
| Antman, EM | 1 |
| Bigonzi, F | 1 |
| Borja, J | 2 |
| Curto, J | 2 |
| Campbell, J | 1 |
| Paz, MA | 1 |
| Olivella, P | 1 |
| Morris, E | 1 |
| Thaler, H | 1 |
| Sim, E | 2 |
| Vormfelde, SV | 1 |
| Hughes, SJ | 1 |
| Choussat, R | 2 |
| Ankri, A | 1 |
| Gallois, V | 1 |
| Drobinski, G | 1 |
| Sotirov, I | 1 |
| Thomas, D | 1 |
| Goldhaber, SZ | 1 |
| Dunn, K | 1 |
| Gerhard-Herman, M | 1 |
| Park, JK | 1 |
| Black, PM | 1 |
| Botteman, MF | 1 |
| Caprini, J | 1 |
| Stephens, JM | 1 |
| Nadipelli, V | 1 |
| Bell, CF | 1 |
| Pashos, CL | 1 |
| Cohen, AT | 7 |
| Eskilson, C | 1 |
| Nylander, I | 1 |
| Frison, L | 4 |
| Ogren, M | 1 |
| Bauer, KA | 7 |
| Andereya, S | 1 |
| Kälicke, T | 1 |
| Hopf, KF | 1 |
| Buschmeier, M | 1 |
| Muhr, G | 1 |
| Konkle, BA | 1 |
| Weinstein, R | 1 |
| Greist, A | 1 |
| Holmes, HE | 1 |
| Bonfiglio, J | 1 |
| Spruill, WJ | 1 |
| Leslie, RB | 1 |
| Frederiksen, SG | 1 |
| Hedenbro, JL | 1 |
| Norgren, L | 3 |
| Ennis, RS | 1 |
| Lalourcey, L | 1 |
| Kirienko, AI | 1 |
| Mishnev, OD | 1 |
| Tsitsiashvili, MSh | 1 |
| Agafonov, VF | 1 |
| Hardy, JF | 1 |
| Schneider, F | 1 |
| Assemi, P | 1 |
| Ba Faye, A | 1 |
| Sauer, B | 1 |
| Lutun, P | 1 |
| Medalion, B | 1 |
| Frenkel, G | 1 |
| Patachenko, P | 1 |
| Hauptman, E | 1 |
| Sasson, L | 1 |
| Schachner, A | 1 |
| Hofmann, T | 1 |
| Schwarcz, TH | 1 |
| Matthews, MR | 1 |
| Hartford, JM | 1 |
| Quick, RC | 1 |
| Kwolek, CJ | 1 |
| Minion, DJ | 1 |
| Endean, ED | 1 |
| Mentzer, RM | 1 |
| Tai, CY | 1 |
| Ierardi, R | 1 |
| Alexander, JB | 1 |
| Abdel-Razeq, H | 1 |
| De Groote, K | 1 |
| Annemans, L | 1 |
| Jaffer, AK | 1 |
| Hurbanek, JG | 1 |
| Morra, N | 1 |
| Pulido, PA | 1 |
| Copp, SN | 1 |
| Walker, RH | 1 |
| Reden, LM | 1 |
| Hardwick, ME | 2 |
| Colwell, CW | 7 |
| Aliev, MA | 1 |
| Dzhakupov, VA | 1 |
| Seĭdalin, AO | 1 |
| Mierbekov, EM | 1 |
| Kalyshev, RS | 1 |
| Hettiarachchi, R | 3 |
| Bravo, ML | 1 |
| Ahnfelt, L | 1 |
| Stangier, J | 1 |
| Kälebo, P | 8 |
| Reilly, P | 1 |
| Juvela, S | 1 |
| Siironen, J | 1 |
| Varis, J | 1 |
| Poussa, K | 1 |
| Porras, M | 1 |
| Enyart, JJ | 1 |
| Jones, RJ | 1 |
| Olsen, J | 1 |
| Gundgaard, J | 1 |
| Borris, LC | 4 |
| Kaul, P | 1 |
| Armstrong, PW | 1 |
| Cowper, PA | 1 |
| Eisenstein, EL | 1 |
| Granger, CB | 1 |
| Van de Werf, F | 1 |
| Mark, DB | 1 |
| Maciejczyk-Pencuła, M | 1 |
| Polak, G | 1 |
| Kotarski, J | 1 |
| Munck, LK | 1 |
| Andersen, SE | 1 |
| Christensen, HR | 1 |
| Spinler, SA | 1 |
| Schellong, S | 1 |
| Hesselschwerdt, HJ | 1 |
| Paar, WD | 2 |
| von Hanstein, KL | 1 |
| Schiff, RL | 1 |
| Kahn, SR | 2 |
| Shrier, I | 1 |
| Strulovitch, C | 1 |
| Hammouda, W | 1 |
| Cohen, E | 1 |
| Zukor, D | 1 |
| Tablov, B | 1 |
| Ruseva, A | 1 |
| Tablov, V | 1 |
| Popov, I | 1 |
| Stoĭkov, S | 1 |
| Senaran, H | 1 |
| Acaroğlu, E | 1 |
| Ozdemir, HM | 1 |
| Atilla, B | 1 |
| Borris, L | 1 |
| Haas, S | 6 |
| Misselwitz, F | 2 |
| Rumelt, S | 1 |
| Stolovich, C | 1 |
| Segal, ZI | 1 |
| Rehany, U | 1 |
| Wilson, ME | 1 |
| Husedzinov, I | 1 |
| Bradic, N | 1 |
| Nikic, N | 1 |
| Barisin, S | 1 |
| Desnica, M | 1 |
| Niazi, AU | 1 |
| Umer, M | 1 |
| Umar, M | 1 |
| Le Feuvre, C | 1 |
| Batisse, A | 1 |
| Batisse, JP | 1 |
| Beygui, F | 1 |
| Helft, G | 1 |
| Metzger, JP | 1 |
| Gibson, CM | 1 |
| Morrow, DA | 1 |
| Murphy, SA | 1 |
| Palabrica, TM | 1 |
| Jennings, LK | 1 |
| Stone, PH | 1 |
| Lui, HH | 1 |
| Bulle, T | 1 |
| Lakkis, N | 1 |
| Kovach, R | 1 |
| Cohen, DJ | 1 |
| Fish, P | 1 |
| McCabe, CH | 1 |
| Braunwald, E | 1 |
| Nadir, Y | 1 |
| Mazor, Y | 1 |
| Reuven, B | 1 |
| Sarig, G | 1 |
| Brenner, B | 1 |
| Krivoy, N | 1 |
| Farina, JA | 1 |
| Piccinato, CE | 1 |
| Campos, AD | 1 |
| Rossi, MA | 1 |
| Buckenmaier, CC | 1 |
| Shields, CH | 1 |
| Auton, AA | 1 |
| Evans, SL | 1 |
| Croll, SM | 1 |
| Bleckner, LL | 1 |
| Brown, DS | 1 |
| Stojadinovic, A | 1 |
| Somonova, OV | 1 |
| Madzhuga, AV | 1 |
| Elizarova, AL | 1 |
| Sel'chuk, VIu | 1 |
| Zubrikhina, GN | 1 |
| Bokhian, AIu | 1 |
| Cantor, WJ | 1 |
| Burnstein, J | 1 |
| Choi, R | 1 |
| Heffernan, M | 1 |
| Dzavik, V | 1 |
| Lazzam, C | 1 |
| Duic, M | 1 |
| Fitchett, D | 1 |
| Tan, M | 1 |
| Wawrzyniak, J | 1 |
| Kassam, S | 1 |
| Dhingra, S | 1 |
| Morrison, LJ | 1 |
| Langer, A | 1 |
| Goodman, SG | 1 |
| Frezza, EE | 1 |
| Wachtel, MS | 1 |
| Myers, J | 1 |
| Lee, MC | 1 |
| Nickisch, F | 1 |
| Limbird, RS | 1 |
| Schulz, SL | 1 |
| Kesselring, C | 1 |
| Seeberger, U | 1 |
| Andresen, D | 1 |
| Renda, G | 1 |
| Di Pillo, R | 1 |
| D'Alleva, A | 1 |
| Sciartilli, A | 1 |
| Zimarino, M | 1 |
| De Candia, E | 1 |
| Landolfi, R | 1 |
| Di Giammarco, G | 1 |
| Calafiore, A | 1 |
| De Caterina, R | 1 |
| Schellong, SM | 1 |
| Beyer, J | 1 |
| Halbritter, K | 1 |
| Sidhu, PS | 1 |
| Hirsh, J | 3 |
| Shorr, AF | 2 |
| Kwong, LM | 1 |
| Happe, L | 1 |
| Mody-Patel, N | 1 |
| Rivas-Gándara, N | 1 |
| Ferreira-González, I | 1 |
| Tornos, P | 1 |
| Torrents, A | 1 |
| Permanyer-Miralda, G | 1 |
| Nicolau, I | 1 |
| Arellano-Rodrigo, E | 1 |
| Vallejo, N | 1 |
| Igual, A | 1 |
| Soler-Soler, J | 1 |
| van Dijk, CN | 2 |
| Frostick, SP | 3 |
| Christiansen, AV | 1 |
| Schnee, J | 2 |
| Ball, ST | 1 |
| Pinsorsnak, P | 1 |
| Amstutz, HC | 1 |
| Schmalzried, TP | 1 |
| Norrie, J | 1 |
| Prins, MH | 1 |
| Sarnes, MW | 1 |
| Peeples, PJ | 1 |
| Stanford, RH | 1 |
| Kothari, SN | 1 |
| Lambert, PJ | 1 |
| Mathiason, MA | 1 |
| Martins, HS | 1 |
| Scalabrini-Neto, A | 1 |
| Velasco, IT | 1 |
| Langford, JR | 1 |
| Trokhan, S | 1 |
| Strauss, E | 1 |
| Karaaslan, P | 1 |
| Pirat, A | 1 |
| Karakayali, H | 1 |
| Can, U | 1 |
| Arslan, G | 1 |
| Fernández-Meré, LA | 1 |
| Fernández Rogríguez, S | 1 |
| Alvarez-Blanco, M | 1 |
| Andersson, M | 1 |
| Bylock, A | 4 |
| Jensen, E | 1 |
| Boberg, B | 1 |
| Fitzgerald, RH | 2 |
| Reiertsen, O | 3 |
| Larsen, S | 3 |
| Størkson, R | 1 |
| Trondsen, E | 1 |
| Løvig, T | 2 |
| Andersen, OK | 1 |
| Lund, H | 1 |
| Mowinckel, P | 2 |
| Samama, MM | 2 |
| Verhaeghe, R | 1 |
| Flosbach, CW | 1 |
| Spiro, TE | 5 |
| Avikainen, V | 1 |
| von Bonsdorff, H | 1 |
| Partio, E | 1 |
| Kaira, P | 1 |
| Hakkinen, S | 1 |
| Usenius, JP | 1 |
| Kaaja, R | 1 |
| Warkentin, TE | 1 |
| Levine, MN | 1 |
| Horsewood, P | 1 |
| Roberts, RS | 1 |
| Kelton, JG | 1 |
| Slunsky, R | 2 |
| Noble, S | 1 |
| Peters, DH | 1 |
| Goa, KL | 1 |
| Saltiel, E | 1 |
| Saya, F | 1 |
| Levin, PE | 1 |
| Ament, PW | 1 |
| Bertolino, JG | 1 |
| Fejgin, MD | 1 |
| Lourwood, DL | 1 |
| O'Brien, BJ | 1 |
| Anderson, DR | 3 |
| Goeree, R | 1 |
| Menzin, J | 1 |
| Richner, R | 1 |
| Huse, D | 1 |
| Colditz, GA | 1 |
| Oster, G | 1 |
| Boneu, B | 3 |
| Carter, CA | 1 |
| Skoutakis, VA | 2 |
| West, ME | 1 |
| Tooms, RE | 1 |
| Joe, RH | 1 |
| Knutson, TJ | 1 |
| Kandrotas, RJ | 1 |
| Trowbridge, AA | 2 |
| Morris, BA | 1 |
| Blaha, JD | 1 |
| Comerota, AJ | 1 |
| Wiig, JN | 1 |
| Solhaug, JH | 3 |
| Bilberg, T | 1 |
| Bjerkeset, T | 1 |
| Edwin, B | 1 |
| Grüner, OP | 1 |
| Havig, O | 1 |
| Holter, O | 1 |
| Knudsen, G | 1 |
| Lundblad, R | 1 |
| Leclerc, JR | 2 |
| Geerts, WH | 3 |
| Desjardins, L | 2 |
| Laflamme, GH | 1 |
| L'Espérance, B | 1 |
| Demers, C | 1 |
| Kassis, J | 1 |
| Cruickshank, M | 1 |
| Whitman, L | 1 |
| Delorme, F | 1 |
| Hynson, JM | 1 |
| Katz, JA | 1 |
| Bueff, HU | 1 |
| Gibaldi, M | 1 |
| Wittkowsky, AK | 1 |
| Vochelle, N | 6 |
| Fagola, M | 3 |
| Bellaud, M | 3 |
| Huet, Y | 2 |
| Gigou, F | 1 |
| Ill, P | 1 |
| Bjerkeseth, O | 1 |
| Thorsen, G | 1 |
| Gerner, T | 1 |
| Løtveit, T | 1 |
| Kalodiki, EP | 1 |
| Hoppensteadt, DA | 2 |
| Nicolaides, AN | 2 |
| Gill, K | 1 |
| Regan, F | 1 |
| al-Kutoubi, A | 2 |
| Cunningham, DA | 2 |
| Birch, R | 1 |
| Harris, N | 1 |
| Hunt, D | 1 |
| Johnson, J | 1 |
| Marx, C | 1 |
| Atkins, CD | 1 |
| Basskin, L | 1 |
| Jacobson, M | 1 |
| Perhoniemi, V | 1 |
| Vuorinen, J | 1 |
| Myllynen, P | 1 |
| Kivioja, A | 1 |
| Lindevall, K | 1 |
| Compan, D | 1 |
| Saliba, E | 1 |
| Weisslinger, N | 1 |
| Nilsson, PE | 2 |
| Benoni, G | 1 |
| Björgell, O | 1 |
| Fredin, H | 1 |
| Hedlund, U | 1 |
| Nicolas, S | 1 |
| Nylander, G | 1 |
| Stone, MH | 2 |
| Limb, D | 2 |
| Campbell, P | 1 |
| Stead, D | 2 |
| Culleton, G | 2 |
| Gallay, S | 1 |
| Waddell, JP | 1 |
| Cardella, P | 1 |
| Morton, J | 1 |
| Eskander, MB | 1 |
| Furlong, AJ | 1 |
| Shardlow, D | 1 |
| Wille-Jørgensen, P | 5 |
| Bösch, P | 1 |
| Baur, M | 1 |
| Ekman, S | 1 |
| Bach, D | 1 |
| Lindbratt, S | 2 |
| Close, P | 1 |
| Ewenstein, BM | 1 |
| Robb, J | 1 |
| Buoncristiani, P | 1 |
| Severi, P | 1 |
| Pini, M | 1 |
| D'Angelo, A | 1 |
| Beltrametti, C | 1 |
| Damiani, M | 1 |
| Andrioli, GC | 1 |
| Pugliese, R | 1 |
| Iorio, A | 1 |
| Brambilla, G | 1 |
| Ginsberg, JS | 2 |
| Davidson, BL | 1 |
| Kovacs, MJ | 3 |
| Weir, K | 1 |
| MacKinnon, K | 1 |
| Keeney, M | 1 |
| Brien, WF | 1 |
| Cruickshank, MK | 2 |
| Kalodiki, E | 1 |
| Mandalia, S | 1 |
| Toksvig-Larsen, S | 1 |
| Magyar, G | 1 |
| Lindstrand, A | 1 |
| Albrechtsson, U | 1 |
| Zidar, JP | 1 |
| Dickinson, LD | 1 |
| Miller, LD | 1 |
| Patel, CP | 1 |
| Gupta, SK | 1 |
| McLaughlin, JA | 1 |
| Paulson, MM | 1 |
| Rosenthal, RE | 1 |
| Lensing, AW | 1 |
| Barre, J | 1 |
| Beau, B | 1 |
| Ziaja, K | 1 |
| Simka, M | 1 |
| Krupowies, A | 1 |
| Dugaj, M | 1 |
| Ludyga, T | 1 |
| Collis, DK | 1 |
| Paulson, R | 1 |
| McCutchen, JW | 1 |
| Bigler, GT | 1 |
| Lutz, S | 1 |
| Rossi, R | 1 |
| Taborelli, P | 1 |
| Fioroni, C | 1 |
| Zerbi, D | 1 |
| Pattacini, P | 1 |
| Giugni, E | 1 |
| Bagatella, P | 1 |
| Vaccarino, A | 1 |
| Rybachuk, OI | 1 |
| Besiedyns'kyĭ, SM | 1 |
| Huliaiev, DV | 1 |
| Dunsworth, GA | 1 |
| Stern, SH | 1 |
| Wixson, RL | 1 |
| O'Connor, D | 1 |
| Gürlich, R | 1 |
| Salaj, P | 1 |
| Hrachovinová, I | 1 |
| Schuurman, B | 1 |
| den Heijer, M | 1 |
| Nijs, AM | 1 |
| Hawkins, DW | 1 |
| Finsen, V | 2 |
| McEvoy, MD | 1 |
| Bailey, M | 1 |
| Taylor, D | 1 |
| Del Schutte, H | 1 |
| Hakki, SI | 1 |
| Abdullah, H | 1 |
| Camblin, J | 1 |
| Nasseri, AF | 1 |
| Hamadeh, O | 1 |
| Wright, T | 1 |
| Harvey, DM | 1 |
| Offord, RH | 1 |
| Street, JT | 1 |
| McGrath, M | 1 |
| O'Regan, K | 1 |
| Wakai, A | 1 |
| McGuinness, A | 1 |
| Redmond, HP | 1 |
| McLeod, RS | 1 |
| Sniderman, KW | 1 |
| Greenwood, C | 1 |
| Gregoire, RC | 1 |
| Taylor, BM | 1 |
| Silverman, RE | 1 |
| Atkinson, KG | 1 |
| Burnstein, M | 1 |
| Marshall, JC | 1 |
| Burul, CJ | 1 |
| Ross, T | 1 |
| Wilson, SR | 1 |
| Barton, P | 1 |
| Janni, W | 1 |
| Bergauer, F | 1 |
| Rjosk, D | 1 |
| Lohscheidt, K | 1 |
| Hagena, FW | 1 |
| Gallus, AS | 1 |
| Rosenberg, RD | 1 |
| Jönsson, B | 1 |
| Comp, PC | 1 |
| Whitsett, TL | 2 |
| Johnson, GJ | 1 |
| Gardiner, GA | 2 |
| Landon, GC | 1 |
| Jové, M | 1 |
| O'Connell, MB | 1 |
| Ohar, JA | 1 |
| Young, TR | 1 |
| Thaler, HW | 1 |
| Roller, RE | 1 |
| Greiner, N | 1 |
| Korninger, C | 1 |
| Wilson, MD | 1 |
| Harrison, K | 1 |
| Heit, JA | 1 |
| Francis, CW | 2 |
| Whipple, J | 1 |
| Peters, G | 1 |
| Ellison, J | 1 |
| Thomson, AJ | 1 |
| Conkie, JA | 1 |
| McCall, F | 1 |
| Walker, D | 1 |
| Greer, A | 1 |
| Diuguid, DL | 1 |
| Murashige, N | 2 |
| Kami, M | 2 |
| Marlovits, S | 1 |
| Priestley, M | 1 |
| Eldor, A | 1 |
| Le Moigne-Amrani, A | 1 |
| Dietrich-Neto, F | 1 |
| Sarasin, FP | 1 |
| Perneger, T | 1 |
| Kormanová, K | 1 |
| Krska, Z | 2 |
| Trca, S | 1 |
| Pesková, M | 1 |
| Korínková, P | 1 |
| Suljevic, I | 1 |
| Basic, S | 1 |
| Surkovic, I | 1 |
| Turan, M | 1 |
| Musija, E | 1 |
| Pathania, YS | 1 |
| Md, AB | 1 |
| Del Bono, R | 1 |
| Martini, G | 1 |
| Volpi, R | 1 |
| Takaue, Y | 1 |
| Mohamed, MS | 1 |
| Boeckl, O | 1 |
| Bordenave, L | 1 |
| Brehm, OA | 1 |
| Brücke, P | 1 |
| Coccheri, S | 1 |
| Galland, F | 1 |
| Jarrige, J | 1 |
| Koppenhagen, K | 2 |
| LeQuerrec, A | 1 |
| Parraguette, E | 1 |
| Roder, JD | 1 |
| Roos, M | 1 |
| Rüschemeyer, C | 1 |
| Siewert, JR | 1 |
| Vinazzer, H | 1 |
| Wenzel, E | 1 |
| Wellington, K | 1 |
| McClellan, K | 1 |
| Jarvis, B | 2 |
| Bischoff, A | 1 |
| Kleindienst, A | 1 |
| Harvey, HB | 1 |
| Mater, E | 1 |
| Bronst, J | 1 |
| Flack, J | 1 |
| Herenz, K | 1 |
| Haupt, WF | 1 |
| Schön, R | 1 |
| Wolf, H | 2 |
| Encke, A | 2 |
| Harenberg, J | 1 |
| Schmidt, JA | 1 |
| Tolle, A | 2 |
| Höntzsch, D | 1 |
| Scheffer, J | 1 |
| Hafner, S | 1 |
| Spannagel, U | 1 |
| Schelde, AB | 1 |
| Petersen, J | 1 |
| Jensen, TB | 1 |
| Gromov, K | 1 |
| Overgaard, S | 1 |
| Olesen, JB | 1 |
| Jimenez-Solem, E | 1 |
| Gan, WK | 1 |
| Xia, ZN | 1 |
| Zhou, Q | 1 |
| Zhu, W | 1 |
| Weng, XS | 1 |
| Craik, JD | 1 |
| Cobb, AG | 1 |
| Eley, KA | 1 |
| Parker, RJ | 1 |
| Watt-Smith, SR | 1 |
| Li, G | 1 |
| Cook, DJ | 1 |
| Levine, MAH | 1 |
| Guyatt, G | 1 |
| Crowther, M | 1 |
| Heels-Ansdell, D | 1 |
| Holbrook, A | 1 |
| Lamontagne, F | 1 |
| Walter, SD | 1 |
| Ferguson, ND | 1 |
| Finfer, S | 1 |
| Arabi, YM | 1 |
| Bellomo, R | 1 |
| Cooper, DJ | 1 |
| Thabane, L | 1 |
| Plante, S | 1 |
| Belzile, EL | 1 |
| Fréchette, D | 1 |
| Lefebvre, J | 1 |
| McKellar, SH | 1 |
| Thompson, JL | 1 |
| Garcia-Rinaldi, RF | 1 |
| Macdonald, RJ | 1 |
| Sundt, TM | 1 |
| Schaff, HV | 1 |
| Fraile, P | 1 |
| García-Cosmes, P | 1 |
| García, T | 1 |
| Tabernero, JM | 1 |
| Dranitsaris, G | 1 |
| Stumpo, C | 1 |
| Smith, R | 1 |
| Bartle, W | 1 |
| Goel, DP | 1 |
| Buckley, R | 1 |
| deVries, G | 1 |
| Abelseth, G | 1 |
| Ni, A | 1 |
| Gray, R | 1 |
| Dindo, D | 1 |
| Breitenstein, S | 1 |
| Hahnloser, D | 1 |
| Seifert, B | 1 |
| Yakarisik, S | 1 |
| Asmis, LM | 1 |
| Muller, MK | 1 |
| Clavien, PA | 1 |
| Wiwanitkit, V | 1 |
| Brzezková, R | 1 |
| Frýba, V | 1 |
| Chrz, K | 1 |
| Kvasnicka, J | 1 |
| Green, L | 1 |
| Lawrie, AS | 1 |
| Patel, S | 2 |
| Hossain, F | 1 |
| Chitolie, A | 1 |
| Mackie, IJ | 1 |
| Haddad, FS | 1 |
| Machin, SJ | 1 |
| Colwell, AS | 1 |
| Reish, RG | 1 |
| Kuter, DJ | 1 |
| Damjanovic, B | 1 |
| Austen, WG | 1 |
| Fogerty, AE | 1 |
| Nagathan, DS | 1 |
| Pahwa, HS | 1 |
| Kumar, A | 1 |
| Goel, A | 1 |
| Eriksson, UG | 2 |
| Welin, L | 1 |
| Gustafsson, D | 3 |
| Malm, K | 1 |
| Dahlbäck, B | 1 |
| Arnljots, B | 1 |
| Arnesen, H | 3 |
| Aspelin, T | 3 |
| Seljeflot, I | 2 |
| Kierulf, P | 2 |
| Lyberg, T | 2 |
| Kearon, C | 1 |
| Rodger, M | 1 |
| Bates, SM | 1 |
| Douketis, J | 1 |
| Solymoss, S | 1 |
| Ezekowitz, MD | 1 |
| Averkov, OV | 1 |
| Hirota, Y | 1 |
| Sakai, M | 1 |
| Nakabayashi, M | 1 |
| Rasmussen, MS | 3 |
| Jorgensen, LN | 2 |
| Nielsen, JD | 1 |
| Horn, A | 1 |
| Mohn, AC | 1 |
| Sømod, L | 1 |
| Olsen, B | 1 |
| Zarei, R | 1 |
| Azimi, R | 1 |
| Moghimi, S | 1 |
| Abdollahi, A | 1 |
| Amini, H | 1 |
| Eslami, Y | 1 |
| Fakhraii, G | 1 |
| Lapidus, LJ | 2 |
| Rosfors, S | 2 |
| Ponzer, S | 2 |
| Levander, C | 2 |
| Elvin, A | 2 |
| Lärfars, G | 2 |
| de Bri, E | 2 |
| Kim, W | 2 |
| Jeong, MH | 1 |
| Hwang, SH | 1 |
| Kim, KH | 1 |
| Hong, YJ | 1 |
| Ahn, YK | 1 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Heilmann, L | 1 |
| Rath, W | 1 |
| Pollow, K | 1 |
| Bick, RL | 1 |
| Ruyter, R | 1 |
| Magnusson, M | 1 |
| Sivertsson, R | 1 |
| Flordal, PA | 2 |
| Berggvist, D | 1 |
| Burmark, US | 1 |
| Ljungström, KG | 2 |
| Törngren, S | 2 |
| Andreassen, G | 1 |
| Müller, C | 1 |
| Mathiesen, P | 1 |
| Nyhus, S | 1 |
| Abdelnoor, M | 1 |
| Howard, PA | 1 |
| Polat, O | 1 |
| Desmarais, S | 1 |
| de Moerloose, P | 1 |
| Huber, O | 1 |
| Pellegrini, VD | 1 |
| Totterman, S | 1 |
| Boyd, AD | 1 |
| Marder, VJ | 1 |
| Liebert, KM | 1 |
| Stulberg, BN | 1 |
| Ayers, DC | 1 |
| Rosenberg, A | 1 |
| Kessler, C | 1 |
| Johanson, NA | 1 |
| Ward, B | 1 |
| Pradhan, S | 1 |
| Anderson, BS | 1 |
| Jensen, HP | 1 |
| Skejø Bro, HP | 1 |
| Andersen, G | 1 |
| Petersen, AO | 1 |
| Siem, P | 1 |
| Hørlyck, E | 1 |
| Jensen, BV | 1 |
| Thomsen, PB | 1 |
| Hansen, BR | 1 |
| Erin-Madsen, J | 1 |
| Møller, JC | 1 |
| Rotwitt, L | 1 |
| Christensen, F | 1 |
| Nielsen, JB | 1 |
| Jørgensen, PS | 1 |
| Paaske, B | 1 |
| Tørholm, C | 1 |
| Hvidt, P | 1 |
| Jensen, NK | 1 |
| Nielsen, AB | 1 |
| Appelquist, E | 1 |
| Tjalve, E | 1 |
| Chillag, KJ | 1 |
| Hoek, KJ | 1 |
| Obernosterer, A | 1 |
| Schippinger, G | 1 |
| Lipp, RW | 1 |
| Wirnsberger, G | 1 |
| Roller, R | 1 |
| Pilger, E | 1 |
| Kemppainen, E | 1 |
| Kokkola, A | 1 |
| Sirén, J | 1 |
| Kiviluoto, T | 1 |
| Chisholm, MA | 1 |
| Dunn, CJ | 1 |
| Hull, RD | 1 |
| Wallentin, L | 1 |
| Cummins, D | 1 |
| Segal, H | 1 |
| Hunt, BJ | 1 |
| Awad, R | 1 |
| Maddox, A | 1 |
| Tinmouth, AH | 1 |
| Morrow, BH | 1 |
| Moore, PM | 1 |
| Maxwell, GL | 1 |
| Synan, I | 1 |
| Dodge, R | 1 |
| Carroll, B | 1 |
| Clarke-Pearson, DL | 1 |
| Arfwidsson, AC | 1 |
| Fager, G | 1 |
| Wåhlander, K | 1 |
| Larson, G | 1 |
| Lindahl, TL | 1 |
| Andersson, C | 1 |
| Auer, RC | 1 |
| Ott, M | 1 |
| Karanicolas, P | 1 |
| Brackstone, MR | 1 |
| Ashamalla, S | 1 |
| Weaver, J | 1 |
| Tagalakis, V | 1 |
| Boutros, M | 1 |
| Stotland, P | 1 |
| Marulanda, AC | 1 |
| Moloo, H | 1 |
| Jayaraman, S | 1 |
| Le Gal, G | 1 |
| Spadafora, S | 1 |
| MacLellan, S | 1 |
| Trottier, D | 1 |
| Jonker, D | 1 |
| Asmis, T | 1 |
| Mallick, R | 1 |
| Pecarskie, A | 1 |
| Ramsay, T | 1 |
| Cooper, C | 1 |
| Antle, O | 1 |
| Lowerison, J | 1 |
| Dersch-Mills, D | 1 |
| Kenny, A | 1 |
| Jassim, SS | 1 |
| McNamara, I | 1 |
| Hopgood, P | 1 |
| Griffiths, S | 1 |
| Woo, C | 1 |
| Mansoubi, V | 1 |
| Riccoboni, A | 1 |
| Sabharwal, A | 1 |
| Napier, S | 1 |
| Columb, M | 1 |
| Laffan, M | 1 |
| Stocks, G | 1 |
| Viguier, JB | 1 |
| Amraoui, S | 1 |
| Solanilla, A | 1 |
| Boulon, C | 1 |
| Constans, J | 1 |
| Conri, C | 1 |
| Jensen, CD | 1 |
| Steval, A | 1 |
| Partington, PF | 1 |
| Muller, SD | 1 |
| Meyer, G | 1 |
| Besse, B | 1 |
| Friard, S | 1 |
| Corbi, P | 1 |
| Azarian, R | 1 |
| Monnet, I | 1 |
| Alifano, M | 1 |
| Chouaid, C | 1 |
| Descourt, R | 1 |
| Dennewald, G | 1 |
| Taillade, L | 1 |
| De Luca, K | 1 |
| Giraud, F | 1 |
| Pichon, E | 1 |
| Chatellier, G | 1 |
| Chibbaro, S | 1 |
| Tacconi, L | 1 |
| Lausen, I | 3 |
| Jørgensen, LN | 2 |
| Jensen, R | 2 |
| Lyng, KM | 2 |
| Andersen, M | 2 |
| Raaschou, HO | 2 |
| Friberg, B | 1 |
| Frisell, J | 1 |
| Hedberg, M | 1 |
| Mätzsch, T | 1 |
| Wang, Z | 1 |
| Zheng, J | 1 |
| Zhao, Y | 1 |
| Xiang, Y | 1 |
| Chen, X | 1 |
| Jin, Y | 1 |
| Goldberg, LH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Pilot Study Comparing the Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery[NCT01431456] | Phase 3 | 148 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Prophylaxis of Venous Thromboembolism in Patients With a Nonsurgical Fracture of the Lower Extremity Immobilised in a Below-Knee Plaster Cast[NCT00881088] | Phase 2/Phase 3 | 669 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
| The Impact of Laparoscopic Versus Open Surgeries on the Incidence of Postoperative Deep Vein Thrombosis in Patients With Gastrointestinal Malignancy ---A Cohort Study[NCT02297269] | 230 participants (Anticipated) | Observational | 2014-12-31 | Not yet recruiting | |||
| A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surger[NCT03891524] | Phase 2 | 1,242 participants (Actual) | Interventional | 2019-06-17 | Completed | ||
| A Randomized, Active-comparator-controlled, Multicenter Study to Assess the Safety and Efficacy of Different Doses of BAY1213790 for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Total Knee Arthroplasty, Open-label to Tr[NCT03276143] | Phase 2 | 813 participants (Actual) | Interventional | 2017-09-21 | Completed | ||
| Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients[NCT03251963] | Phase 2 | 131 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery[NCT02401594] | Phase 3 | 3,608 participants (Actual) | Interventional | 2015-12-08 | Terminated (stopped due to Remaining outdated treatments and additional costs too high for new manufacturing) | ||
| A Multicenter, Open-label, Prospective, Randomized, Active-controlled Study on the Efficacy and Safety of Oral Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis After Major Gynecological Cancer Surgery.[NCT04999176] | Phase 3 | 440 participants (Anticipated) | Interventional | 2020-10-22 | Recruiting | ||
| The Safety of Oral Apixaban (Eliquis) Versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design[NCT02366871] | Phase 2 | 400 participants (Actual) | Interventional | 2015-04-28 | Completed | ||
| Optimization of Enoxaparin Prophylaxis Using Real-time Anti-Factor Xa Levels in Major Reconstructive Surgery Patients[NCT02687204] | Phase 1 | 118 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Enoxaparin Metabolism in Reconstructive Surgery Patients[NCT02411292] | Phase 2 | 110 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Frequency of Vascular Events With Short-term Thromboprophylaxis in Fast-track Hip and Knee-arthroplasty[NCT01557725] | 4,924 participants (Actual) | Observational | 2010-02-28 | Completed | |||
| Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose[NCT02704052] | Early Phase 1 | 116 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| A Multinational, Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery[NCT00679588] | Phase 3 | 4,413 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients[NCT01448746] | Phase 3 | 682 participants (Actual) | Interventional | 2011-10-31 | Active, not recruiting | ||
| An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Patients Undergoing Total Knee Arthroplasty[NCT01713361] | Phase 2 | 315 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Prophylactic Use of Enoxaparin in Morbidly Obese Adolescents During Bariatric Surgery[NCT01587781] | 12 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| Analgesic and Hemodynamic Effects of Continuous Epidural Analgesia Compared to Paravertebral Block in Liver Resection Patients[NCT02909322] | Phase 4 | 50 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurre[NCT01550523] | Phase 1 | 13 participants (Actual) | Interventional | 2012-02-09 | Completed | ||
| A Phase 3 Randomized, Double-Blind Active-Controlled (Enoxaparin), Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery[NCT00371683] | Phase 3 | 3,608 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study)[NCT00452530] | Phase 3 | 3,221 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Antic[NCT00423319] | Phase 3 | 5,407 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Comp[NCT00657150] | Phase 3 | 2,055 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial[NCT02615366] | Phase 4 | 800 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| Randomized Clinical Trial Evaluating Anti-inflammatory Effect of Low Molecular-Weight Heparin in Pediatric Cataract and Intraocular Lens Surgery[NCT00986076] | Phase 4 | 23 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Focus on Cost-effective Analysis and Safety Comparison Between Rivaroxaban and Enoxaparin[NCT03299296] | Phase 3 | 100 participants (Actual) | Interventional | 2017-01-01 | Enrolling by invitation | ||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| Pharmacokinetics of Recombinant Antithrombin III in Neonates Undergoing Extracorporeal Membrane Oxygenation[NCT01913444] | Phase 4 | 0 participants (Actual) | Interventional | 2013-07-31 | Withdrawn (stopped due to Unable to enroll patients into study.) | ||
| Comparative Feasibility and Efficacy of a Five Compartment Technique Using 0.25% Bupivacaine vs a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka; a Single Blinded Randomized Controlled Study[NCT03303794] | Phase 3 | 25 participants (Actual) | Interventional | 2017-10-25 | Terminated (stopped due to Interim Analysis showed no significance) | ||
| A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 [NCT00168818] | Phase 3 | 3,494 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| "The EXTEND Study: A Randomized, Double-blind, Parallel-group, Phase III b, Multi-centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergo[NCT00206089] | Phase 3 | 3,300 participants | Interventional | 2005-09-30 | Terminated (stopped due to Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety.) | ||
| A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices[NCT02345642] | 20 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Major Lung Resection: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Lung Resection[NCT02258958] | 150 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928] | 70 participants (Actual) | Observational | 2012-12-03 | Completed | |||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients[NCT00531843] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study.[NCT02597218] | 350 participants (Anticipated) | Observational | 2015-10-31 | Recruiting | |||
| Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698[NCT00769873] | Phase 2 | 35 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered trial.) | ||
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)[NCT00182143] | Phase 3 | 3,659 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Comparison of Combined Phacotrabeculectomy and Trabeculectomy Only in the Treatment of Primary Angle-closure Glaucoma[NCT01298635] | 31 participants (Actual) | Interventional | 2005-01-31 | Completed | |||
| A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colorectal Cancer[NCT01455831] | Phase 3 | 616 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729] | Phase 4 | 294 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Apparent clearance of a drug was defined as a measure of the rate at which a drug got metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liter per hour (L/h) (Geometric Mean) |
|---|---|
| Overall | 7.72 |
V/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liter (Geometric Mean) |
|---|---|
| Overall | 125 |
Impact of age on CL/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | L/h (Geometric Mean) |
|---|---|
| Age: Less Than or Equal to (<=) 68 Years | 8.70 |
| Age: Greater Than (>) 68 Years | 6.83 |
Impact of weight on CL/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | L/h (Geometric Mean) |
|---|---|
| Weight: <= 82 Kilograms (kg) | 7.04 |
| Weight: Greater Than (>) 82 kg | 8.54 |
Impact of age on V/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liters (Geometric Mean) |
|---|---|
| AGE <= 68 Years | 135 |
| AGE >68 Years | 116 |
Impact of weight on V/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liters (Geometric Mean) |
|---|---|
| Weight <= 82kg | 109 |
| Weight > 82kg | 145 |
Impact of demographic character (sex) on CL/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liter per hour (L/h) (Geometric Mean) |
|---|---|
| Female | 7.14 |
| Male | 9.32 |
Impact of sex on V/F was assessed. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liters (Geometric Mean) |
|---|---|
| Female | 118 |
| Male | 143 |
Impact of renal function on CL/F was assessed. The outcome measure was reported based on CRCL. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | L/h (Geometric Mean) |
|---|---|
| Creatinine Clearance (CRCL): Less Than (<) 90 | 6.71 |
| CRCL: Greater Than or Equal to (>=) 90 | 8.83 |
Impact of renal function on V/F was assessed. The outcome measure is reported based on CRCL. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Liters (Geometric Mean) |
|---|---|
| CRCL < 90 | 116 |
| CRCL >= 90 | 135 |
Number of participants with deaths (CEC-adjudicated) were reported. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 |
| JNJ-70033093 50 mg BID | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 0 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 1 |
Number of participants with deaths (CEC-adjudicated) were reported. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 |
| JNJ-70033093 50 mg BID | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 0 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 1 |
Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 2 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 1 |
| JNJ-70033093 50 mg BID | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 2 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 4 |
Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 2 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 1 |
| JNJ-70033093 50 mg BID | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 2 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 4 |
Number of participants with nonfatal PE (adjudicated by CEC) were reported. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 |
| JNJ-70033093 50 mg BID | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 1 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 1 |
Number of participants with nonfatal PE (adjudicated by CEC) were reported. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 |
| JNJ-70033093 50 mg BID | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 |
| JNJ-70033093 100 mg + Placebo BID | 1 |
| JNJ-70033093 200 mg BID | 0 |
| Enoxaparin 40 mg Once Daily | 1 |
Total VTE was defined as the composite of clinical events committee (CEC)-adjudicated proximal and/or distal Deep Vein Thrombosis (DVT) (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal pulmonary embolism (PE), or any death. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 7 |
| JNJ-70033093 50 mg Once Daily + Placebo | 30 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 27 |
| JNJ-70033093 50 mg BID | 14 |
| JNJ-70033093 200 mg Once Daily + Placebo | 8 |
| JNJ-70033093 100 mg + Placebo BID | 12 |
| JNJ-70033093 200 mg BID | 10 |
| Enoxaparin 40 mg Once Daily | 54 |
Total VTE was defined as the composite of (CEC-adjudicated) proximal and/or DVT (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal PE, or any death. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 7 |
| JNJ-70033093 50 mg Once Daily + Placebo | 30 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 27 |
| JNJ-70033093 50 mg BID | 14 |
| JNJ-70033093 200 mg Once Daily + Placebo | 8 |
| JNJ-70033093 100 mg + Placebo BID | 12 |
| JNJ-70033093 200 mg BID | 10 |
| Enoxaparin 40 mg Once Daily | 54 |
The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate. (NCT03891524)
Timeframe: Up to 14 days
| Intervention | proportion of participants (Number) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0.35 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0.21 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0.20 |
| JNJ-70033093 50 mg BID | 0.13 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0.09 |
| JNJ-70033093 100 mg + Placebo BID | 0.09 |
| JNJ-70033093 200 mg BID | 0.07 |
The dose-response trend test based on the MCP-Mod framework consisted of contrast tests defined by prespecified candidate models (4 Emax dose-response models with varying degrees of ED50). Each model was evaluated for significance of trend, based on its optimal contrast, resulting in four t-test statistics, one for each candidate model. The t-test statistics were adjusted for the fact that 4 candidate models were included in the trend testing. The dose response of the drug was then established if the maximum of the t-test statistics exceeded the 95th percentile critical value. Here 'number' signifies the estimated response rate. (NCT03891524)
Timeframe: Up to 14 days
| Intervention | proportion of participants (Number) |
|---|---|
| JNJ-70033093 25 mg Once Daily + Placebo | 0.02 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0.01 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0.01 |
| JNJ-70033093 50 mg BID | 0.01 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0.01 |
| JNJ-70033093 100 mg + Placebo BID | 0.01 |
| JNJ-70033093 200 mg BID | 0.01 |
Any bleeding was defined as the composite of major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria modified for the surgical setting, clinically relevant nonmajor bleeding events, or minimal bleeding events as assessed by the CEC. (NCT03891524)
Timeframe: Up to Day 14; Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 12 | 12 |
| JNJ-70033093 100 mg + Placebo BID | 7 | 7 |
| JNJ-70033093 200 mg BID | 6 | 6 |
| JNJ-70033093 200 mg Once Daily + Placebo | 11 | 11 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 2 | 2 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 7 | 7 |
| JNJ-70033093 50 mg Once Daily + Placebo | 8 | 8 |
Composite of Major bleeding event (BE): Fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hemoglobin (Hb) level of 20 grams per liter (g/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; surgical site bleeding that requires second intervention open, arthroscopic, endovascular,or hemarthrosis resulting in prolonged hospitalization, deep wound infection and/or either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: Epistaxis, Gastrointestinal bleed,Hematuria,Bruising/ecchymosis,Hemoptysis,Hematoma. (NCT03891524)
Timeframe: Up to Day 14, Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 5 | 5 |
| JNJ-70033093 100 mg + Placebo BID | 1 | 1 |
| JNJ-70033093 200 mg BID | 1 | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 1 | 2 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 2 | 2 |
| JNJ-70033093 50 mg Once Daily + Placebo | 2 | 2 |
Number of participants with CRNM bleeding events (adjudicated by CEC) were reported. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma. (NCT03891524)
Timeframe: Up to Day 14; Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 4 | 4 |
| JNJ-70033093 100 mg + Placebo BID | 1 | 1 |
| JNJ-70033093 200 mg BID | 1 | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 1 | 2 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 2 | 2 |
| JNJ-70033093 50 mg Once Daily + Placebo | 2 | 2 |
Number of participants with distal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Asymptomatic | Symptomatic | |
| Enoxaparin 40 mg Once Daily | 50 | 0 |
| JNJ-70033093 100 mg + Placebo BID | 10 | 1 |
| JNJ-70033093 200 mg BID | 10 | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 8 | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 26 | 2 |
| JNJ-70033093 25 mg Once Daily + Placebo | 7 | 0 |
| JNJ-70033093 50 mg BID | 13 | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 27 | 2 |
Number of participants with distal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Asymptomatic | Symptomatic | |
| Enoxaparin 40 mg Once Daily | 50 | 0 |
| JNJ-70033093 100 mg + Placebo BID | 10 | 1 |
| JNJ-70033093 200 mg BID | 10 | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 8 | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 26 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 7 | 0 |
| JNJ-70033093 50 mg BID | 13 | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 27 | 2 |
Number of participants with major BE (adjudicated by CEC) were reported. Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. (NCT03891524)
Timeframe: Up to Day 14; Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 1 | 1 |
| JNJ-70033093 100 mg + Placebo BID | 0 | 0 |
| JNJ-70033093 200 mg BID | 0 | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 0 | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 | 0 |
Major Bleeding events were defined as: fatal bleeding; bleeding that is symptomatic and occurs in critical area/organ and/or; extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; either unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma. (NCT03891524)
Timeframe: Up to Day 14; Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 5 | 5 |
| JNJ-70033093 100 mg + Placebo BID | 1 | 1 |
| JNJ-70033093 200 mg BID | 1 | 1 |
| JNJ-70033093 200 mg Once Daily + Placebo | 1 | 2 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 2 | 2 |
| JNJ-70033093 50 mg Once Daily + Placebo | 2 | 2 |
Number of participants with minimal bleeding events (adjudicated by CEC) were reported. Minimal bleeding event was defined as any bleeding event not met major or CRNM criteria. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE is still considered clinically relevant for example: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, hematoma. (NCT03891524)
Timeframe: Up to Day 14; Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Up to Day 14 | Up to Day 52 | |
| Enoxaparin 40 mg Once Daily | 8 | 8 |
| JNJ-70033093 100 mg + Placebo BID | 7 | 7 |
| JNJ-70033093 200 mg BID | 4 | 5 |
| JNJ-70033093 200 mg Once Daily + Placebo | 8 | 9 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 2 | 2 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 5 | 5 |
| JNJ-70033093 50 mg Once Daily + Placebo | 6 | 6 |
Number of participants with proximal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. (NCT03891524)
Timeframe: Up to Day 14
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Asymptomatic | Symptomatic | |
| Enoxaparin 40 mg Once Daily | 1 | 0 |
| JNJ-70033093 100 mg + Placebo BID | 0 | 0 |
| JNJ-70033093 200 mg BID | 0 | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 0 | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 | 0 |
Number of participants with proximal DVT (CEC-adjudicated) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. (NCT03891524)
Timeframe: Up to Day 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Asymptomatic | Symptomatic | |
| Enoxaparin 40 mg Once Daily | 1 | 0 |
| JNJ-70033093 100 mg + Placebo BID | 0 | 0 |
| JNJ-70033093 200 mg BID | 0 | 0 |
| JNJ-70033093 200 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 25 mg + Placebo Twice Daily (BID) | 0 | 0 |
| JNJ-70033093 25 mg Once Daily + Placebo | 0 | 0 |
| JNJ-70033093 50 mg BID | 0 | 0 |
| JNJ-70033093 50 mg Once Daily + Placebo | 0 | 0 |
Bleeding events requiring alteration in the course of care within 90 days of surgery (NCT03251963)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fixed Dose Enoxaparin | 1 |
| Weight Tiered Enoxaparin | 3 |
Any symptomatic venous thromboembolism events, including deep venous thrombosis or pulmonary embolus occurring within 90 days of surgery (NCT03251963)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fixed Dose Enoxaparin | 1 |
| Weight Tiered Enoxaparin | 0 |
Number of patients with in range initial peak Xa level (NCT03251963)
Timeframe: 36 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fixed Dose Enoxaparin | 27 |
| Weight Tiered Enoxaparin | 27 |
Participants were monitored for up to 28 days. This was measured through self-report, patient diaries, and the return of all medication bottles/syringes. This was the number of participants that did not miss more than 2 days of study medication over 28 days (less than 4 pills or 2 injections missed). (NCT02366871)
Timeframe: Day 1 post-op/standard of care first dose of medication to Day 28 (+/- 4 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 173 |
| Subcutaneous Enoxaparin | 164 |
Participants were monitored for up to 90 days. This is the number of participants with bleeding events that did not meet the ISTH criteria but still required intervention. This is the number of participants who had at least one non-major bleeding event during the time of observation. (NCT02366871)
Timeframe: Day 1 post-op/standard of care first dose of medication to day 90 (+/- 14 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 12 |
| Subcutaneous Enoxaparin | 19 |
The International Society on Thrombosis and Hemostasis criteria (ISTH) will be used to assess incidence of major bleeding. Participants were monitored for up to 90 days. This is the number of participants who have had at least one major bleeding incidence during the time of observation. (NCT02366871)
Timeframe: Day 1 post-op/standard of care first medication dose to day 90 (+/-14 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 1 |
| Subcutaneous Enoxaparin | 1 |
Participants were monitored for up to 90 days. Both DVTs and PEs will be measured using the Wells criteria, ultrasound, and/or CT. This is the number of participants who had at least one DVT or PE during the time of observation. (NCT02366871)
Timeframe: Day 1 post-op/standard of care to day first dose of medication 90 (+/- 14 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 2 |
| Subcutaneous Enoxaparin | 3 |
This was measured through a validated health survey (SF-8™) provided by a healthcare company (Optum®), which measured overall physical and mental well-being, with responses ranging from none to very, not at all to extremely, etc. Change was calculated as the difference at baseline versus 28 days post op. The score was 0-100 and a higher score was considered a better outcome. (NCT02366871)
Timeframe: At baseline, and visit 4, which is 28 days (+/- 4 days) post-op/standard of care
| Intervention | score on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| physical score-baseline | physical score-visit 4 | Physical change | mental score-baseline | mental score-visit 4 | Mental change | |
| Oral Apixaban | 50.7 | 39.2 | -5.9 | 50.7 | 50.7 | 0.8 |
| Subcutaneous Enoxaparin | 49.7 | 38.5 | -6.2 | 49.7 | 49.3 | 0.0 |
Participants were monitored at the 28 (+/- 4) day post-op visit. This was measured through administering a participant satisfaction questionnaire ranging from strongly agree to strongly disagree.This is the number of participants that completed the questionnaire in response to agreeing it was difficult to remember to take the medication, agreeing that there was pain associated with the medication, and agreeing that the medication was easy to use. (NCT02366871)
Timeframe: On visit 4, which is 28 days (+/- 4 days) post-op/standard of care
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Difficult remembering to take medication72102815 | Difficult remembering to take medication72102814 | Pain associated with taking the medication72102814 | Pain associated with taking the medication72102815 | Was medication easy to take72102814 | Was medication easy to take72102815 | |||||||||||||
| Agree | Neutral | Disagree | ||||||||||||||||
| Oral Apixaban | 23 | |||||||||||||||||
| Subcutaneous Enoxaparin | 23 | |||||||||||||||||
| Oral Apixaban | 16 | |||||||||||||||||
| Subcutaneous Enoxaparin | 15 | |||||||||||||||||
| Oral Apixaban | 149 | |||||||||||||||||
| Subcutaneous Enoxaparin | 149 | |||||||||||||||||
| Oral Apixaban | 4 | |||||||||||||||||
| Subcutaneous Enoxaparin | 92 | |||||||||||||||||
| Oral Apixaban | 10 | |||||||||||||||||
| Subcutaneous Enoxaparin | 25 | |||||||||||||||||
| Oral Apixaban | 173 | |||||||||||||||||
| Subcutaneous Enoxaparin | 70 | |||||||||||||||||
| Oral Apixaban | 186 | |||||||||||||||||
| Subcutaneous Enoxaparin | 110 | |||||||||||||||||
| Oral Apixaban | 2 | |||||||||||||||||
| Subcutaneous Enoxaparin | 21 | |||||||||||||||||
| Oral Apixaban | 0 | |||||||||||||||||
| Subcutaneous Enoxaparin | 56 | |||||||||||||||||
Bleeding events requiring alteration in the course of care within 90 days of surgery (NCT02411292)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Enoxaparin Metabolism | 3 |
Any symptomatic venous thromboembolism events, including deep venous thrombosis or pulmonary embolus occurring within 90 days of surgery (NCT02411292)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Low aFXa Level | 5 |
| In-Range or High aFXa Level | 0 |
Event rate was number of participants with all-cause death divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 0.19 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.19 |
An ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 1.97 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.40 |
ICAC adjudicated suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 1.25 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.00 |
ICAC adjudicated suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 1.19 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.81 |
ICAC adjudicated cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 0.13 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.00 |
ICAC adjudicated VTE, acute clinically overt bleeding events, suspected thrombocytopenia, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 9.90 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 10.60 |
ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 2.13 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.97 |
ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. VTE includes DVT and PE. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 2.05 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.73 |
VTE / VTE-related death was defined as the combination of fatal or non-fatal PE, and symptomatic or asymptomatic DVT. A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. An ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 8.91 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 8.61 |
A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. An ICAC adjudicated all venograms, suspected proximal DVT and non-fatal PE, and all-cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed and reported as percentage (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 2.05 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.64 |
An Independent Central Adjudication Committee (ICAC) adjudicated all venograms, suspected symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed and reported as percentage (%). Surgery=Day 1; Randomization/Treatment started on Day of Surgery or the next day (Day 1 or Day 2). A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. Intended Treatment Period=starts on the day of randomization; for treated participants, the period ends at the latter of 2 days after last dose of study drug or 14 days after the first dose of study drug; for randomized participants who were not treated, the period ends 14 days after randomization. (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 8.99 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 8.85 |
ICAC adjudicated acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From first dose to last dose, plus 2 days (12 days, plus 2)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| MI/Stroke | MI | Stroke | Thrombocytopenia | |
| Apixaban 2.5mg BID | 0.06 | 0.06 | 0.00 | 0.00 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.31 | 0.25 | 0.13 | 0.13 |
ICAC adjudicated acute clinically overt bleeding events as per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). Follow up Period was from the end of the treatment period (last dose) up to 60 days post last dose, Day 72. (NCT00371683)
Timeframe: Last dose of study drug to Day 72 (60 days)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Major Bleeding (n=1563, 1553) | CR N-M Bleeding (n=1563, 1553) | Major or CR N-M Bleeding (n=1563, 1553) | Any Bleeding (n=1563, 1553) | |
| Apixaban 2.5mg BID | 0.13 | 0.26 | 0.38 | 0.90 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.13 | 0.45 | 0.58 | 1.29 |
ICAC adjudicated acute clinically overt bleeding events as per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). Clinically relevant (CR); Non-Major (N-M) Bleeding. Day 1=Day of surgery. Treatment started (first dose) day of surgery or next day. Treatment continued for 12 days. (NCT00371683)
Timeframe: First dose of study drug to last dose, plus 2 days post last dose
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Major Bleeding (n=1596, 1588) | CR N-M Bleeding (n=1596, 1588) | Major or CR N-M Bleeding(n=1596, 1588) | Any Bleeding (n=1596, 1588) | |
| Apixaban 2.5mg BID | 0.69 | 2.19 | 2.88 | 5.33 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.39 | 2.96 | 4.28 | 6.80 |
An ICAC adjudicated all venograms, suspected symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| PE (Fatal or Non-Fatal) (n=1599, 1596) | Non-Fatal PE (n=1599, 1596) | All DVT n=1142, 1122 | Symptomatic DVT (n=1599, 1596) | Asymptomatic DVT (n=1139,1115) | Symptomatic Proximal DVT (n=1599,1596) | Symptomatic Distal DVT (n=1599,1596) | |
| Apixaban 2.5mg BID | 1.00 | 0.88 | 7.79 | 0.19 | 7.55 | 0.13 | 0.06 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.44 | 0.44 | 8.20 | 0.44 | 7.62 | 0.19 | 0.38 |
ICAC adjudicated all venograms and suspected symptomatic DVT. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Proximal DVT (n=1254, 1207) | Distal DVT (n=1146, 1133) | Asymptomatic Proximal DVT (n=1252, 1204) | Asymptomatic Distal DVT (n=1145, 1127) | |
| Apixaban 2.5mg BID | 0.72 | 7.24 | 0.56 | 7.16 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.91 | 8.03 | 0.66 | 7.54 |
A 60-day follow-up period started after the last dose of study drug and continued until the End of Study Visit on Day 72 (60 days ± 3 days, after the last dose of study drug). Event rate was number of participants with the endpoint divided by the number of participants analyzed (%). ICAC adjudicated acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke per ISTH guidelines modified for surgical patients. (NCT00371683)
Timeframe: Post last dose of study drug to Day 72 (60 days)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| MI/Stroke | MI | Stroke | Thrombocytopenia | |
| Apixaban 2.5mg BID | 0.06 | 0.06 | 0.00 | 0.00 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.06 | 0.06 | 0.00 | 0.00 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug (12 + 2 days). Baseline=measurement prior to first dose of study drug. Heart rate was measured during screening (pre-operative, post-operative) and in the treatment period on Days 1 (day of first dose), 2, 3, 4,12 (end of treatment). Heart rate was measured in beats per minute (bpm). (NCT00371683)
Timeframe: Baseline to last dose of study drug, plus 2 days
| Intervention | bpm (Mean) | ||||
|---|---|---|---|---|---|
| Heart Rate Day 1 (n=240,237) | Heart Rate Day 2 (n=1575,1574) | Heart Rate Day 3 (n=1490,1498) | Heart Rate Day 4 (n=127,134) | Heart Rate Day 12 (n=1495, 1462) | |
| Apixaban 2.5mg BID | 2.3 | 4.6 | 4.5 | 7.6 | -0.3 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 2.7 | 4.5 | 5.0 | 9.4 | -0.1 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug (12 + 2 days). Baseline=measurement prior to first dose of study drug. Blood pressures (BP) were measured during screening (pre-operative, post-operative) and in the treatment period on Days 1 (day of first dose), 2, 3, 4,12 (end of treatment). Systolic and diastolic pressures were measured in millimeters of mercury (mmHg). (NCT00371683)
Timeframe: Baseline to last dose of study drug, plus 2 days
| Intervention | mmHg (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Diastolic BP Day 1 (n=240, 237) | Diastolic BP Day 2 (n=1577, 1574) | Diastolic BP Day 3 (n=1489,1498) | Diastolic BP Day 4 (n=127,134) | Diastolic BP Day 12 (n=1495,1463) | Systolic BP Day 1 (n=240,237) | Systolic BP Day 2 (n=1577,1574) | Systolic BP Day 3 (n=1489,1498) | Systolic BP Day 4 (n=127,134) | Systolic BP Day 12 (n=1495,1463) | |
| Apixaban 2.5mg BID | -0.4 | 1.7 | 2.3 | 0.6 | 7.3 | 1.5 | 5.4 | 4.7 | 2.8 | 9.1 |
| Enoxaparin 30 mg SC Injection q 12 Hours | -0.9 | 1.5 | 2.1 | 0.3 | 7.5 | -0.7 | 4.2 | 4.3 | 1.4 | 8.9 |
Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Potassium: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*predose or > ULN if pre-dose > ULN then use > 1.1*predose or < LLN. Calcium: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*predose or > ULN If pre-dose > ULN then use > 1.25*predose or < LLN. Chloride: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*predose or > ULN if pre-dose > ULN then use > 1.1*predose or < LLN. Sodium: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*predose or >ULN if pre-dose > ULN then use > 1.05*predose or < LLN. Bicarbonate: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*predose or > ULN if pre-dose > ULN then use > 1.25*predose or < LLN. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Calcium low (n=1569,1562) | Calcium high (n=1569,1562) | Chloride low (n=1568,1562) | Chloride high (n=1568,1562) | Bicarbonate low (n=1568,1561) | Potassium low(n=1568,1559) | Potassium high(n=1568,1559) | Sodium low (n=1568,1562) | Sodium high (n=1568,1562) | |
| Apixaban 2.5mg BID | 1 | 0 | 11 | 0 | 11 | 54 | 26 | 23 | 2 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 5 | 1 | 17 | 1 | 13 | 56 | 20 | 39 | 0 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Hematology profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 2, 3, 4, 12 (end of treatment). Upper limit of normal (ULN); lower limit of normal (LLN). Platelet Count low: < 100,000/mm^3 (or < 100*109 cells/L). Erythrocytes low: < 0.75 *pre-dose. Hemoglobin low: > 2 g/dL decrease compared to pre-dose or Value ≤ 8 g/dL. Hematocrit low: < 0.75*pre-dose . Leukocytes: < 0.75*LLN or > 1.25* ULN, or if pre-dose < LLN then use < 0.8*predose or > ULN if pre-dose > ULN then use > 1.2*predose or < LLN. Lymphocytes (absolute): < 0.750*10^3 cells/µL or > 7.50*10^3 cells/ µL. Eosinophils (absolute) high: > 0.750*10^3 cells/µL. Basophils(absolute) high: > 400/mm^3 (or > 0.4*103 cells/µL). Monocytes (absolute) high: > 2000/mm^3 (or > 2*103 cells/µL). Neutrophils(absolute) high: < 1.0*103 cells/µL. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin low (n=1561,1549) | Hematocrit low (n=1558,1547) | Platelet count low (n=1556,1543) | Erythrocytes low (n=1557,1547) | Leukocytes low(n=1583,1572) | Leukocytes high(n=1583,1572) | Basophils high (n=1577, 1564) | Eosinophils high (n=1577, 1564) | Lymphocytes low (n=1577,1564) | Lymphocytes high (n=1577,1564) | Monocytes high (n=1577,1564) | Neutrophils low (n=1577,1564) | |
| Apixaban 2.5mg BID | 386 | 135 | 6 | 130 | 8 | 214 | 0 | 32 | 125 | 2 | 4 | 4 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 392 | 157 | 9 | 149 | 11 | 210 | 2 | 13 | 117 | 4 | 4 | 5 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Bilirubin (direct) high: > 1.5*ULN. Total bilirubin: : > 2*ULN, Alanine Aminotransferase (ALT) high: > 3*ULN. Alkaline Phosphatase (ALP): > 2*ULN. Aspartate Aminotransferase (AST): > 3*ULN. Creatinine: > 1.5*ULN. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| ALP high (n=1573,1563) | ALT high (n=1573,1562) | AST high (n=1573,1562) | Bilirubin direct high (n=1563,1553) | Bilirubin total high(n=1572,1562) | Creatinine high (n=1569,1562) | |
| Apixaban 2.5mg BID | 42 | 33 | 29 | 63 | 2 | 17 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 55 | 45 | 40 | 54 | 8 | 28 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Fasting Glucose: if pre-dose < LLN then use < 0.8*predose; or > ULN if pre-dose > ULN then use > 2.0*predose or
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Fasting Glucose low (n=611, 579) | Fasting Glucose high (n=611, 579) | Total Protein low (n=1568,1562) | CK high (n=1573,1563) | Uric Acid high (n=1567,1562) | |
| Apixaban 2.5mg BID | 8 | 54 | 527 | 52 | 22 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 5 | 28 | 513 | 45 | 12 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00371683)
Timeframe: First dose to last dose, plus 2 days for AEs (12 + 2 days) or plus 30 days for SAEs (12 + 30 days)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| SAE | Bleeding AE | AEs leading to discontinuation | Deaths | |
| Apixaban 2.5mg BID | 123 | 110 | 60 | 3 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 123 | 144 | 58 | 5 |
Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization; for randomized patients who did not receive study drug, the period ends 14 days after randomization. Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause. (NCT00452530)
Timeframe: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID + Placebo | 1.09 |
| Enoxaparin, 40 mg QD + Placebo | 2.17 |
Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization.Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause. (NCT00452530)
Timeframe: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study drug
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID | 15.06 |
| Enoxaparin, 40 mg QD | 24.37 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Bleeding AEs=all serious or nonserious bleeding-related AEs. (NCT00452530)
Timeframe: Days 1 through 12 + 2 days (nonserious AEs, bleeding AES) or 30 days (SAES, deaths) after last dose of study drug
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| SAE | Bleeding AE | Discontinuations due to AEs | Deaths | |
| Apixaban, 2.5 mg BID + Placebo | 72 | 90 | 40 | 2 |
| Enoxaparin, 40 mg QD + Placebo | 88 | 112 | 44 | 0 |
Event rate=Number of events divided by number of patients evaluated. Adjusted difference of event rates takes into consideration type of surgery as a stratification factor. Bleeding Criteria: Major bleeding=an event consisting of clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. CRNM bleeding= clinically overt bleeding; that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event; that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding; or a change in antithrombic treatment. (NCT00452530)
Timeframe: Days 1 to 12
| Intervention | Percentage of events/patients evaluated (Number) | |||
|---|---|---|---|---|
| Major bleeding (n=9, 14) | CRNM (n=44, 58) | Major bleeding or CRNM (n=53, 72) | Any bleeding | |
| Apixaban, 2.5 mg BID + Placebo | 0.60 | 2.93 | 3.53 | 6.93 |
| Enoxaparin, 40 mg QD + Placebo | 0.93 | 3.85 | 4.77 | 8.36 |
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Calcium, total (mg/dL): <0.8*LLN or >1.2*ULN, or if preRx
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calcium, total (low) (n=1447, 1457) | Chloride, serum (low)(n=1442, 1454) | Bicarbonate (low) (n=1435, 1447) | Potassium, serum (low) (n=1438, 1453) | Potassium, serum (high)(n=1438, 1453) | Sodium, serum (low) (n=1442, 1454) | Sodium, serum (high) (n=1442, 1454) | Glucose, fasting serum (low) (n=715, 713) | Glucose, fasting serum (high) (n=715, 713) | Protein, total (low) (n=1447, 1457 | Creatine kinase (CK) (high) (n=1463, 1476) | Uric acid (high) (n=1446, 1458) | |
| Apixaban, 2.5 mg BID + Placebo | 5 | 1 | 0 | 38 | 34 | 5 | 1 | 8 | 46 | 223 | 66 | 1 |
| Enoxaparin, 40 mg QD + Placebo | 9 | 0 | 3 | 41 | 40 | 10 | 0 | 1 | 25 | 243 | 65 | 2 |
preRX=pretreatment. Blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; glucose, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; protein, urine: If missing preRx use ≥ 2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; Red blood cells , urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; white blood cells, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4. (NCT00452530)
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (± 5 days) of follow-up
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Blood, urine (high) (n=1421, 1430) | Glucose, urine (high) (n=1421, 1429) | Protein, urine (high) (n=1421, 1430) | Red blood cells, urine (high) (n=441, 385) | White blood cells, urine (high)(n=441, 386) | |
| Apixaban, 2.5 mg BID + Placebo | 169 | 160 | 60 | 133 | 101 |
| Enoxaparin, 40 mg QD + Placebo | 113 | 154 | 89 | 116 | 102 |
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal; abs=absolute. Hemoglobin (g/dL): >2 decrease from preRx value or value <=8; hematocrit (%): <0.75*preRx; platelets: <100*10^9 cells/L; erythrocytes (*10^6 cells/μL): <0.75*preRx; leukocytes: <0.75*LLN or >1.25*ULN, or if preRx
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up
| Intervention | Participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, low (n=1424, 1442) | Hematocrit, low n=(1369, 1396) | Platelet count, low (n=1413, 1425) | Erythrocytes, low (n=1368, 1396) | Leukocytes, low (n=1457, 1471) | Leukocytes, high (n=1457, 1471) | Basophils (absolute), high (n=1448, 1465) | Eosinophils (absolute), high (n=1448, 1465) | Lymphocytes (absolute), low (n=1448, 1465) | Lymphocytes (absolute), high (n=1448, 1465) | Monocytes (absolute), high (n=1448, 1465) | Neutrophils (absolute), low (n=1448, 1465) | Alkaline phosphatase (ALP), high (n=1465, 1476) | Alanine aminotransferase (ALT), high (n=1459,1472) | Aspartate aminotransferase (AST) , high (n=1459,14 | Bilirubin, direct (high) (n=1447,1457) | Bilirubin, total (high) (n=1461,1476) | Blood urea nitrogen (BUN) (high)(n=1447,1458) | Creatinine (high) (n=1447,1458) | |
| Apixaban, 2.5 mg BID + Placebo | 1127 | 668 | 7 | 690 | 27 | 193 | 2 | 43 | 203 | 1 | 5 | 5 | 15 | 32 | 34 | 87 | 15 | 15 | 17 |
| Enoxaparin, 40 mg QD + Placebo | 1178 | 723 | 5 | 735 | 26 | 213 | 4 | 60 | 215 | 0 | 2 | 2 | 31 | 26 | 26 | 76 | 9 | 17 | 23 |
Event rate=Number of events divided by the number of patients evaluated. Each patient was categorized as having no proximal DVT, having proximal DVT, being nonevaluable for proximal DVT, having no distal DVT, having distal DVT, or being nonevaluable for distal DVT. Adjudication criteria were: Normal=All deep veins were visualized, and there was no intraluminal filling defect (ILFD). ILFD=An area of reduced, or absent filling, at least partially surrounded with contrast medium in ≥ 2 projections or a lack of filling in a vessel in which there was a cut-off that had the configuration of a thrombus. Indeterminate=A lack of filling of a region of the deep vein system, proximal or distal, without the presence of an ILFD elsewhere in the same region. Not Done=A venography was not performed. Proximal DVT was found if any of the proximal veins had an ILFD. Pulmonary embolism was radiographically (angiography, V/Q scan, computed tomography) determined. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID Plus Placebo | 0.45 |
| Enoxaparin, 40 mg QD Plus Placebo | 1.14 |
Event rate=Number of events divided by the number of patients evaluated. A mandatory bilateral ascending contrast venogram was to be obtained on Day 35 (± 3). Patients with confirmed symptomatic DVT at any time, or asymptomatic DVT upon venography, were to receive treatment for DVT according to the investigator's standard of care. Signs and symptoms suggestive of VTE included, but were not limited to: 1) lower extremity DVT: erythema, warmth, pain, swelling, tenderness; and 2) PE: pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia. Intended Treatment Period started on day of randomization and, for patients who received treatment, ended at the later of 2 days after last dose of study drug or 38 days after the first dose (presurgery) of study drug. For randomized patients who did not receive study drug, the period ended 38 days after randomization. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID Plus Placebo | 1.39 |
| Enoxaparin, 40 mg QD Plus Placebo | 3.86 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Postprocedural hematoma | Operative hemorrhage | Incision site hematoma | Incision site hemorrhage | Postprocedural hemorrhagic | Hematuria traumatic | Periorbital hematoma | Subcutaneous hematoma | Traumatic hematoma | Hematoma | Wound hemorrhage | Hemorrhage | Hematuria | Hemorrhage urinary tract | Urethral hemorrhage | Epistaxis | Hemoptysis | |
| Apixaban, 2.5 mg BID Plus Placebo | 20 | 19 | 14 | 13 | 4 | 1 | 1 | 1 | 0 | 34 | 18 | 13 | 41 | 1 | 0 | 33 | 3 |
| Enoxaparin, 40 mg QD Plus Placebo | 23 | 14 | 10 | 19 | 7 | 1 | 0 | 0 | 1 | 38 | 15 | 13 | 39 | 1 | 2 | 25 | 1 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemorrhagic anemia | Ecchymosis | Petechiae | Hemorrhage subcutaneous | Increased tendency to bruise | Vaginal hemorrhage | Menorrhagia | Uterine hemorrhage | Conjunctival hemorrhage | Hematoma infection | Spinal hematoma | |
| Apixiban, 2.5 mg BID Plus Placebo | 20 | 5 | 2 | 1 | 0 | 2 | 1 | 0 | 1 | 1 | 0 |
| Enoxaparin, 40 mg QD Plus Placebo | 15 | 9 | 2 | 0 | 5 | 0 | 0 | 1 | 0 | 0 | 1 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bloody discharge | Catheter site hemorrhage | Injection site hemorrhage | Injection site hematoma | Infusion site hematoma | Vessel puncture site hematoma | Hematocrit decreased | Red blood cell count decreased | Blood urine present | Blood urine | Occult blood positive | Fibrin D dimer increased | Hematochezia | Mallory-Weiss Syndrome | Hematemesis | Melaena | Rectal hemorrhage | Gingival bleeding | Anal hemorrhage | Diarrhea hemorrhagic | Diverticulum intestinal hemorrhagic | Gastrointestinal hemorrhage | Intra-abdominal hematoma | Duodenal ulcer hemorrhage | Hemorrhoidal hemorrhage | Mouth hemorrhage | |
| Apixaban, 2.5 mg BID Plus Placebo | 16 | 6 | 4 | 3 | 1 | 1 | 18 | 14 | 8 | 1 | 1 | 0 | 6 | 4 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Enoxaparin, 40 mg QD Plus Placebo | 13 | 5 | 10 | 28 | 0 | 0 | 21 | 20 | 6 | 1 | 0 | 1 | 2 | 0 | 2 | 1 | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
Treatment guidelines were provided for jaundice and elevated results of liver function tests. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 30 days after the last dose of study drug
| Intervention | Participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspartate aminotransferase increased | Alanine aminotransferase increased | Gamma-glutamyltransferase increased | Blood bilirubin increased | Bilirubin conjugated increased | Hepatic enzyme increased | Liver function test results abnormal | Transaminases increased | Cholelithiasis | Hepatitis toxic | Cholecystitis acute | Cholestasis | Hyperbilirubinemia | Postcholecystectomy syndrome | Cholecystitis | Hepatic pain | Hepatitis | Hepatomegaly | Jaundice cholestatic | Hypoalbuminemia | Hypoproteinemia | Yellow skin | |
| Apixaban, 2.5 mg BID Plus Placebo | 48 | 40 | 27 | 17 | 11 | 9 | 4 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Enoxaparin, 40 mg QD Plus Placebo | 67 | 61 | 54 | 7 | 12 | 16 | 9 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. MA criteria: Hemoglobin: >2 g/dL decrease from preRx or value ≤ 8 g/dL; hematocrit (%): <0.75*preRx; platelet count (*10^9 cells/L): <100,000/mm^3; erythrocytes (*10^6 cells/μL): <0.75*preRx level; leukocytes (*10^3 cells/μL): < 0.75*LLN or >1.25*ULN, or if preRx LLN use < 0.8*preRx or >ULN if preRx >ULN use >1.2*preRx or
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, low (n=2605, 2587) | Hematocrit, low (n=2554, 2536) | Platelet count, low (n=2597, 2576) | Erythrocytes, low (n=2558, 2540) | Leukocytes, low (n=2632, 2617) | Leukocytes, high (n=2632, 2617) | Basophils (absolute), high (n=2629, 2613) | Eosinophils (absolute), high (n=2629, 2613) | Lymphocytes (absolute), low (n=2629, 2613) | Lymphocytes (absolute), high (n=2629, 2613) | Monocytes (absolute), high (n=2629, 2613) | Neutrophils (absolute), low (n=2629, 2613) | |
| Apixaban, 2.5 mg BID Plus Placebo | 2189 | 1274 | 6 | 1310 | 54 | 385 | 1 | 75 | 383 | 3 | 9 | 5 |
| Enoxaparin, 40 mg QD Plus Placebo | 2218 | 1350 | 9 | 1377 | 54 | 360 | 3 | 70 | 382 | 3 | 11 | 4 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Alanine aminotransferase (ALT) (U/L): >3 *ULN: alkaline phosphatase (ALP) (U/L): >2* ULN; aspartate aminotransferase (ASP) (U/L): >3 *ULN; bilirubin, direct (mg/dL): >2*ULN; bilirubin, total (mg/dL): >2*ULN; BUN (mg/dL): >2*ULN; creatinine (mg/dL): >1.5*ULN; calcium (mg/dL): < 0.8*LLN or >1.2 *ULN, or if preRx
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline phosphatase, high (n=2631, 2618) | Alanine aminotransferase, high (n=2629, 2616) | Aspartate aminotransferase, high (n=2629, 2616) | Bilirubin, direct, high (n=2622, 2604) | Bilirubin, total, high (n=2630, 2617) | Blood urea nitrogen (BUN), high (n=2618, 2598) | Creatinine, high (n=2618, 2598) | Calcium, total, low (n=2618, 2598) | Calcium, total, high (n=2618, 2598) | Chloride, serum, low (n=2615, 2594) | Bicarbonate, low (n=2615, 2595) | Potassium, serum, low (n=2614, 2594) | Potassium, serum, high (n=2614, 2594) | Sodium, serum, low (n=2615, 2594) | Sodium, serum, high (n=2615, 2594) | |
| Apixaban, 2.5 mg BID Plus Placebo | 55 | 50 | 73 | 145 | 24 | 19 | 21 | 7 | 0 | 6 | 8 | 73 | 61 | 29 | 5 |
| Enoxaparin, 40 mg QD Plus Placebo | 57 | 83 | 73 | 139 | 12 | 17 | 25 | 18 | 1 | 6 | 8 | 73 | 47 | 23 | 4 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Glucose, fasting (mg/dL): <.8*LLN or >1.5*ULN, or if preRx
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose, fasting serum, high (n=14, 17) | Protein, total, low (n=2618, 2596) | Protein, total, high (n=2618, 2596) | Creatine kinase, high (n=2630, 2616) | Uric acid, high (n=2618, 2597) | Blood, urine, high (n=2588, 2568) | Glucose, urine, high (n=2588, 2568) | Leukocyte esterase, urine, high (n=21, 41) | Protein, urine (n=2588, 2568) | Red blood cells (RBC), urine, high (n=1310, 1230) | White blood cells (WBC),urine, high (n=1311, 1228) | |
| Apixaban, 2.5 mg BID Plus Placebo | 0 | 747 | 3 | 615 | 2 | 275 | 68 | 0 | 169 | 216 | 217 |
| Enoxaparin, 40 mg QD Plus Placebo | 1 | 752 | 1 | 642 | 3 | 234 | 76 | 4 | 168 | 173 | 229 |
Neurologic events were based on Medical Dictionary for Regulatory Activities search categories.For new or worsening events that were not related to the site of surgery, additional information was collected on a specific form. In addition, neurology consultation was to be obtained for these patients. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paraesthesia | Hypoaesthesia | Burning sensation | Peroneal nerve palsy | Hypotonia | Dysarthria | Paresis | Cervicobrachial syndrome | Coordination abnormal | Hypertonia | Neuropathy peripheral | Peripheral nerve lesion | Radiculitis | Paralysis | Muscular weakness | Nerve injury | Femoral nerve injury | Sciatic nerve injury | Peroneal nerve injury | Diplopia | Gait disturbance | |
| Apixaban, 2.5 mg BID Plus Placebo | 32 | 29 | 7 | 5 | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 | 2 | 1 | 1 | 0 | 1 | 1 |
| Enoxaparin, 40 mg QD Plus Placebo | 19 | 35 | 5 | 6 | 4 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 1 | 11 | 1 | 0 | 0 | 1 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. All suspected bleeding events were to be reported by the investigator as either an AE or SAE and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 30 days after the last dose of study drug
| Intervention | Participants (Number) | ||
|---|---|---|---|
| SAEs | Bleeding AEs | Death | |
| Apixaban, 2.5 mg BID Plus Placebo | 18 | 15 | 2 |
| Enoxaparin, 40 mg QD Plus Placebo | 18 | 21 | 0 |
Event rate=Number of events divided by the number of patients evaluated. Major bleeding event defined as a bleeding event that was 1) Acute clinically overt bleeding accompanied by at least 1 of the following: decrease in hemoglobin of ≥ 2 g/dL over a 24-hour period, transfusion of ≥2 units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intra-spinal, intraocular, pericardial, an operated joint and requires reoperation or intervention, intramuscular with compartment syndrome, or retroperitoneal; 2) Fatal. CRNM was defined as acute clinically overt bleeding that did not satisfy the criteria for a major bleeding event and met at least 1 of the following: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, or hemoptysis. Minor bleeding was defined as an acute clinically overt bleeding event that did not meet the criteria for major bleeding or a CRNM. Fatal bleeding event was defined as bleeding that was the primary (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Percentage of events/patients evaluted (Number) | |||
|---|---|---|---|---|
| Major bleeding | CRNM | Major or CRNM | Any bleeding | |
| Apixaban, 2.5 mg BID Plus Placebo | 0.82 | 4.08 | 4.83 | 11.71 |
| Enoxaparin, 40 mg QD Plus Placebo | 0.68 | 4.51 | 5.04 | 12.56 |
VTE=venous thromboembolic event; VTE-related death=combination of fatal or nonfatal PE and symptomatic or asymptomatic DVT. Event rate=Number of events divided by the number of patients evaluated. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percentage of events/patients evaluated (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All-cause death | VTE-related death | PE (fatal or nonfatal) | Nonfatal PE | All DVT (n=1944, 1911) | Symptomatic DVT | Asymptomatic DVT (n=1943, 1907) | Proximal DVT (n=2196, 2190) | Distal DVT (1951, 1908) | Symptomatic proximal DVT | Asymptomatic proximal DVT (n=2195, 2187) | Symptomatic distal DVT | Asymptomatic distal DVT (n=1950, 1907) | |
| Apixaban, 2.5 mg BID Plus Placebo | 0.11 | 0.04 | 0.11 | 0.07 | 1.13 | 0.04 | 1.08 | 0.32 | 1.03 | 0.04 | 0.27 | 0.04 | 0.97 |
| Enoxaparin, 40 mg QD Plus Placebo | 0.04 | 0.00 | 0.19 | 0.19 | 3.56 | 0.19 | 3.30 | 0.91 | 2.99 | 0.15 | 0.73 | 0.04 | 2.94 |
Event rate=Number of events divided by the number of patients evaluated. All suspected events were reported by investigator. Acute MI=the presence of a clinical situation (eg, abnormal history, physical examination, new electrocardiogram changes) suggestive of an MI and at least 1 of the following: elevated creatine kinase (CK)-MB or troponin T or troponin I ≥2*upper limit of normal (ULN); if CK-MB or troponin values not available, total CK ≥2*ULN; or new significant (≥0.04 sec) Q waves in ≥2 contiguous leads. Stroke=a new focal neurologic deficit of sudden onset lasting at least 24 hours that was not due to a readily identifiable nonvascular cause. Adjudication classified each reported stroke as primary hemorrhagic, nonhemorrhagic, infarction with hemorrhagic conversion, or unknown type. Thrombocytopenia=after 3 days as drop in platelet count to <100,000/mm^3 for patients with a baseline value >150,000/mm^3 or a >50% decline, if the baseline value was ≤150,000/mm^3. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percent of events/patients evaluated (Number) | |||
|---|---|---|---|---|
| MI/stroke | MI | Stroke | Thrombocytopenia | |
| Apixaban, 2.5 mg BID Plus Placebo | 0.22 | 0.19 | 0.04 | 0.07 |
| Enoxaparin, 40 mg QD Plus Placebo | 0.26 | 0.11 | 0.15 | 0.11 |
All cause death, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 1 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 18 |
| Enoxaparin | 33 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 17 |
| Enoxaparin | 31 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 1 |
| Enoxaparin | 2 |
Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 4 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 60 |
| Enoxaparin | 67 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 61 |
| Enoxaparin | 69 |
Volume of blood loss for treated and operated patients during surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 404.9 |
| Enoxaparin | 411.0 |
Number of treated and operated patients with required blood transfusion on day of surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Transfusions required | Missing | |
| Dabigatran 220mg | 246 | 4 |
| Enoxaparin | 237 | 7 |
Frequency of patients with possible clinically significant abnormalities. (NCT00657150)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(964;962) | AST decrease N=(964;962) | ALT increase N=(966;962) | ALT decrease N=(966;962) | Bilirubin increase N=(966;962) | Bilirubin decrease N=(966;962) | |
| Dabigatran 220mg | 28 | 0 | 34 | 0 | 3 | 0 |
| Enoxaparin | 44 | 0 | 67 | 0 | 1 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major bleeding events | Major and clinically relevant bleeding events | Any bleeding events | |
| Dabigatran 220mg | 14 | 37 | 98 |
| Enoxaparin | 9 | 29 | 83 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00657150)
Timeframe: 3 months
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptomatic Deep Vein Thrombosis | symptomatic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 220mg | 2 | 0 | 1 | 1 | 0 |
| Enoxaparin | 4 | 1 | 0 | 2 | 1 |
AM-PAC (activity measure for post-acute care) will be used to determine if a patient is fit to discharge based on mobility with 6 being unable to mobilize up to 24 being independent. Patients who scored above 20 were considered fit to discharge. (NCT03303794)
Timeframe: Post-Operation Day 1
| Intervention | score on scale (Mean) |
|---|---|
| Bupivicaine | 23 |
| Bupivicaine + Exparel | 23 |
Monitor how much opioid patient consumes (NCT03303794)
Timeframe: During the first 48 hours after surgery
| Intervention | milligram (Mean) |
|---|---|
| Bupivicaine | 90 |
| Bupivicaine + Exparel | 76 |
Will use Numeric Pain Rating Scale (NPRS) to measure pain with 0 being no pain and 10 being the worst pain. (NCT03303794)
Timeframe: 48 hours postoperatively
| Intervention | score on scale (Mean) |
|---|---|
| Bupivicaine | 4 |
| Bupivicaine + Exparel | 4 |
All cause death, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 3 |
| Dabigatran 150mg | 3 |
| Enoxaparin | 0 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 28 |
| Dabigatran 150mg | 38 |
| Enoxaparin | 36 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 23 |
| Dabigatran 150mg | 35 |
| Enoxaparin | 33 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 5 |
| Dabigatran 150mg | 1 |
| Enoxaparin | 3 |
Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 6 |
| Dabigatran 150mg | 9 |
| Enoxaparin | 1 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 46 |
| Dabigatran 150mg | 72 |
| Enoxaparin | 57 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 53 |
| Dabigatran 150mg | 75 |
| Enoxaparin | 60 |
Volume of blood loss for treated and operated patients during surgery. (NCT00168818)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 457 |
| Dabigatran 150mg | 435 |
| Enoxaparin | 463 |
Blood transfusion for treated and operated patients on Day of surgery. (NCT00168818)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Patients with >=1 transfusions | Patients with >=1 non-autologous transfusions | |
| Dabigatran 150mg | 531 | 266 |
| Dabigatran 220mg | 517 | 259 |
| Enoxaparin | 542 | 286 |
Frequency of patients with possible clinically significant abnormalities. (NCT00168818)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(1103;1097;1103) | AST decrease N=(1103;1097;1103) | ALT increase N=(1103;1098;1103) | ALT decrease N=(1103;1098;1103) | Bilirubin increase N=(1102;1094;1102) | Bilirubin decrease N=(1102;1094;1102) | |
| Dabigatran 150mg | 16 | 0 | 29 | 0 | 24 | 0 |
| Dabigatran 220mg | 11 | 0 | 28 | 0 | 25 | 0 |
| Enoxaparin | 29 | 0 | 59 | 0 | 34 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma greater than or equal to 25 cm²~wound hematoma greater than or equal to 100 cm²~spontaneous nose bleed lasting longer than 5 min~macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention~spontaneous rectal bleeding (more than a spot on toilet paper)~gingival bleeding lasting longer than 5 min~any other bleeding event considered clinically relevant by the investigator~Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major | Clinical relevant | Minor | None | |
| Dabigatran 150mg | 15 | 55 | 72 | 1021 |
| Dabigatran 220mg | 23 | 48 | 70 | 1005 |
| Enoxaparin | 18 | 40 | 74 | 1022 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00168818)
Timeframe: end of treatment to day 91±7
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptotic Deep Vein Thrombosis | symptotic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 150mg | 4 | 1 | 1 | 0 | 2 |
| Dabigatran 220mg | 1 | 0 | 1 | 0 | 0 |
| Enoxaparin | 5 | 3 | 0 | 1 | 1 |
Ultrasound of the venous system just below the saphenofemoral junction to assess the venous velocity will be taken before and after application the VenaFlow and the ActiveCare+S.F.T pneumatic compression devices. Change from Baseline in Peak Venous Velocity 30 minutes after Device is applied is recorded. (NCT02345642)
Timeframe: Change from Baseline in Peak Venous Velocity 30 minutes after Device is Applied
| Intervention | cm/s (Mean) | |||
|---|---|---|---|---|
| Delta PVV from before to after Venaflow (Standing) | Delta PVV from before to after Venaflow (Supine) | delta PVV from before to after Activeca (Standing) | delta PVV from before to after Activecare (supine) | |
| 10 Healthy Patients Without THA | 127.9 | 87.1 | 32.6 | 40.5 |
| 10 Patients With THA on Post-Op Day 2 | 155.7 | 86.8 | 41.9 | 37.8 |
Coagulopathic bleeding due to fondaparinux was suspected in patients requiring packed red cell transfusions after initiation of fondaparinux therapy only if the change in hematocrit prompting transfusion was not clinically commensurate with the degree of injuries that the patient had sustained (primarily orthopaedic) and/or the hematocrit did not respond appropriately post-transfusion. (NCT00531843)
Timeframe: 3 weeks post injury
| Intervention | participants (Number) |
|---|---|
| Fondaparinux Sodium | 0 |
Serum samples were collected 30 minutes before (trough) and 2 hours after (peak) the third dose of fondaparinux. Normative data plots comparing study participants with healthy volunteers were supplied by the company outsourced to analyze samples. (NCT00531843)
Timeframe: Day 3
| Intervention | Participants (Number) | |
|---|---|---|
| Trough values outside normative range | Peak values outside normative range | |
| Fondaparinux Sodium | 0 | 0 |
Color-flow duplex venous ultrasonography examinations of upper and lower extremities were performed within 48 hours of injury, and then weekly until discharge or 3 weeks. DVT was defined as any clot occurring in the subclavian, iliac, femoral, or popliteal location. Patients were examined daily for clinical signs and symptoms of venous thromboembolism (VTE) and PE. Small, nonocclusive clots discovered in other locations were observed for progression on sequential ultrasonography examinations. (NCT00531843)
Timeframe: within 3 weeks post injury
| Intervention | participants (Number) | ||
|---|---|---|---|
| DVT | DVT after fondaparinux | PE | |
| Fondaparinux Sodium | 2 | 1 | 0 |
| No Fondaparinux | 2 | NA | 0 |
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
| VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
| VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
| VTE Prophylaxis With Aspirin 81mg BID | 53 |
61 reviews available for dalteparin and Complication, Postoperative
| Article | Year |
|---|---|
[Prevention of deep venous thrombosis after knee arthroscopy. Recent advances].
Topics: Anticoagulants; Arthroscopy; Combined Modality Therapy; Follow-Up Studies; Hemorrhage; Humans; Incid | 2009 |
[Per and early postoperative use of low molecular weight heparin in carotid surgery].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Vessel Prosthesis Implantation; Brain Ischemia | 2003 |
Low-molecular-weight heparin for the prevention of postoperative venous thromboembolism after abdominal surgery: a review.
Topics: Anticoagulants; Colonic Diseases; Digestive System Diseases; Digestive System Neoplasms; Digestive S | 2005 |
Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
Topics: Absorption; Aging; Anticoagulants; Chemical Fractionation; Cost-Benefit Analysis; Dose-Response Rela | 1997 |
[Preventive treatment in internal medicine by low-molecular-weight heparin (nadroparine calcium)].
Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Internal Medicine; Nadropari | 1998 |
Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.
Topics: Absorption; Animals; Biological Availability; Blood Coagulation; Half-Life; Heparin; Heparin, Low-Mo | 1994 |
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Lo | 2017 |
Rivaroxaban is as efficient and safe as bemiparin as thromboprophylaxis in knee arthroscopy.
Topics: Adult; Aged; Arthroscopy; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Follow-Up Studies; Hepa | 2014 |
Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism.
Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Postoperative | 2003 |
Low Anti-Factor Xa Level Predicts 90-Day Symptomatic Venous Thromboembolism in Surgical Patients Receiving Enoxaparin Prophylaxis: A Pooled Analysis of Eight Clinical Trials.
Topics: Anticoagulants; Enoxaparin; Humans; Postoperative Complications; Postoperative Hemorrhage; Prospecti | 2022 |
Surgical Management of Placenta Accreta Spectrum.
Topics: Anticoagulants; Cesarean Section; Enoxaparin; Female; Gestational Age; Humans; Hysterectomy; Magneti | 2018 |
Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Humans; Male; Middle Aged | 2018 |
Systematic review of prophylaxis for venous thromboembolism after knee arthroplasty: enoxaparin versus rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Enoxaparin; Humans; Postopera | 2019 |
Does the form of venous thromboembolism prophylaxis following primary total knee arthroplasty alter the rate of early reoperation or revision surgery?
Topics: Arthroplasty, Replacement, Knee; Aspirin; Australia; Case-Control Studies; Clinical Decision-Making; | 2019 |
Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis.
Topics: Anticoagulants; Bariatric Surgery; Comparative Effectiveness Research; Enoxaparin; Heparin, Low-Mole | 2013 |
Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs.
Topics: Anticoagulants; Clinical Protocols; Clinical Trials as Topic; Drug Dosage Calculations; Enoxaparin; | 2014 |
Mesenteric venous thrombosis.
Topics: Abdominal Pain; Adult; Anticoagulants; Colectomy; Colitis, Ulcerative; Enoxaparin; Fibrinolysis; Hum | 2015 |
Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brain Ischemi | 2015 |
Utility of anti-factor Xa monitoring in surgical patients receiving prophylactic doses of enoxaparin for venous thromboembolism prophylaxis.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Monitoring, Intraoperative; Postoperative | 2017 |
Should we be following anti-factor Xa levels in patients receiving prophylactic enoxaparin perioperatively?
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Fe | 2017 |
[Rivaroxaban (Xarelto): efficacy and safety].
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III | 2008 |
Safety evaluation of enoxaparin in currently approved indications.
Topics: Adult; Animals; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Myocardial Infarction; Posto | 2009 |
Anticoagulant therapy for percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clinical Trials as Topic; Coronary Th | 2010 |
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Enox | 2010 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhib | 2011 |
[Spontaneous resolution of a paraparesis due to a dorsolumbar epidural haematoma associated with subarachnoid anaesthesia and postoperative analgesia using an epidural catheter].
Topics: Aged; Analgesia, Epidural; Anesthesia, Epidural; Anesthesia, Spinal; Anticoagulants; Arthroplasty, R | 2012 |
Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Enoxaparin; Health Ca | 2002 |
Venous thromboembolism in cancer patients: expanding horizons.
Topics: Antineoplastic Agents; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular- | 2002 |
A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Fondaparinux; Humans; Middle Aged; Orthopedic P | 2002 |
The design of venous thromboembolism prophylaxis trials: is enoxaparin more effective than fondaparinux?
Topics: Anticoagulants; Clinical Trials as Topic; Double-Blind Method; Enoxaparin; Fondaparinux; Humans; Pol | 2003 |
Improvements in the prevention of postoperative venous thromboembolism in hip fracture patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials, Phase III | 2003 |
New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Factor | 2003 |
Clinical application of enoxaparin.
Topics: Anticoagulants; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Enoxaparin; Fibrinolytic Ag | 2004 |
Pentasaccharides. The new anticoagulants.
Topics: Anticoagulants; Enoxaparin; Female; Fondaparinux; Humans; Male; Orthopedic Procedures; Polysaccharid | 2004 |
Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic | 2004 |
Massive retroperitoneal hematoma during enoxaparin treatment of pulmonary embolism after primary total hip arthroplasty: case reports and review of the literature.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Female; Hematoma; Humans; Postoper | 2006 |
Prevention of postoperative thromboembolism in general surgery with enoxaparin.
Topics: Adult; Aged; Blood Loss, Surgical; Enoxaparin; Hematologic Tests; Hemorrhage; Heparin; Humans; Middl | 1994 |
Clinical profile of enoxaparin in a high-risk situation.
Topics: Clinical Trials as Topic; Dextrans; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1994 |
Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.
Topics: Biological Availability; Blood Coagulation; Dose-Response Relationship, Drug; Enoxaparin; Female; He | 1995 |
Enoxaparin in the prevention of deep venous thrombosis.
Topics: Clinical Trials as Topic; Drug Costs; Enoxaparin; Hip Prosthesis; Humans; Postoperative Complication | 1994 |
Low molecular weight heparins and their use in obstetrics and gynecology.
Topics: Clinical Trials as Topic; Enoxaparin; Female; Fetus; Gynecology; Hemorrhage; Heparin, Low-Molecular- | 1994 |
Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
Topics: Cost-Benefit Analysis; Enoxaparin; Hip Prosthesis; Humans; Postoperative Complications; Thrombophleb | 1994 |
Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications.
Topics: Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complicat | 1993 |
Contemporary use of and future roles for heparin in antithrombotic therapy.
Topics: Anticoagulants; Antithrombins; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; | 1995 |
The role of low-molecular-weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin.
Topics: Dose-Response Relationship, Drug; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Meta-Analysis as | 1996 |
Prolonged prophylaxis against postoperative venous thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Disease Susceptibility; Double-Blind Method; Drug Ad | 1996 |
Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty.
Topics: Adult; Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Clinical Trials as Topic; Co | 2000 |
Management of venous and cardiovascular thrombosis: enoxaparin.
Topics: Angina, Unstable; Anticoagulants; Coronary Thrombosis; Enoxaparin; Fibrinolytic Agents; Humans; Myoc | 2000 |
Update on low molecular weight heparins at the beginning of third millennium. Focus on reviparin.
Topics: Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Ri | 2011 |
Efficacy and safety of Clivarin and other LMWHs in general surgery: a meta-analysis.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Hematoma; Heparin, Low-Molecular-Weight; Huma | 1993 |
Patients at risk of venous thromboembolism--clinical results with reviparin.
Topics: Abdomen; Anticoagulants; Clinical Trials as Topic; Fibrinolytic Agents; Heparin, Low-Molecular-Weigh | 1996 |
Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis.
Topics: Anticoagulants; Cost-Benefit Analysis; Heparin, Low-Molecular-Weight; Humans; Postoperative Complica | 1996 |
Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
Topics: Adult; Anticoagulants; Catheterization, Central Venous; Child; Female; Hemorrhage; Heparin, Low-Mole | 2001 |
Low molecular weight heparin for the prevention of deep venous thrombosis after total knee arthroplasty: A systematic review and meta-analysis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Transfusion; Dalteparin; Female; Hepari | 2018 |
Dalteparin: a low-molecular-weight heparin.
Topics: Abdomen; Adult; Aged; Anticoagulants; Biological Availability; Dalteparin; Drug Costs; Female; Hepar | 1997 |
Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
Topics: Blood Coagulation; Coronary Disease; Dalteparin; Drug Costs; Drug Interactions; Economics, Pharmaceu | 2000 |
Death after joint replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; | 2000 |
New insights into extended prophylaxis after orthopaedic surgery - the North American Fragmin Trial experience.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Cost-Benefit Analysis; Dalteparin; Decision Making; | 2000 |
Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
Topics: Algorithms; Angina, Unstable; Anticoagulants; Biomarkers; Combined Modality Therapy; Coronary Angiog | 2000 |
Is there a need for long-term thromboprophylaxis following general surgery?
Topics: Bandages; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Follow-Up Studie | 1993 |
Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis.
Topics: Anticoagulants; Aspirin; Databases, Factual; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Join | 2017 |
193 trials available for dalteparin and Complication, Postoperative
| Article | Year |
|---|---|
Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study.
Topics: Activities of Daily Living; Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Female; Hum | 2021 |
Influence of Fondaparinux Versus Nadroparin Calcium Thromboprophylaxis on Clinical Parameters Following Total Knee Arthroplasty
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Female; Fondaparinux; | 2016 |
Nadroparin or fondaparinux versus no thromboprophylaxis in patients immobilised in a below-knee plaster cast (PROTECT): A randomised controlled trial.
Topics: Adult; Anticoagulants; Casts, Surgical; Female; Fondaparinux; Humans; Immobilization; Leg Injuries; | 2017 |
A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Colorectal Neoplasms; Enoxaparin; Female; Fibrinolyt | 2006 |
[A clinical trial of the preparation Fraxiparin].
Topics: Adult; Aged; Analysis of Variance; Blood Platelets; Factor Xa; Female; Hemostasis; Humans; Middle Ag | 1993 |
Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
Topics: Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Hemorrhage; Humans; Nadrop | 1996 |
Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium)
Topics: Aged; Anticoagulants; Drug Administration Schedule; Female; Hip Fractures; Humans; Leg Injuries; Mal | 1996 |
[Comparison of 2 low molecular weight heparins in patients undergoing major abdominal surgery].
Topics: Abdomen; Adult; Aged; Blood Coagulation Factors; Blood Loss, Surgical; Dalteparin; Female; Fibrinoly | 1996 |
Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Female; Humans; Mid | 1999 |
[The drug prevention of postoperative thromboses in patients with critical lower limb ischemia].
Topics: Anticoagulants; Aspirin; Critical Illness; Humans; Ischemia; Leg; Nadroparin; Platelet Aggregation I | 1999 |
Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial.
Topics: Adult; Anastomosis, Roux-en-Y; Anticoagulants; Body Mass Index; Female; Gastric Bypass; Humans; Inje | 2001 |
Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).
Topics: Adult; Anticoagulants; Bariatric Surgery; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weigh | 2009 |
Prophylaxis of thromboembolism in bariatric surgery with parnaparin.
Topics: Adult; Anticoagulants; Bariatric Surgery; Blood Coagulation Tests; Body Mass Index; Combined Modalit | 2007 |
Efficiency and safety evaluation of prophylaxes for venous thrombosis after gynecological surgery.
Topics: Anticoagulants; Arginine; Endometrial Neoplasms; Female; Gynecologic Surgical Procedures; Heparin, L | 2020 |
Prevention of deep venous thrombosis by a new low molecular weight heparin (Fluxum) in cardiac surgery.
Topics: Female; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Myoc | 1993 |
Randomized Trial of Deep Vein Thrombosis Chemoprophylaxis with Bemiparin and Enoxaparin in Patients with Moderate to High Thrombogenic Risk Undergoing Plastic and Reconstructive Surgery Procedures.
Topics: Adult; Anticoagulants; Chemoprevention; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; P | 2020 |
Extended use of bemiparin as thromboprophylaxis during bariatric surgery: results of anti-factor Xa activity measurements.
Topics: Adult; Anticoagulants; Bariatric Surgery; Body Mass Index; Drug Administration Schedule; Factor Xa; | 2018 |
A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Female | 2000 |
Milvexian for the Prevention of Venous Thromboembolism.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Dose | 2021 |
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Aust | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Edema; Enoxaparin; Humans; Postoperative Com | 2022 |
Is Enoxaparin Associated With a Higher Risk of Persistent Wound Drainage Than Aspirin? A Secondary Analysis of Data From the CRISTAL Randomized Trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Australia; Drainage; Enoxaparin; Huma | 2023 |
Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial.
Topics: Anticoagulants; Biosimilar Pharmaceuticals; Enoxaparin; Gastrointestinal Neoplasms; Humans; Postoper | 2023 |
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Respo | 2020 |
Fixed or Weight-Tiered Enoxaparin After Thoracic Surgery for Venous Thromboembolism Prevention.
Topics: Aged; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; Male; Middle Aged; Postoperative Comp | 2020 |
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
Topics: Administration, Oral; Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hu | 2020 |
Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, F | 2020 |
Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, F | 2020 |
Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, F | 2020 |
Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, F | 2020 |
Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial.
Topics: Aged; Anticoagulants; Colorectal Neoplasms; Enoxaparin; Female; Hemorrhage; Humans; Intermittent Pne | 2020 |
Efficacy and Safety of Low-Molecular-Weight Heparin on Prevention of Venous Thromboembolism after Laparoscopic Operation for Gastrointestinal Malignancy in Japanese Patients: A Multicenter, Open-Label, Prospective, Randomized Controlled Trial.
Topics: Adult; Aged; Contrast Media; Drug Administration Schedule; Enoxaparin; Female; Gastrointestinal Neop | 2020 |
Optimal Dosing of Prophylactic Enoxaparin after Surgical Procedures: Results of the Double-Blind, Randomized, Controlled FIxed or Variable Enoxaparin (FIVE) Trial.
Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Humans; Male; Middle Aged; Postopera | 2021 |
Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Gastrectomy; Humans; Incidence; Japan; Male; Middle Aged; P | 2021 |
Abelacimab for Prevention of Venous Thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Rep | 2021 |
Weight-Based Dosing for Once-Daily Enoxaparin Cannot Provide Adequate Anticoagulation for Venous Thromboembolism Prophylaxis.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Body Weight; Dose-Response Relationship, Drug; Drug | 2017 |
Enoxaparin 40 mg per Day Is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgical Procedure.
Topics: Academic Medical Centers; Adult; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Fem | 2018 |
Sodium pentosan polysulfate efficacy as thromboprophylaxis agent in high-risk women following gynecological surgery.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Gynecologic Surgical Procedures; Humans; Middle Age | 2018 |
Prophylaxis of Postoperative Venous Thromboembolism Using Enoxaparin After Esophagectomy: A Prospective Observational Study of Effectiveness and Safety.
Topics: Aged; Anticoagulants; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Hu | 2018 |
Enoxaparin versus No Anticoagulation Prophylaxis after Total Knee Arthroplasty in Thai Patients: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxa | 2017 |
Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial.
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Biosimilar Pharmaceuticals; Enoxaparin; Female; Humans; Mal | 2018 |
OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Doubl | 2019 |
Safety of In-Hospital Only Thromboprophylaxis after Fast-Track Total Hip and Knee Arthroplasty: A Prospective Follow-Up Study in 17,582 Procedures.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dalteparin; D | 2018 |
Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study.
Topics: Aged; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Hemorrhage; Heparin, Low-Molecular-We | 2019 |
Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Colorectal Surgery; Dose-Res | 2019 |
Efficacy and safety of enoxaparin for preventing venous thromboembolic events after laparoscopic colorectal cancer surgery: a randomized-controlled trial (YCOG 1404).
Topics: Adult; Aged; Anticoagulants; Colorectal Neoplasms; Digestive System Surgical Procedures; Enoxaparin; | 2020 |
Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cos | 2013 |
A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).
Topics: Aged; Anticoagulants; Austria; Cause of Death; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2013 |
The effect of enoxaparin-containing irrigation fluid used during cataract surgery on postoperative inflammation in patients with diabetes.
Topics: Aged; Anterior Chamber; Anticoagulants; Cataract; Cataract Extraction; Diabetes Mellitus; Diabetic R | 2013 |
Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial.
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind | 2014 |
[Prophylaxis of thrombotic complications in patients after reconstructive operations on the main arteries of the lower extremities, made for arteriosclerosis obliterans in a critical ischemia stage].
Topics: Aged; Anticoagulants; Arteriosclerosis Obliterans; Blood Coagulation; Enoxaparin; Female; Humans; Is | 2014 |
Thromboprophylaxis and Incidence of Venous Thromboembolism in Patients With Hemophilia A or B Who Underwent High-Risk Orthopedic Surgeries.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Compression Bandages; Enoxaparin; Fa | 2016 |
Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Gastrectomy; Humans; Incidence; | 2014 |
Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Cohort Studies; Enoxaparin; Fema | 2014 |
Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.
Topics: Adult; Anticoagulants; Bariatric Surgery; Body Weight; Dose-Response Relationship, Drug; Enoxaparin; | 2015 |
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Clinical Protocols; | 2015 |
Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study.
Topics: Adolescent; Anticoagulants; Bariatric Surgery; Chemoprevention; Drug Administration Schedule; Enoxap | 2015 |
Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, Female; Gynecologic Surgical Procedures | 2015 |
Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2015 |
Prevention of Postoperative Venous Thromboembolism in Thoracic Surgical Patients: Implementation and Evaluation of a Caprini Risk Assessment Protocol.
Topics: Adult; Aged; Anticoagulants; Clinical Audit; Clinical Protocols; Drug Administration Schedule; Enoxa | 2016 |
Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Factor Xa Inhibitors; Female; Hemo | 2016 |
Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study.
Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Confidence Intervals; Dabigatran; Double | 2017 |
A Phase II Clinical Trial of the Efficacy and Safety of Short-term (3 days) Enoxaparin for the Prevention of Venous Thromboembolism after Gastric Cancer Surgery.
Topics: Anticoagulants; Clinical Protocols; Drug Administration Schedule; Enoxaparin; Humans; Middle Aged; P | 2016 |
Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Drug Interactions; Enoxapa | 2017 |
Femoral vascular complications following catheter ablation of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Catheter Ablation; Enoxaparin; Female; Femoral Artery; Hematoma | 2009 |
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2009 |
Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Drug Administration Schedule; Elec | 2010 |
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; En | 2010 |
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; En | 2010 |
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; En | 2010 |
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; En | 2010 |
A combinative effect of low-molecular-weight heparin and intermittent pneumatic compression device for thrombosis prevention during laparoscopic fundoplication.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Coagulants; Enoxaparin; Female; Fibrin | 2010 |
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Enox | 2010 |
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2010 |
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip | 2010 |
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimida | 2011 |
Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population?
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Combined Modality Therapy; Compression Bandage | 2011 |
[Prophylaxis of thromboembolic events in surgery. DVT prophylaxis: a comparison of out-patient and hospitalized patients].
Topics: Ambulatory Care; Comorbidity; Enoxaparin; Female; Fibrinolytic Agents; Germany; Hospitalization; Hum | 2013 |
[Enoxaparin for the prevention of post surgical pulmonary embolism].
Topics: Adult; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Postoperative C | 2011 |
Anti-inflammatory effect of low-molecular-weight heparin in pediatric cataract surgery: a randomized clinical trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cataract Extraction; Child, Preschool; Double-Blind Method; | 2012 |
Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; F | 2013 |
Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; Electro | 2002 |
Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis.
Topics: Bandages; Brain Neoplasms; Combined Modality Therapy; Craniotomy; Double-Blind Method; Enoxaparin; F | 2002 |
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip | 2003 |
A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Fondaparinux; Humans; Middle Aged; Orthopedic P | 2002 |
Preoperative use of enoxaparin is not a risk factor for postoperative bleeding after coronary artery bypass surgery.
Topics: Aged; Anticoagulants; Blood Transfusion; Coronary Artery Bypass; Enoxaparin; Female; Heparin; Humans | 2003 |
Can low molecular weight heparin replace unfractionated heparin during peripheral arterial reconstruction? An open label prospective randomized controlled trial.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Logistic Models; Male; Peripheral Vascula | 2004 |
[The use of low-molecular heparins in reconstructive surgery of ascending aortic aneurysms].
Topics: Adult; Anticoagulants; Aorta; Aortic Aneurysm; Cardiac Surgical Procedures; Enoxaparin; Female; Hepa | 2004 |
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip | 2005 |
Risk factors for ischemic lesions following aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Aneurysm, Ruptured; Anticoagulants; Cerebral Infarction; Double-Blind Method; Enoxapari | 2005 |
Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
Topics: Angiography; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort | 2005 |
Serum acute phase protein concentrations after hysterectomy with and without low-molecular-weight heparin thrombosis prophylaxis.
Topics: Acute-Phase Proteins; Biomarkers; C-Reactive Protein; Dose-Response Relationship, Drug; Drug Adminis | 2005 |
Rates of proximal deep vein thrombosis as assessed by compression ultrasonography in patients receiving prolonged thromboprophylaxis with low molecular weight heparin after major orthopedic surgery.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Hospitalization; Humans; In | 2005 |
Enoxaparin and heparin comparison of deep vein thrombosis prophylaxis in total hip replacement patients.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Female; Heparin; Humans; Injections, Sub | 2006 |
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relati | 2006 |
Prophylaxis of DVT with enoxaparin in patients undergoing total knee replacement.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Humans; Male; Midd | 2006 |
Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Contrast Media; Coronary Angio | 2006 |
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Drug Therapy, Combin | 2006 |
[Low molecular-weight heparin (clexane) in the prevention of thrombotic events in patients with malignancies].
Topics: Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Postoperative Care; Postoperative Comp | 2006 |
Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: the TRANSFER-AMI pilot feasibility study.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Coronary Angiogra | 2006 |
Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Blood Loss, Surgical; Coronary Artery Bypass; | 2007 |
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study.
Topics: Anticoagulants; Enoxaparin; Hip Prosthesis; Humans; Knee Prosthesis; Morpholines; Orthopedic Procedu | 2007 |
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; Clin | 2007 |
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Double-Blind Metho | 2007 |
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticoagulants; Arthroplasty, Replacement, Hip | 2009 |
Preventing DVT following total knee replacement: a review of recent clinical trials.
Topics: Adult; Aged; Anticoagulants; Chemoprevention; Drug Administration Schedule; Enoxaparin; Female; Huma | 1995 |
Consortium data: comparative efficacy of low molecular weight heparin and warfarin following total hip replacement.
Topics: Aged; Anticoagulants; Chemoprevention; Enoxaparin; Female; Hip Prosthesis; Humans; Male; Middle Aged | 1995 |
Safety of enoxaparin and dextran-70 in the prevention of venous thromboembolism in digestive surgery. A play-the-winner-designed study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Dextrans; Digestive System Surgica | 1993 |
Prevention of postoperative thromboembolism in general surgery with enoxaparin.
Topics: Adult; Aged; Blood Loss, Surgical; Enoxaparin; Hematologic Tests; Hemorrhage; Heparin; Humans; Middl | 1994 |
Comparison of enoxaparin versus unfractionated heparin in general surgery. SURGEX-Study Group.
Topics: Blood Loss, Surgical; Double-Blind Method; Enoxaparin; Hemorrhage; Hemostasis; Heparin; Humans; Post | 1994 |
Antithromboembolic efficacy and safety of enoxaparin in general surgery. German multicentre trial.
Topics: Adult; Aged; Enoxaparin; Female; Hematologic Tests; Hemorrhage; Humans; Incidence; Male; Middle Aged | 1994 |
Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female | 1995 |
Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement.
Topics: Aged; Drug Administration Schedule; Enoxaparin; Female; Heparin; Hip Prosthesis; Humans; Male; Posto | 1995 |
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.
Topics: Confidence Intervals; Double-Blind Method; Enoxaparin; Female; Heparin; Humans; Immunoglobulin G; Od | 1995 |
Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation.
Topics: Adult; Aged; Aged, 80 and over; Economics, Pharmaceutical; Enoxaparin; Heparin; Hip Prosthesis; Huma | 1994 |
Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery.
Topics: Aged; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Hip Prosthesis; H | 1993 |
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
Topics: Aged; Alanine Transaminase; Drug Administration Schedule; Enoxaparin; Female; Hemoglobins; Hemorrhag | 1994 |
Prophylaxis of venographically diagnosed deep vein thrombosis in gastrointestinal surgery. Multicentre trials 20 mg and 40 mg enoxaparin versus dextran.
Topics: Adult; Dextrans; Digestive System Surgical Procedures; Double-Blind Method; Enoxaparin; Female; Huma | 1995 |
Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.
Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans | 1996 |
Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo.
Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hip Prosthesis; Humans; Male; Middle | 1996 |
Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. Enoxart Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Vessel Prosthesis; Enoxaparin; Female; Heparin | 1995 |
Characterization of 'winners' to enoxaparin in the prevention of postoperative venous thromboembolism in digestive surgery.
Topics: Anticoagulants; Dextrans; Digestive System Surgical Procedures; Discriminant Analysis; Enoxaparin; F | 1996 |
Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial.
Topics: Aged; Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Enoxaparin; Female; | 1996 |
Prolonged prophylaxis against postoperative venous thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Disease Susceptibility; Double-Blind Method; Drug Ad | 1996 |
The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.
Topics: Adult; Aged; Anticoagulants; Dihydroergotamine; Double-Blind Method; Drug Combinations; Drug Therapy | 1996 |
Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial.
Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hip Prosthesis; Humans; M | 1996 |
The post-hospital discharge venous thrombosis risk of the orthopedic patient.
Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Hip Prosthesis; Humans; Patient Discharge; P | 1997 |
The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hip Prosthe | 1997 |
A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Bandages; Enoxaparin; Female; Hip Prosthesis; Humans | 1996 |
Sequential mechanical and pharmacological thromboprophylaxis in the surgery of hip fractures. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Femor | 1997 |
A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 1997 |
Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.
Topics: Adult; Aged; Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Elective Surg | 1998 |
Development of play-the-winner design: weighting and accumulation of information.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dextrans; Enoxaparin; Female; Humans; In | 1998 |
The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort Studie | 1998 |
Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the French study--venographic outcome at 35 days.
Topics: Aged; Anti-Bacterial Agents; Arthroplasty, Replacement, Hip; Enoxaparin; Female; Follow-Up Studies; | 1998 |
Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the Swedish study.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Humans; Postoperative Complications; Rad | 1998 |
How "gold" is the standard? Interobservers' variation on venograms.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Bandages; Enoxaparin; Female; Humans; Incidenc | 1998 |
Prevention of deep vein thrombosis in knee arthroplasty. Preliminary results from a randomized controlled study of low molecular weight heparin vs foot pump compression.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Bandages; Enoxaparin; Female; Humans; Intraop | 1998 |
Low molecular weight heparin in coronary stenting.
Topics: Coronary Disease; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pilot Proj | 1998 |
Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors.
Topics: Adult; Aged; Anticoagulants; Brain Neoplasms; Cerebral Hemorrhage; Enoxaparin; Female; Humans; Male; | 1998 |
Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor | 1998 |
Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin.
Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Female; Fibrinolytic A | 1999 |
Thrombocytosis after prophylactic administration of enoxaparin: unexpected findings in a Polish prospective multicenter trial on the efficacy and safety of enoxaparin in the prevention of postoperative thromboembolism.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Humans; Middle Aged; Orthopedic Procedures; Platelet | 1999 |
Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug A | 1999 |
Local versus central assessment of venographies in a multicenter trial on the prevention of deep vein thrombosis in neurosurgery.
Topics: Anticoagulants; Double-Blind Method; Enoxaparin; Humans; Neurosurgical Procedures; Observer Variatio | 1999 |
[The prevention of postoperative deep venous thrombosis in orthopedic surgery].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Ortho | 1999 |
Prevention of deep vein thrombosis after hip replacement.
Topics: Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Heparin, Low-M | 2000 |
Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial.
Topics: Anticoagulants; Blood Loss, Surgical; Canada; Colectomy; Double-Blind Method; Enoxaparin; Female; He | 2001 |
[Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2001 |
A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Res | 2001 |
Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Cost-Benefit Analysis; Drug Costs; Enoxaparin; Home | 2000 |
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2001 |
Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female; | 2001 |
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Azetidines; Benz | 2001 |
Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Cesarean Section; Dalteparin; Enoxaparin; Facto | 2001 |
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Topics: Aged; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Hip Fr | 2001 |
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; F | 2001 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Topics: Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cost-Benefit Analysis; Dal | 2002 |
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Fem | 2002 |
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Fem | 2002 |
An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group.
Topics: Adult; Aged; Double-Blind Method; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Inciden | 1993 |
Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.
Topics: Adult; Aged; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Heparin; Heparin, Low-Molecula | 1997 |
Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin.
Topics: Adult; Aged; Anticoagulants; Double-Blind Method; Female; Heparin; Heparin, Low-Molecular-Weight; Hu | 2005 |
Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy.
Topics: Anticoagulants; Cause of Death; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle | 2005 |
Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Body Weight; Cohort Studies; Female; Hemorrhage; Heparin | 2000 |
[Fully automated injection pen for prevention of thrombosis. Tolerance, convenience and patient compliance].
Topics: Heparin, Low-Molecular-Weight; Humans; Injections, Jet; Patient Compliance; Postoperative Complicati | 1999 |
Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients.
Topics: Aged; Anticoagulants; APACHE; Critical Illness; Dalteparin; Female; Heparin; Humans; Intensive Care | 2015 |
Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial.
Topics: Adult; Aged; Ankle Injuries; Anticoagulants; Dalteparin; Double-Blind Method; Female; Fractures, Bon | 2009 |
The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2010 |
Abdominal contouring procedures increase activity of the coagulation cascade.
Topics: Abdominoplasty; Adult; Anticoagulants; Biomarkers; Dalteparin; Humans; Intermittent Pneumatic Compre | 2012 |
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetid | 2002 |
Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Blood Coagulation Factors; Dalteparin; Female; | 2003 |
Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Atrial Fibrillation; Blood Loss, Surgical; Coh | 2004 |
Changes in plasma coagulation markers with prophylactic treatment of low molecular weight heparin after cesarean section.
Topics: Adult; Biomarkers; Blood Coagulation; Cesarean Section; Dalteparin; Female; Fibrin Fibrinogen Degrad | 2005 |
Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study.
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Humans; Incidence; Male | 2006 |
Inhibition of intraocular fibrin formation after infusion of low-molecular-weight heparin during combined phacoemulsification-trabeculectomy surgery.
Topics: Aged; Cataract; Dalteparin; Double-Blind Method; Female; Fibrin; Fibrinolytic Agents; Glaucoma; Huma | 2006 |
Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Ankle Injuries; Anticoagulants; Dalteparin; Double-Blind M | 2007 |
The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood.
Topics: Adult; Biomarkers; Blood Coagulation; Blood Viscosity; Cesarean Section; Dalteparin; Female; Hemorhe | 2007 |
Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: a randomized placebo-controlled, double-blind study.
Topics: Adolescent; Adult; Aged; Ankle Injuries; Anticoagulants; Casts, Surgical; Dalteparin; Double-Blind M | 2007 |
Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. The Fragmin Multicentre Study Group.
Topics: Abdomen; Anticoagulants; Dalteparin; Elective Surgical Procedures; Hemorrhagic Disorders; Humans; Mu | 1996 |
Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
Topics: Adult; Aged; Anticoagulants; Dalteparin; Double-Blind Method; Female; Hip; Hip Prosthesis; Humans; M | 1997 |
Antithrombotic prophylaxis in patients undergoing laparoscopic cholecystectomy.
Topics: Adult; Aged; Anticoagulants; Cholecystectomy, Laparoscopic; Dalteparin; Double-Blind Method; Female; | 1997 |
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
Topics: Anticoagulants; Blood Loss, Surgical; Dalteparin; Female; Hemorrhage; Hip Prosthesis; Humans; Male; | 1997 |
Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery.
Topics: Anticoagulants; Dalteparin; Female; Genital Diseases, Female; Heparin; Humans; Injections, Subcutane | 1998 |
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Double-B | 1998 |
New insights into extended prophylaxis after orthopaedic surgery - the North American Fragmin Trial experience.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Cost-Benefit Analysis; Dalteparin; Decision Making; | 2000 |
Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
Topics: Algorithms; Angina, Unstable; Anticoagulants; Biomarkers; Combined Modality Therapy; Coronary Angiog | 2000 |
Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Feasibility Studies; Female; Hemorrhage; Hospitalization; H | 2001 |
Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Bandages; Dalteparin; Female; Genital Neoplasms, Fem | 2001 |
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in
Topics: Administration, Oral; Adolescent; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement | 2002 |
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthropl | 2002 |
Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial.
Topics: Adolescent; Adult; Anticoagulants; Colorectal Neoplasms; Disease-Free Survival; Heparin, Low-Molecul | 2022 |
[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Combined Modality Therapy; Follow-Up Studies; He | 2011 |
Safety of deep venous thrombosis prophylaxis with low-molecular-weight heparin in brain surgery. Prospective study on 746 patients.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; F | 2008 |
Is there a need for long-term thromboprophylaxis following general surgery?
Topics: Bandages; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Follow-Up Studie | 1993 |
Colour Doppler flow imaging ultrasonography versus venography as screening method for asymptomatic postoperative deep venous thrombosis.
Topics: Abdomen; Bandages; Elective Surgical Procedures; Femoral Vein; Fibrinolytic Agents; Heparin, Low-Mol | 1995 |
Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial.
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Double-Blind Method; Emergencies; Female; Fibrinolytic Agen | 1996 |
Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; | 1998 |
306 other studies available for dalteparin and Complication, Postoperative
| Article | Year |
|---|---|
Nadroparin Plus Compression Stockings versus Nadroparin Alone for Prevention of Venous Thromboembolism in Cerebellopontine Angle Tumour Excisions: A Cohort Study.
Topics: Adult; Aged; Anticoagulants; Body Mass Index; Cerebellar Neoplasms; Cerebellopontine Angle; Female; | 2020 |
[Prevention of thrombohemorrhagic postoperative complications in patients with benign prostatic hyperplasia].
Topics: Fibrinolytic Agents; Hemorrhage; Humans; Low-Level Light Therapy; Male; Nadroparin; Postoperative Co | 2017 |
Pulmonary embolism after abdominal flap breast reconstruction: prediction and prevention.
Topics: Adult; Aged; Anticoagulants; Body Mass Index; BRCA1 Protein; BRCA2 Protein; DNA Mutational Analysis; | 2013 |
Rivaroxaban versus high dose nadroparin for thromboprophylaxis after hip or knee arthroplasty.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Causality; Dose-Response Relationsh | 2015 |
Rare cause of abdominal swelling and edema: iliac vein thrombosis.
Topics: Abdomen; Adult; Anticoagulants; Edema; Female; Humans; Iliac Vein; Magnetic Resonance Imaging; Nadro | 2009 |
[Some aspects of abdominal surgical interventions in the presence of obesity].
Topics: Anticoagulants; Cholecystitis, Acute; Female; Follow-Up Studies; Hernia, Diaphragmatic; Hernia, Vent | 2008 |
Low agreement for assessing the risk of postoperative deep venous thrombosis when deciding prophylaxis strategies: a study using clinical vignettes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Bandages; Decision Making; Early Ambulation; Female; Hepa | 2002 |
[Prophylactic and correctional measures for thromboembolic complications in performance of the upper extremity replantation and microvascular autotransplantation of combined complex of tissues].
Topics: Adolescent; Adult; Aged; Anticoagulants; Child; Female; Humans; Male; Microsurgery; Middle Aged; Nad | 2002 |
Heparin-induced thrombocytopenia with pulmonary embolism and disseminated intravascular coagulation associated with low-molecular-weight heparin.
Topics: Arthroplasty, Replacement, Hip; Disseminated Intravascular Coagulation; Female; Humans; Immunoglobul | 2003 |
Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery.
Topics: Adult; Aged; Anticoagulants; Bandages; Cohort Studies; Female; Hematoma; Hemorrhage; Humans; Laminec | 2004 |
Comparative effectiveness of several agents for preventing postoperative adhesions.
Topics: Abdomen; Animals; Aprotinin; Biocompatible Materials; Carboxymethylcellulose Sodium; Hyaluronic Acid | 2004 |
[Hypovolemic shock during surgery caused by a rectus sheath hematoma].
Topics: Adenoma; Anticoagulants; Atrial Fibrillation; Hematoma; Humans; Intraoperative Complications; Male; | 2005 |
[Determination of factor Xa inhibition doses of low-molecular heparin, nadroparin and reviparin in urological patients].
Topics: Anticoagulants; Body Mass Index; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Nadrop | 2007 |
[Prevention of thrombosis with fraxiparin 0.3 after arthroscopic interventions].
Topics: Adolescent; Adult; Aged; Arthroscopy; Dose-Response Relationship, Drug; Drug Administration Schedule | 1995 |
[Therapy of the fibrin reaction after intraocular surgery using fibrinolytic agents].
Topics: Cataract Extraction; Eye Diseases; Fibrinolytic Agents; Humans; Lenses, Intraocular; Nadroparin; Pos | 1995 |
[The use of fraxiparin in orthopedic trauma patients to prevent and treat pulmonary embolism and deep venous thrombosis of the extremities].
Topics: Adult; Drug Evaluation; Female; Fractures, Bone; Humans; Knee Injuries; Male; Middle Aged; Nadropari | 1993 |
[Prevention of thrombosis with fraxiparin 0.3 after ambulatory surgery].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Surgical Procedures; Anticoagulants; Dose-Res | 1996 |
[Use of low molecular weight heparins].
Topics: Anesthesia, Epidural; Anesthesia, Obstetrical; Anticoagulants; Antithrombin III Deficiency; Cesarean | 1997 |
[Risk patients in dentistry].
Topics: Acenocoumarol; Adult; Anti-Bacterial Agents; Anticoagulants; Blood Coagulation Disorders; Blood Loss | 1999 |
Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy.
Topics: Fibrinolytic Agents; Humans; Italy; Nadroparin; Postoperative Complications; Pulmonary Embolism; Thr | 1997 |
Prevention of deep-vein thrombosis after total knee replacement.
Topics: Arthroplasty, Replacement, Knee; Humans; Nadroparin; Physical Therapy Modalities; Postoperative Comp | 2000 |
[The impact of hemodilution and low-molecular-weight fraxiparin on volumetric indexes and frequency of postoperative complications in surgical treatment of patients with oncological diseases].
Topics: Anticoagulants; Hemodilution; Hypovolemia; Molecular Weight; Nadroparin; Neoplasms; Postoperative Co | 2001 |
Deep venous thrombosis after laparoscopic cholecystectomy and prevention with nadroparin.
Topics: Cholecystectomy, Laparoscopic; Female; Fibrinolytic Agents; Humans; Incidence; Male; Middle Aged; Na | 2002 |
Bemiparin vs enoxaparin in the prevention of thrombosis in microvascular head and neck reconstruction.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Post | 2022 |
[Intracranial hemorrhage due to pulmonary thromboembolism in heparin therapy and therapeutic management of patients hospitalized with massive pulmonary embolism after discharge].
Topics: Angiography; Anticoagulants; Embolectomy; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; In | 2013 |
[Changes of the hemostasis system in patients with obturation jaundice caused by choledocholithiasis, and possibilities of their correction with the help of miniinvasive operative interventions].
Topics: Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Disorders; Choledocholithiasis; Drug Admi | 2014 |
A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery.
Topics: Adult; Aged; Algorithms; Body Weight; Cohort Studies; Female; Follow-Up Studies; Heparin, Low-Molecu | 2009 |
[Hip fracture during pregancy in a woman with transient osteporosis].
Topics: Accidental Falls; Adult; Anticoagulants; Bone Screws; Cesarean Section; Female; Fracture Fixation, I | 2010 |
Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Drug A | 2007 |
Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice.
Topics: Adult; Aged; Chemoprevention; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hemorrhage; | 2008 |
Postoperative fever secondary to enoxaparin usage with pork allergy.
Topics: Animals; Anticoagulants; Enoxaparin; Fever of Unknown Origin; Humans; Hypersensitivity; Male; Middle | 2022 |
Rare presentation of enoxaparin-induced skin necrosis in a postoperative patient.
Topics: Anticoagulants; Enoxaparin; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Necrosis; Postop | 2022 |
Cost-Effective Modeling of Thromboembolic Chemoprophylaxis for Total Ankle Arthroplasty.
Topics: Ankle; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Che | 2022 |
Assessment of BMI and Venous Thromboembolism Rates in Patients on Standard Chemoprophylaxis Regimens After Undergoing Free Tissue Transfer to the Head and Neck.
Topics: Anticoagulants; Body Mass Index; Chemoprevention; Cohort Studies; Enoxaparin; Female; Humans; Male; | 2022 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty-Reply.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Time to rethink extended thromboprophylaxis after cancer surgery?
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Postoperative Complica | 2023 |
Enoxaparin Is Better Than Aspirin for the Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Postoperative Complica | 2023 |
Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy.
Topics: Anticoagulants; Canada; Enoxaparin; Female; Genital Neoplasms, Female; Hemorrhage; Humans; Laparotom | 2023 |
Increased bleeding risk with enoxaparin venothromboembolism prophylaxis compared with heparin in patients undergoing bariatric surgery.
Topics: Adult; Bariatric Surgery; Enoxaparin; Female; Fibrinolytic Agents; Gastrectomy; Gastric Bypass; Hepa | 2023 |
Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; Humans; Postoperative Complicat | 2023 |
Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer.
Topics: Anticoagulants; Endometrial Neoplasms; Enoxaparin; Female; Humans; Postoperative Complications; Retr | 2023 |
Hemorrhagic Shock After Lumbar Puncture.
Topics: Anticoagulants; Atrial Fibrillation; Central Nervous System Diseases; Computed Tomography Angiograph | 2019 |
Underdosing of Prophylactic Enoxaparin Is Common in Orthopaedic Trauma and Predicts 90-Day Venous Thromboembolism.
Topics: Academic Medical Centers; Adult; Aged; Anticoagulants; Cohort Studies; Dose-Response Relationship, D | 2019 |
Postoperative Venous Thromboembolism Prophylaxis Utilizing Enoxaparin Does Not Increase Bleeding Complications After Abdominal Body Contouring Surgery.
Topics: Aftercare; Anticoagulants; Body Contouring; Enoxaparin; Humans; Patient Discharge; Postoperative Com | 2020 |
Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Ther | 2019 |
Venous Thromboembolism Prophylaxis: Safe, but Still Provocative?
Topics: Anticoagulants; Brain Neoplasms; Craniotomy; Enoxaparin; Humans; Postoperative Complications; Precis | 2019 |
Defects in Processes of Care for Pharmacologic Prophylaxis Are Common Among Neurosurgery Patients Who Develop In-Hospital Postoperative Venous Thromboembolism.
Topics: Aged; Algorithms; Anticoagulants; Chemoprevention; Enoxaparin; Female; Guideline Adherence; Heparin; | 2020 |
A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting.
Topics: Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Female; Humans; Postoperative Complications; Qual | 2020 |
Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients.
Topics: Abdominal Neoplasms; Aged; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Incidence; Male; Mid | 2020 |
Successful Long-term Anticoagulation with Enoxaparin in a Patient with a Mechanical Heart Valve.
Topics: Aged; Anticoagulants; Aortic Valve Stenosis; Coronary Artery Bypass; Enoxaparin; Heart Valve Prosthe | 2020 |
Prophylaxis for Pediatric Venous Thromboembolism: Current Status and Changes Across Pediatric Orthopaedic Society of North America From 2011.
Topics: Aspirin; Enoxaparin; Guideline Adherence; Humans; North America; Orthopedic Procedures; Pediatrics; | 2020 |
Venous thromboembolism rates after hip and knee arthroplasty and hip fractures.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2020 |
Aspirin compared to enoxaparin or rivaroxaban for thromboprophylaxis following hip and knee replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2020 |
Incidence of venous thromboembolism after robotic-assisted hysterectomy in obese patients with endometrial cancer: do we need extended prophylaxis?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Endometrial Neoplasms; Enoxaparin; Female; Heparin; | 2021 |
Practice patterns for extended venous thromboembolism chemoprophylaxis among urologic oncologists after radical cystectomy.
Topics: Aftercare; Anticoagulants; Chemoprevention; Cystectomy; Enoxaparin; Humans; Postoperative Complicati | 2020 |
Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy.
Topics: Aged; Anticoagulants; Biological Variation, Population; Body Mass Index; Chemotherapy, Adjuvant; Cys | 2020 |
Adherence to postoperative thromboprophylactic medication among gynecologic oncology patients: A subanalysis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, Female; Humans; Medication Adherence; M | 2020 |
Liver Injury Among Japanese Patients Treated Using Prophylactic Enoxaparin After Colorectal Surgery.
Topics: Anticoagulants; Asian People; Case-Control Studies; Chemical and Drug Induced Liver Injury; Colorect | 2021 |
Multi-Criteria Model for Evaluating Drugs to Prevent Deep Venous Thrombosis Associated With Orthopedic Surgery: A Hospital-Based Case Study.
Topics: Anticoagulants; Brazil; Enoxaparin; Hemorrhage; Humans; Orthopedic Procedures; Pharmaceutical Prepar | 2020 |
A Pregnant Woman With Shortness of Breath.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anticoagulants; Cesarean Section; Dyspnea; Echocardio | 2021 |
Clinical analysis of postoperative venous thromboembolism in Japanese patients after colorectal cancer surgery.
Topics: Aged; Anticoagulants; Asian People; Colorectal Neoplasms; Enoxaparin; Female; Fibrin Fibrinogen Degr | 2021 |
Thromboelastography-Guided Management of Anticoagulated COVID-19 Patients to Prevent Hemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anticoagulants; Blood Coagulation Tests; Blood Proteins; | 2021 |
Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Revision Hip and Knee Arthroplasty as Reported by American Board of Orthopaedic Surgery Part II Candidates.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; | 2021 |
Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Postoperative Complications; Py | 2021 |
Inadequate Enoxaparin Dosing Predicts 90-Day Venous Thromboembolism Risk among Plastic Surgery Inpatients: An Examination of Enoxaparin Pharmacodynamics.
Topics: Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Humans; Male; Middle Aged; Plastic Surgery Proce | 2017 |
The Perioperative Management of Antithrombotic Therapies Using Enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Heparin, Lo | 2017 |
Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; D | 2017 |
Anti-Factor Xa measurements in acute care surgery patients to examine enoxaparin dose.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Critical Care; Dose-Response Relationshi | 2018 |
Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study.
Topics: Adult; Aged; Analysis of Variance; Anticoagulants; Cohort Studies; Databases, Factual; Enoxaparin; G | 2017 |
Thromboembolic Events Following Splenectomy: Risk Factors, Prevention, Management and Outcomes.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Male; Mesenteric Ischemia; Middle Aged; Ope | 2018 |
Delayed Catheter-Related Intracranial Hemorrhage After a Ventriculoperitoneal or Ventriculoatrial Shunt in Hydrocephalus.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain; Cerebrospinal Fluid Shunts; Enoxaparin; Femal | 2017 |
Wound Discharge After Pharmacological Thromboprophylaxis in Lower Limb Arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2018 |
Pulmonary Embolism Presenting as Persistent Hiccups.
Topics: Anticoagulants; Baclofen; Computed Tomography Angiography; Elective Surgical Procedures; Enoxaparin; | 2018 |
Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy.
Topics: Aged; Anticoagulants; Chemoprevention; Cystectomy; Enoxaparin; Female; Humans; Injections, Subcutane | 2018 |
Are factor Xa inhibitors effective thromboprophylaxis following hip fracture surgery?: A large national database study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Databases, Factual; Enoxapa | 2017 |
Assessing risk factors, presentation, and management of portomesenteric vein thrombosis after sleeve gastrectomy: a multicenter case-control study.
Topics: Adult; Aged; Anticoagulants; Bariatric Surgery; Drug Therapy, Combination; Enoxaparin; Epidemiologic | 2018 |
Comparison of face-to-face interaction and the electronic medical record for venous thromboembolism risk stratification using the 2005 Caprini score.
Topics: Adult; Aged; Anesthesia, General; Anticoagulants; Electronic Health Records; Enoxaparin; Female; Hum | 2018 |
Comparison of face-to-face interaction and the electronic medical record for venous thromboembolism risk stratification using the 2005 Caprini score.
Topics: Adult; Aged; Anesthesia, General; Anticoagulants; Electronic Health Records; Enoxaparin; Female; Hum | 2018 |
Comparison of face-to-face interaction and the electronic medical record for venous thromboembolism risk stratification using the 2005 Caprini score.
Topics: Adult; Aged; Anesthesia, General; Anticoagulants; Electronic Health Records; Enoxaparin; Female; Hum | 2018 |
Comparison of face-to-face interaction and the electronic medical record for venous thromboembolism risk stratification using the 2005 Caprini score.
Topics: Adult; Aged; Anesthesia, General; Anticoagulants; Electronic Health Records; Enoxaparin; Female; Hum | 2018 |
Twice-Daily Enoxaparin among Plastic Surgery Inpatients: An Examination of Pharmacodynamics, 90-Day Venous Thromboembolism, and 90-Day Bleeding.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male | 2018 |
Evaluation of VTE prophylaxis and the impact of alternate regimens on post-operative bleeding and thrombotic complications following bariatric procedures.
Topics: Adolescent; Adult; Anticoagulants; Blood Transfusion; Drug Therapy, Combination; Enoxaparin; Female; | 2018 |
Clinical effect of enoxaparin on international normalized ratio following hepato-pancreatico-biliary and gastroesophageal resection.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Digestive System Neoplasms; Digestive System Surgica | 2018 |
Rectus sheath haematoma causing ureteric obstruction.
Topics: Adenocarcinoma; Aged, 80 and over; Anticoagulants; Colonic Neoplasms; Enoxaparin; Female; Gastrointe | 2018 |
Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Clin | 2018 |
Thromboprophylaxis in gynecologic cancer surgery: Is extended prophylaxis with low molecular weight heparin justified?
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Genital Neoplasms, Female; Gynecol | 2018 |
Enoxaparin: A cause of postoperative fever?
Topics: Aged; Animals; Anticoagulants; Arthroplasty, Replacement, Knee; Cattle; Diabetes Complications; Enox | 2018 |
The Timing of Chemoprophylaxis in Autologous Microsurgical Breast Reconstruction.
Topics: Anticoagulants; Blood Transfusion; Breast Neoplasms; Chemoprevention; Enoxaparin; Female; Free Tissu | 2018 |
Aspirin Alone Is Not Enough to Prevent Deep Venous Thrombosis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Chem | 2019 |
Thromboprophylaxis for varicose vein procedures - A national survey.
Topics: Enoxaparin; Female; Humans; Ireland; Male; Middle Aged; Postoperative Complications; Surveys and Que | 2019 |
Routine monitoring for heparin-induced thrombocytopenia following lower limb arthroplasty: Is it necessary? A prospective study in a UK district general hospital.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; F | 2019 |
Development of bilateral dural arteriovenous fistulae following pial synangiosis for moyamoya syndrome: case report.
Topics: Adolescent; Anterior Cerebral Artery; Anticoagulants; Carotid Arteries; Central Nervous System Vascu | 2019 |
Cost-Effectiveness of Extended Thromboprophylaxis in Patients Undergoing Colorectal Surgery from a Canadian Health Care System Perspective.
Topics: Anticoagulants; Chemoprevention; Colectomy; Colonic Neoplasms; Cost-Benefit Analysis; Decision Suppo | 2019 |
[Compliance of patients undergoing thromboprophylaxis with enoxaparin: the COMFORT study].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Female; | 2013 |
Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Chemopreventi | 2013 |
[Comparison of effects of two anticoagulants on hidden blood loss after total hip arthroplasty].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2013 |
Is extended thromboprophylaxis necessary in elective colorectal cancer surgery?
Topics: Aged; Anticoagulants; Australia; Clinical Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; El | 2013 |
A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost- | 2013 |
NICE thromboprophylaxis guidelines are not associated with increased pericardial effusion after surgery of the proximal thoracic aorta.
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Coronary Artery Bypass; Enoxaparin; Humans; Middle | 2013 |
Therapeutic effect of low-molecular weight heparin and incidence of lower limb deep venous thrombosis and pulmonary embolism after laparoscopic bariatric surgery.
Topics: Adolescent; Adult; Anastomosis, Roux-en-Y; Bariatric Surgery; Enoxaparin; Female; Heparin, Low-Molec | 2013 |
Penile Mondor's syndrome after endovenous treatment of the great saphenous vein with 1470 nm diode laser.
Topics: Diclofenac; Endovascular Procedures; Enoxaparin; Humans; Laser Therapy; Male; Middle Aged; Postopera | 2015 |
The necessity of pharmacological prophylaxis against venous thromboembolism in major joint arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; H | 2014 |
Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery.
Topics: Anticoagulants; Cohort Studies; Enoxaparin; Female; Health Care Costs; Heparin; Humans; Injections; | 2014 |
Safety of postoperative thromboprophylaxis after major hepatobiliary-pancreatic surgery in Japanese patients.
Topics: Aged; Anticoagulants; Asian People; Enoxaparin; Female; Fondaparinux; Hemorrhage; Hepatectomy; Human | 2014 |
Maximizing chemoprophylaxis against venous thromboembolism in abdominoplasty patients with the use of preoperative heparin administration.
Topics: Abdominoplasty; Adult; Anticoagulants; Enoxaparin; Humans; Middle Aged; Postoperative Complications; | 2014 |
[Comparison of rivaroxaban and enoxaparin on blood loss after total knee arthroplasty].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Bloo | 2014 |
[Hemorrhage after accidental overdosage of enoxaparin: monitoring and therapy].
Topics: Anticoagulants; Cardiac Surgical Procedures; Drug Overdose; Enoxaparin; Humans; Male; Medical Errors | 2014 |
Efficacy of postoperative anticoagulation therapy with enoxaparin for portal vein thrombosis after hepatic resection in patients with liver cancer.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Portal Vein; P | 2014 |
Safety of Outpatient Implantation of the Implantable Cardioverter-defibrillator.
Topics: Acenocoumarol; Ambulatory Care; Ambulatory Surgical Procedures; Anticoagulants; Costs and Cost Analy | 2015 |
Prophylactic effect of fondaparinux and enoxaparin for preventing pulmonary embolism after total hip or knee arthroplasty: A retrospective observational study using the Japanese Diagnosis Procedure Combination database.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2015 |
Activated clotting time monitoring during osteocutaneous free fibula flap surgery.
Topics: Aged; Anticoagulants; Blood Coagulation; Carcinoma, Squamous Cell; Enoxaparin; Facial Neoplasms; Fem | 2015 |
Perioperative Management of Antiplatelets and Anticoagulants Among Patients Undergoing Elective Transurethral Resection of the Prostate--A Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogre | 2015 |
Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgery.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Blood Coagulation; Enoxaparin; Female; Hep | 2015 |
An unusual case of enoxaparin induced thrombocytopenia in intensive care unit.
Topics: Anticoagulants; Autoantibodies; Drug Substitution; Duodenal Neoplasms; Enoxaparin; Female; Fondapari | 2015 |
Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Female; Fibrinolytic Age | 2015 |
Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
Topics: Aged; Arthroplasty, Replacement, Knee; Australia; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrha | 2016 |
[Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities].
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Arthroplasty, Replacement, Hip; Blood Coagulation | 2016 |
Abdominal thrombotic complications following bariatric surgery.
Topics: Abdomen; Adult; Anticoagulants; Bariatric Surgery; Drug Administration Schedule; Enoxaparin; Female; | 2017 |
Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin.
Topics: Aged; Anticoagulants; Blood Transfusion; Cystectomy; Enoxaparin; Female; Heparin; Humans; Inpatients | 2017 |
A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Dabigatran; | 2017 |
Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; China; Cost-Benefit Analysis; Decision Trees; Enoxap | 2017 |
Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Topics: Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enoxaparin; Facto | 2017 |
Venous thromboembolic events: How low can you go?
Topics: Anticoagulants; Case-Control Studies; Enoxaparin; Female; Guideline Adherence; Humans; Male; Middle | 2017 |
Safety and efficacy of postoperative pharmacologic thromboprophylaxis with enoxaparin after pancreatic surgery.
Topics: Adult; Aged; Aged, 80 and over; Digestive System Surgical Procedures; Enoxaparin; Female; Fibrinolyt | 2017 |
Safety and Effectiveness of Enoxaparin as Venous Thromboembolism Prophylaxis after Gastric Cancer Surgery in Japanese Patients.
Topics: Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Anticoagulants; Case-Control Studies; Enoxapa | 2016 |
Selective factor Xa inhibition for thromboprophylaxis.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Pos | 2008 |
Venous thromboembolism clinically detected after hip fracture surgery with prophylaxis in a clinical practice setting.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Cohort Studies; Dalteparin; Enoxapari | 2008 |
Prevention of venous thromboembolism: improving practice in surgical patients.
Topics: Adult; Clinical Protocols; Decision Support Techniques; Enoxaparin; Fibrinolytic Agents; Guideline A | 2009 |
Epidural analgesia and liver resection: postoperative coagulation disorders and epidural catheter removal.
Topics: Aged; Analgesia, Epidural; Anticoagulants; Blood Coagulation Disorders; Blood Transfusion; Catheteri | 2011 |
[Summary and perspectives. Rivaroxaban].
Topics: Administration, Oral; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Comorbidity; Enoxap | 2008 |
[Leg venous thrombosis after work accident: serious surprise in echocardiography].
Topics: Accidents, Occupational; Adult; Casts, Surgical; Critical Care; Echocardiography, Doppler, Color; En | 2008 |
Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Cohort Studies; En | 2009 |
[Postoperative ischemic acute stroke and thrombolytic therapy].
Topics: Acute Disease; Aged; Anticoagulants; Aphasia, Broca; Aspirin; Cholesteatoma; Ear Diseases; Ear, Exte | 2009 |
[Subdural spinal hematoma and intraventricular bleeding after lumbar puncture].
Topics: Aged; Anticoagulants; Back Pain; Cerebral Hemorrhage; Cerebral Ventricles; Enoxaparin; Fatal Outcome | 2009 |
Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Chemotherapy, Adjuvant; Enoxaparin; Female; Humans; | 2009 |
Thromboprophylaxis following surgery for colorectal cancer - is it worthwhile after hospital discharge?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Colorectal Neoplasms; Enoxaparin; Humans; Length of | 2009 |
Enoxaparin induced intracerebral haemorrhage after deep brain stimulation surgery.
Topics: Aged; Anticoagulants; Cerebral Hemorrhage; Deep Brain Stimulation; Enoxaparin; Humans; Male; Postope | 2009 |
New observations in postpartum ovarian vein thrombosis: experience of single center.
Topics: Adult; Anticoagulants; Aspirin; Cesarean Section; Early Diagnosis; Enoxaparin; Female; Humans; Incid | 2010 |
Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
Topics: Chemoprevention; Cost-Benefit Analysis; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agent | 2010 |
Apixaban or enoxaparin for thromboprophylaxis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Postoperative Complications; Pu | 2009 |
Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery.
Topics: Adenocarcinoma; Adult; Aged; Anticoagulants; Biomarkers; Carcinoma, Squamous Cell; Combined Modality | 2010 |
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2010 |
New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; | 2009 |
[Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential].
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2010 |
Apixaban to prevent venous thromboembolism after knee replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Fibrinolytic Agents; Humans; Postoperat | 2010 |
[Cost-effectiveness analysis of methods for thromboprophylaxis after orthopedic surgery].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2010 |
Ruptured colonic intramural hematoma with massive hemorrhage after aortic valve replacement.
Topics: Aortic Valve Stenosis; Coronary Artery Bypass; Coronary Artery Disease; Enoxaparin; Fibrinolytic Age | 2010 |
Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.
Topics: Adult; Aged; Anticoagulants; Creatinine; Enoxaparin; Factor Xa; Female; Heparin, Low-Molecular-Weigh | 2010 |
Transoesophageal echocardiography predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Catheter Ablation; Echocardiography | 2010 |
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benz | 2010 |
How should we define major bleeding events in thromboprophylaxis?
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Bandages; Enoxaparin; Hemorrhage; Heparin, Low-Molec | 2010 |
Bridge-therapy with enoxaparin in the preoperative period of endarterectomy.
Topics: Aged; Anticoagulants; Endarterectomy, Carotid; Enoxaparin; Female; Hematoma; Humans; Male; Neck; Pos | 2010 |
Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Male; Mammaplasty; Middle Aged; Plastic Surgery Procedur | 2011 |
Mechanical thromboprophylaxis for patients undergoing hip fracture surgery.
Topics: Aged; Aged, 80 and over; Cohort Studies; Enoxaparin; Female; Fibrinolytic Agents; Fracture Fixation; | 2010 |
Deep vein thrombosis after total knee arthroplasty in asian patients without prophylactic anticoagulation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthritis, Rheumatoid; Arthroplasty, Replacement, Kn | 2011 |
Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relationship, | 2011 |
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigat | 2011 |
Metastatic osteosarcoma presenting as a single pulmonary microembolus.
Topics: Adolescent; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2011 |
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2011 |
Apixaban vs. enoxaparin after hip replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Hemorrhage; Humans; Outcome Assessment, | 2011 |
Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation--a study in 200 patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiac Surgical Procedures; Enoxaparin; Female; Heart Fail | 2011 |
Heparin-induced thrombocytopenia: an increasingly common cause of bilateral adrenal hemorrhage.
Topics: Adrenal Gland Diseases; Adrenal Glands; Adrenal Insufficiency; Aged; Anticoagulants; Arthroplasty, R | 2011 |
Changing practice: implementation of a venous thromboembolism prophylaxis protocol at an academic medical center.
Topics: Academic Medical Centers; Adult; Enoxaparin; Female; Follow-Up Studies; Guideline Adherence; Humans; | 2011 |
Pharmaco-economics and decision making in health care. The case of "Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis".
Topics: Enoxaparin; Fibrinolytic Agents; Humans; Orthopedic Procedures; Polysaccharides; Postoperative Compl | 2011 |
Practice in the perioperative prevention of deep vein thrombosis in german neurosurgical departments: is there a trend towards homogenization?
Topics: Brain; Contraindications; Drug Utilization; Enoxaparin; Fibrinolytic Agents; Germany; Health Care Su | 2011 |
The effect of postoperative enoxaparin on risk for reoperative hematoma.
Topics: Anticoagulants; Bariatric Surgery; Benchmarking; Clinical Protocols; Enoxaparin; Hematoma; Humans; M | 2012 |
[Gastrointestinal stromal tumor in pregnancy and control. Case report].
Topics: Adult; Anticoagulants; Cesarean Section; Embolism, Amniotic Fluid; Emergencies; Enoxaparin; Female; | 2010 |
Comparative effectiveness of dalteparin and enoxaparin in a hospital setting.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dalteparin; Data Interpretation, Statistica | 2012 |
Postoperative enoxaparin prevents symptomatic venous thromboembolism in high-risk plastic surgery patients.
Topics: Adult; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxapa | 2011 |
Can enoxaparin prevent arthrofibrosis?
Topics: Animals; Enoxaparin; Fibrinolytic Agents; Fibrosis; Joint Diseases; Knee Joint; Male; Orthopedic Pro | 2012 |
[ADOPT study. Longer thrombosis prevention in internal medicine patients has no advantage].
Topics: Administration, Oral; Anticoagulants; Double-Blind Method; Enoxaparin; Humans; Injections, Subcutane | 2011 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis | 2012 |
Preoperative enoxaparin is safe to use in major gynecologic surgery for prophylaxis of venous thromboembolism: a retrospective cohort study.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Genital Neoplasms, Female; Gynec | 2012 |
Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Body Mass | 2012 |
Reference ranges for thromboelastography (TEG(®) ) and traditional coagulation tests in term parturients undergoing caesarean section under spinal anaesthesia*.
Topics: Adolescent; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anticoagulants; Blood Coagulation; B | 2012 |
Thrombotic complications and thromboprophylaxis across all three stages of single ventricle heart palliation.
Topics: Anticoagulants; Cross-Sectional Studies; Enoxaparin; Female; Fontan Procedure; Heart Defects, Congen | 2012 |
Postoperative anticoagulation in patients with mechanical heart valves following surgical treatment of subdural hematomas.
Topics: Aged; Anticoagulants; Aspirin; Enoxaparin; Female; Follow-Up Studies; Heart Valve Prosthesis Implant | 2013 |
Outcome of noncardiac and nonvascular surgery in patients with mechanical heart valves.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Case-Control | 2012 |
Postoperative stress-related stomach bleeding in a flap surgery patient.
Topics: Enoxaparin; Female; Humans; Male; Postoperative Complications; Surgery, Plastic; Venous Thromboembol | 2012 |
A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analys | 2012 |
[Comparative analysis of arterial bioprostheses with various antithrombotic modification].
Topics: Biological Availability; Bioprosthesis; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantatio | 2012 |
Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients.
Topics: Adult; Aged; Cost-Benefit Analysis; Enoxaparin; Female; Humans; Markov Chains; Middle Aged; Ovarian | 2012 |
Practice patterns in high-risk bariatric venous thromboembolism prophylaxis.
Topics: Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Health Care Surveys; Heparin; Humans | 2013 |
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Topics: Anticoagulants; Arthroplasty, Replacement, Ankle; Arthroplasty, Replacement, Knee; Clinical Trials, | 2012 |
Anti-inflammatory effect of low-molecular-weight heparin in pediatric cataract surgery.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cataract Extraction; Enoxaparin; Female; Humans; Lens Impla | 2012 |
Successful treatment with enoxaparin of glans ischemia due to local anesthesia after circumcision.
Topics: Anesthesia, Local; Child; Circumcision, Male; Enoxaparin; Epinephrine; Fibrin Fibrinogen Degradation | 2013 |
Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; China; Combined Modality Therapy; Coronary Art | 2002 |
Fondaparinux for post-operative venous thrombosis prophylaxis.
Topics: Canada; Clinical Trials, Phase III as Topic; Contraindications; Costs and Cost Analysis; Drug Approv | 2002 |
Enoxaparin after high-risk coronary stenting.
Topics: Anticoagulants; Blood Vessel Prosthesis Implantation; Enoxaparin; Humans; Myocardial Infarction; Pos | 2002 |
Fondaparinux versus enoxaparin for prevention of venous thromboembolism.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fonda | 2002 |
Fondaparinux versus enoxaparin for prevention of venous.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fonda | 2002 |
Fondaparinux versus enoxaparin for prevention of venous.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fonda | 2002 |
Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery.
Topics: Arthroplasty; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Polysaccharides; Po | 2002 |
Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery.
Topics: Arthroplasty; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysacch | 2002 |
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation | 2002 |
Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Cost-Benefit Analysis; Drug | 2002 |
[Serious complication after subcutaneous injection of heparin for prophylaxis of thromboembolism. Case report].
Topics: Aged; Anticoagulants; Bursitis; Drug Administration Schedule; Elbow Joint; Enoxaparin; Epigastric Ar | 2003 |
Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2003 |
Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Costs and Cost Analysis; Drug Costs; Enoxaparin; Female; Fibri | 2003 |
Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients.
Topics: Adult; Aged; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; Male; Middle Aged; Obesity; Pe | 2003 |
Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Frac | 2003 |
[The problem of postoperative venous thromboembolic complications in general surgery].
Topics: Adult; Aged; Anticoagulants; Digestive System Surgical Procedures; Enoxaparin; Female; Humans; Leg; | 2003 |
Best evidence in anesthetic practice: prevention: fondaparinux is better than enoxaparin for prevention of major venous thromboembolism after orthopedic surgery.
Topics: Anticoagulants; Enoxaparin; Evidence-Based Medicine; Fondaparinux; Humans; Orthopedic Procedures; Po | 2003 |
[A puzzling circulatory failure after total hip replacement].
Topics: Acute Disease; Adrenal Insufficiency; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Fe | 2003 |
Surveillance venous duplex is not clinically useful after total joint arthroplasty when effective deep venous thrombosis prophylaxis is used.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement; Bandages; Enoxaparin; Female; Femoral Vei | 2004 |
A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency.
Topics: Anticoagulants; Arterial Occlusive Diseases; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-M | 2004 |
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Belgium; Cost-Benef | 2004 |
Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Case-Contr | 2004 |
The efficacy of a single daily dose of enoxaparin for deep vein thrombosis prophylaxis following total knee arthroplasty.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Cohort Studies; D | 2004 |
[The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost Savings; Cost- | 2005 |
Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiac Catheterization; Co | 2005 |
[Thrombosis prophylaxis and rational pharmacotherapy].
Topics: Anticoagulants; Drug Costs; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Humans; Polysaccharides; | 2005 |
Comment: low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
Topics: Anticoagulants; Enoxaparin; Humans; International Normalized Ratio; Orthopedic Procedures; Postopera | 2005 |
Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
Topics: Adult; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2005 |
[Use of low molecular weight heparin (Clexane) together with selective COX-2 inhibitor (Dynastat--once or twice per day)].
Topics: Anticoagulants; Cyclooxygenase Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; | 2005 |
Intraoperative enoxaparin minimizes inflammatory reaction after pediatric cataract surgery.
Topics: Acetates; Cataract; Cataract Extraction; Cell Count; Drug Combinations; Endothelium, Corneal; Enoxap | 2006 |
Low molecular-weight heparin in the intraocular irrigating solution in pediatric cataract and intraocular lens surgery.
Topics: Acetates; Cataract; Cataract Extraction; Drug Combinations; Endothelium, Corneal; Enoxaparin; Fibrin | 2006 |
Two cases of heparin induced thrombocytopenia type II post cardiopulmonary bypass.
Topics: Aged; Angina, Unstable; Cardiopulmonary Bypass; Enoxaparin; Female; Follow-Up Studies; Humans; Male; | 2006 |
A fatal case of enoxaparin induced skin necrosis and thrombophilia.
Topics: Aged; Anticoagulants; Diagnosis, Differential; Drug Eruptions; Enoxaparin; Factor V; Factor VIII; Fa | 2006 |
Comparative study of isovolemic hemodilution with 3% albumin, dextran-40, and prophylactic enoxaparin (LMWH) on thrombus formation at venous microanastomosis in rats.
Topics: Anastomosis, Surgical; Animals; Dextrans; Disease Models, Animal; Drug Therapy, Combination; Enoxapa | 2006 |
Continuous peripheral nerve block in combat casualties receiving low-molecular weight heparin.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Humans; Iraq; Male; Middle | 2006 |
A simple venous thromboembolism prophylaxis protocol for patients undergoing bariatric surgery.
Topics: Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Hemorrhage; Heparin; Humans; Obesity | 2006 |
Selecting an agent for prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Enoxaparin; Fibrinolytic Agents; Formularies, Hos | 2006 |
Venous thromboembolism in a general hospital. An update with low molecular weight heparin prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug A | 2007 |
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Hip Prosthesis; Humans; Knee Prosthesis; Phleb | 2007 |
Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.
Topics: Aged; Chemoprevention; Cohort Studies; Dalteparin; Data Collection; Enoxaparin; Female; Fondaparinux | 2007 |
Enoxaparin as bridging anticoagulant treatment in cardiac surgery.
Topics: Aged; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Humans; Intraoperative Care; M | 2008 |
Extended travel after hip arthroplasty surgery. Is it safe?
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Enoxaparin; Fondaparinux; Hip Joint; Hum | 2007 |
Trials of venous thromboembolism prevention.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Post | 2007 |
[Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Topics: Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Sched | 2007 |
Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Topics: Aged; Aged, 80 and over; Anticoagulants; Chemoprevention; Cost-Benefit Analysis; Dalteparin; Enoxapa | 2007 |
Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin.
Topics: Adult; Enoxaparin; Fibrinolytic Agents; Gastric Bypass; Heparin; Humans; Laparoscopy; Middle Aged; P | 2007 |
Dabigatran versus enoxaparin after total hip replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; E | 2007 |
External iliac artery thrombosis after open reduction of an acetabular fracture: a case report.
Topics: Acetabulum; Adult; Angiography; Anticoagulants; Enoxaparin; Female; Fracture Fixation, Internal; Fra | 2008 |
Bilateral thalamic infarct after general anaesthesia for laparotomy: an unusual case of perioperative cryptogenic stroke.
Topics: Adult; Anesthesia, General; Anticoagulants; Blood Loss, Surgical; Enoxaparin; Female; Humans; Infarc | 2008 |
[Stents, antiplatelet therapy, and surgery].
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cesarean Section; Enoxaparin; Female | 2008 |
[Histologic changes in ligated stumps of ovarian blood vessels in preoperative low-molecular weight preventive heparin administration].
Topics: Endothelium, Vascular; Enoxaparin; Female; Humans; Hysterectomy; Injections, Subcutaneous; Ligation; | 1995 |
Comment: enoxaparin--the low-molecular-weight heparin for prevention of postoperative thromboembolic complications.
Topics: Enoxaparin; Humans; Postoperative Complications; Thromboembolism; Thrombophlebitis; Warfarin | 1994 |
Recent advances in the use of low molecular weight heparins as prophylaxis for deep vein thrombosis.
Topics: Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Hip Prosthesis; Humans; Knee Pr | 1994 |
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety.
Topics: Clinical Trials as Topic; Enoxaparin; Heparin; Hip Prosthesis; Humans; Postoperative Complications; | 1994 |
[Some acquired facts apropos of the effectiveness of heparins in the prevention of postoperative phlebitis and pulmonary embolism].
Topics: Enoxaparin; Heparin; Humans; Phlebitis; Postoperative Complications; Pulmonary Embolism | 1993 |
Low-molecular-weight heparins: do good things really come in small packages?
Topics: Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Thromboembo | 1993 |
[General perioperative prevention of thromboembolism in gynecology with low-molecular weight heparin: clinical experiences with enoxaparin over 7 years].
Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Combined Modality Therapy; Dose-Response Relat | 1995 |
Epidural hematoma associated with enoxaparin.
Topics: Aged; Anticoagulants; Bone Nails; Enoxaparin; External Fixators; Female; Femoral Neck Fractures; Fra | 1996 |
Post-discharge deep-vein thrombosis after orthopaedic surgery.
Topics: Anticoagulants; Enoxaparin; Hip Prosthesis; Humans; Phlebography; Postoperative Complications; Throm | 1996 |
Prevention of venous thrombosis in knee arthroplasty.
Topics: Anticoagulants; Enoxaparin; Humans; Knee Prosthesis; Postoperative Complications; Thrombophlebitis; | 1997 |
Prevention of venous thrombosis in knee arthroplasty.
Topics: Anticoagulants; Enoxaparin; Humans; Knee Prosthesis; Postoperative Complications; Research Design; T | 1997 |
Managing the risk of thrombosis in the perioperative period in patients undergoing orthopedic and trauma surgery with low-molecular-weight heparin: enoxaparin.
Topics: Anticoagulants; Bone and Bones; Enoxaparin; Hemorrhage; Hip Prosthesis; Humans; Joint Prosthesis; Kn | 1997 |
A short course of low-molecular-weight heparin to prevent deep venous thrombosis after elective total hip replacement.
Topics: Anticoagulants; Chi-Square Distribution; Drug Evaluation; Elective Surgical Procedures; Enoxaparin; | 1997 |
Antithrombotic agents and thromboembolic disease.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Fibrinolytic Agents; Hirudin Therapy; Hi | 1997 |
Recombinant hirudin compared with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Hirudin Therapy; Hirudins; Humans; Posto | 1998 |
Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Body Weight; | 1998 |
Delayed onset of anterior tibial compartment syndrome in a patient receiving low-molecular-weight heparin. A case report.
Topics: Adult; Anterior Compartment Syndrome; Anticoagulants; Enoxaparin; Femoral Fractures; Humans; Male; P | 1998 |
Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Clinical Trials as Topic; Costs and Cost Analysis; D | 2000 |
Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Case-Control Studies; Enoxaparin; Female; Hum | 2000 |
[Anti-Xa activity during administration of low-molecular weight heparin in the prevention of postoperative thromboembolic complications].
Topics: Adult; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; | 1999 |
Thrombosis prophylaxis in hospitalised medical patients: does prophylaxis in all patients make sense?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Humans; Incidence; Male; Neoplasms; | 2000 |
[Thrombosis prophylaxis in orthopedic surgery].
Topics: Dalteparin; Dextrans; Enoxaparin; Femoral Fractures; Fibrinolytic Agents; Heparin, Low-Molecular-Wei | 2000 |
Noncompliance in the inpatient administration of enoxaparin in conjunction with epidural or spinal anesthesia.
Topics: Anesthesia, Epidural; Anesthesia, Spinal; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplas | 2000 |
Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery.
Topics: Biomarkers; Double-Blind Method; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Age | 2000 |
Thromboprophylaxis using a low molecular weight heparin delays fracture repair.
Topics: Animals; Anticoagulants; Biomechanical Phenomena; Bone and Bones; Bony Callus; Disease Models, Anima | 2000 |
Redesigning heparin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Heparin; Humans; Oligosaccharides; Posto | 2001 |
Duration of thrombosis prophylaxis in orthopaedic surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Hip Fractu | 2001 |
Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Comorbidity; Drug Administration Schedule; Enoxapari | 2001 |
Severe postoperative haemorrhage and airway obstruction following high-dose enoxaparin.
Topics: Airway Obstruction; Blepharoplasty; Enoxaparin; Female; Humans; Injections, Subcutaneous; Laryngeal | 2001 |
Choosing a parenteral anticoagulant agent.
Topics: Angina, Unstable; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecu | 2001 |
Prevention of venous thromboembolism with fondaparinux.
Topics: Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hip Fractures; Humans; | 2002 |
Prevention of venous thromboembolism with fondaparinux.
Topics: Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Humans; Polysaccharides | 2002 |
Prevention of venous thromboembolism with fondaparinux.
Topics: Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Polysaccharide | 2002 |
Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention.
Topics: Arthroplasty, Replacement, Hip; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Fondapari | 2002 |
[Heparin-induced thrombocytopenia in patients and prevention with low molecular weight heparin].
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; | 2001 |
The Effect of Prophylactic Doses of Reviparin on the Postoperative Value of Platelets.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cholecystectomy; Female; Heparin, Low-Molecular-Weig | 2019 |
Acral hemorrhagic blisters induced by reviparin.
Topics: Anticoagulants; Blister; Coronary Artery Disease; Fingers; Foot; Heparin, Low-Molecular-Weight; Huma | 2019 |
Reviparin after leg injury requiring immobilization.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Immobilization; Leg Injuries; Postoperative C | 2003 |
[Facilitated patient management with low molecular weight heparin].
Topics: General Practice; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Thrombosis | 2016 |
Early antithrombotic prophylaxis with low molecular weight heparin in neurosurgery.
Topics: Adult; Aged; Aged, 80 and over; Brain Injuries; Brain Neoplasms; Cerebrospinal Fluid Shunts; Contrai | 2003 |
Thromboembolic and bleeding complications following primary total knee arthroplasty : a Danish nationwide cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Knee; Dabigatr | 2021 |
Delayed-onset heparin-induced skin necrosis: a rare complication of perioperative heparin therapy.
Topics: Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Diagnosis, Differenti | 2017 |
Heparin-induced thrombocytopenia following hip and knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dalteparin; Female; | 2013 |
Low molecular weight heparin in patients undergoing free tissue transfer following head and neck ablative surgery: review of efficacy and associated complications.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Dru | 2013 |
Analysis of contributing factors influencing thromboembolic events after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Dalteparin; Electiv | 2017 |
Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine.
Topics: Administration, Oral; Animals; Aspirin; Bioprosthesis; Clopidogrel; Dalteparin; Disease Models, Anim | 2008 |
[An infrequent cause of hypertriglyceridemia in kidney transplantation].
Topics: Adult; Anticoagulants; Dalteparin; Humans; Hypertriglyceridemia; Kidney Transplantation; Male; Posto | 2008 |
Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
Topics: Anticoagulants; Canada; Cost-Benefit Analysis; Dalteparin; Drug Administration Schedule; Humans; Met | 2009 |
Kinetics of D-dimer after general surgery.
Topics: Abdomen; Abdominal Neoplasms; Adult; Aged; Anticoagulants; Cohort Studies; Dalteparin; Female; Fibri | 2009 |
Dalteparin in total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Dalteparin; Humans; Postopera | 2010 |
[Prolonged prophylaxis of thromboembolic disease in patients with colorectal surgical resections for malignancy].
Topics: Anticoagulants; Colorectal Neoplasms; Dalteparin; Female; Humans; Male; Middle Aged; Postoperative C | 2009 |
Anticoagulant-induced priapism progressing to penile gangrene: a devastating complication!
Topics: Adult; Anticoagulants; Brachial Artery; Dalteparin; Drug Therapy, Combination; Gangrene; Hemopneumot | 2012 |
Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury.
Topics: Animals; Carotid Artery Thrombosis; Dalteparin; Dose-Response Relationship, Drug; Endarterectomy, Ca | 2003 |
Anticoagulation interruptus: not without risk.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Blood Loss, Surgical; Carotid Arteri | 2004 |
[Prevention and treatment of venous thromboses and thromboembolism: pentasaccharides as novel anticoagulants selectively blocking Xe factor, their position and potential (data of the XIX International Congress on Thromboses and Hemostasis)].
Topics: Adult; Anticoagulants; Complement Factor H; Dalteparin; Fondaparinux; Humans; Middle Aged; Polysacch | 2004 |
Comparison of abciximab combined with dalteparin or unfractionated heparin in high-risk percutaneous coronary intervention in acute myocardial infarction patients.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Blood Loss, Surgi | 2006 |
Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery.
Topics: Aged; Anticoagulants; Antithrombin III; Dalteparin; Female; Hip Prosthesis; Humans; Male; Peptide Hy | 1995 |
Is colour Doppler ultrasound a sensitive screening method in diagnosing deep vein thrombosis after hip surgery?
Topics: Anticoagulants; Dalteparin; Dextrans; Hip Fractures; Hip Prosthesis; Hirudin Therapy; Hirudins; Huma | 1996 |
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Humans; Postoperative Complications; Pul | 1998 |
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Humans; Postoperative Complications; Pul | 1998 |
Thromboembolic events following arthroscopic knee surgery.
Topics: Adult; Aged; Anticoagulants; Arthroscopy; Dalteparin; Female; Humans; Knee Joint; Male; Middle Aged; | 1999 |
Superior mesenteric and portal vein thrombosis following laparoscopic nissen fundoplication.
Topics: Abdominal Pain; Anticoagulants; Dalteparin; Fundoplication; Gastroesophageal Reflux; Humans; Male; M | 2000 |
Cost effectiveness of deep venous thrombosis prophylaxis after hip fracture.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Hip Fractures; Humans; Leg; Postoperative Complic | 2000 |
Chronic disseminated intravascular coagulation after surgery for abdominal aortic aneurysm: clinical and haemostatic response to dalteparin.
Topics: Aged; Anticoagulants; Antithrombins; Aortic Aneurysm, Abdominal; Chronic Disease; Dalteparin; Dissem | 2001 |
Impact of Weight-Band Dosing of Tinzaparin for Venous Thromboembolism Prophylaxis on Persistent Wound Drainage in Adult Patients Undergoing Hip and Knee Arthroplasty.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drainage; Hu | 2022 |
Distal femoral replacement in periprosthetic fracture around total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgica | 2014 |
Thromboelastography (TEG®) demonstrates that tinzaparin 4500 international units has no detectable anticoagulant activity after caesarean section.
Topics: Adult; Anticoagulants; Cesarean Section; Female; Heparin, Low-Molecular-Weight; Humans; Middle Aged; | 2017 |
[An image of vena cava thrombosis].
Topics: Adenocarcinoma, Clear Cell; Aged, 80 and over; Angiogenesis Inhibitors; Fibrinolytic Agents; Heart A | 2009 |
Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Fem | 2011 |
Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy.
Topics: Aged; Anticoagulants; Aspirin; Carcinoma, Basal Cell; Clopidogrel; Drug Administration Schedule; Fem | 2002 |